

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2003**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2003

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23RD EDITION

Cumulative Supplement 12

December 2003

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Nitroglycerin, Film, Extended Release; Transdermal 23 rd Annual Edition	v
1.4 NDA Patent 30-month Rule.....	vi
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Change Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text suggests that organizations should implement robust systems to track every aspect of their operations, from procurement to sales.

2. The second part of the document addresses the challenges of data management in a rapidly changing environment. It highlights the need for flexible and scalable solutions that can adapt to new technologies and data sources. The author argues that organizations must invest in training and development to ensure their staff are equipped to handle complex data sets and analyze them effectively.

3. The third part of the document focuses on the role of leadership in driving organizational success. It stresses that leaders must be able to inspire and motivate their teams, set clear goals, and provide the necessary resources and support. The text also discusses the importance of communication and collaboration, suggesting that leaders should foster a culture of open dialogue and teamwork.

4. The fourth part of the document explores the impact of external factors on organizational performance. It discusses how economic conditions, market trends, and regulatory changes can influence an organization's ability to achieve its objectives. The author suggests that organizations should conduct regular risk assessments and develop contingency plans to mitigate potential threats.

5. The fifth part of the document concludes by summarizing the key points discussed and offering final thoughts on the future of the organization. It reiterates the importance of continuous improvement and innovation, encouraging the organization to stay ahead of the competition by embracing change and seeking new opportunities.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 12
December 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

**FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)**

**NEW APPLICANT NAME
(NEW ABBREVIATED NAME)**

AAIPHARMA INC
(AAIPHARMA)
BAYER CORP
(BAYER)
BAYER CORP CONSUMER CARE DIV
(BAYER CORP CONSUMER)
BAYER CORP PHARMACEUTICALS DIV
(BAYER)
ESI LEDERLE INC
(ESI LEDERLE)
FAULDING PHARMACEUTICAL CO
(FAULDING)
FAULDING PHARMACEUTICALS INC
(FAULDING PHARMS)
FH FAULDING AND CO LTD
(FAULDING)
GENEVA PHARMACEUTICALS INC
(GENEVA PHARMS)
ICN PHARMACEUTICALS INC
(ICN)
LEK SERVICES INC
(LEK SVCS)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO
(LEK LJUBLJANA)
LEK PHARMACEUTICAL AND CHEMICAL DD
(LEK PHARM)
NEOSAN PHARMACEUTICALS
(NEOSAN PHARMS)
NOVARTIS OPHTHALMICS INC
(NOVARTIS)
ORGANON INC
(ORGANON INC)
ORGANON INC SUB AKZO INC
(ORGANON)
ORGANON INC SUB AKZO NOBEL INC
(ORGANON INC)
SIDMAK LABORATORIES INC
(SIDMAK LABS)
SYNTEX (USA) INC LLC
(SYNTEX USA INC)
WALLACE LABORATORIES DIV CARTER WALLACE INC
(WALLACE LABS)

WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC
(WALLACE PHARMS)

AAIPHARMA LLC
(AAIPHARMA LLC)
BAYER PHARMACEUTICALS CORP
(BAYER PHARMS)
BAYER CORP CONSUMER CARE LLC
(BAYER)
BAYER PHARMACEUTICALS CORP
(BAYER PHARMS)
CLONMEL HEALTHCARE INC
(CLONMEL HEALTHCARE)
MAYNE PHARMA USA INC
(MAYNE PHARMA USA)
ALPHARMA PHARMACEUTICALS INC
(ALPHARMA USPD)
MAYNE PHARMA USA INC
(MAYNE PHARMA USA)
SANDOZ INC
(SANDOZ)
VALEANT PHARMACEUTICALS INTERNATIONAL
(VALEANT PHARM INTL)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
AAIPHARMA LLC
(AAIPHARMA LLC)
NOVARTIS PHARMACEUTICALS CORPORATION
(NOVARTIS PHARMS)
ORGANON USA INC
(ORGANON USA INC)
ORGANON USA INC
(ORGANON USA INC)
ORGANON USA INC
(ORGANON USA INC)
PLIVA INC
(PLIVA)
ROCHE PALO ALTO LLC
(ROCHE PALO)
MEDPOINTE PHARMACEUTICALS MEDPOINTE
HEALTHCARE INC
(MEDPOINTE PHARM HLC)
MEDPOINTE PHARMACEUTICALS MEDPOINTE
HEALTHCARE INC
(MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

<u>PRODUCT NAME</u>	<u>APPLICANT</u>	<u>TE CODE</u>	<u>STRENGTH</u>	<u>NDA</u>	<u>PRODUCT</u>
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001

MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001
NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 NDA PATENT 30-MONTH RULE

The Food and Drug Administration has amended its patent submission and listing requirements for new drug applications (NDAs). This final rule became effective on August 18, 2003. The final rule, among other things, limits to one per ANDA or 505(b)(2) application the maximum number of statutory 30-month stays of approval to which an innovator will be entitled when multiple patents are submitted for the same NDA.

Patents listed prior to August 18, 2003 will be designated by a “#” sign and are considered listed under the previous regulations that permitted multiple 30-month stays for an NDA. Patents listed after the effective date of the final rule will not have the # designation displayed and are considered listed under the new rule.

1.5 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs.

There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/23bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.htm>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2002</u>	<u>JUN 2003</u>	<u>SEP 2003</u>	<u>DEC 2003</u>
DRUG PRODUCTS LISTED	10465	10514	10624	10665
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)	2406 (22.7%)	2423 (22.7%)
MULTISOURCE	7939 (75.9%)	7989 (76.0%)	8110 (76.3%)	8134 (76.3%)
THERAPEUTICALLY EQUIVALENT	7659 (73.2%)	7708 (73.3%)	7830 (73.7%)	7856 (73.7%)
NOT THERAPEUTICALLY EQUIVALENT	280 (2.7%)	281 (2.7%)	280 (2.6%)	278 (2.6%)
EXCEPTIONS ¹	106 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	6	6	6	6
NUMBER OF APPLICANTS	598	604	602	601

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will

display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 23RD EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - DEC 2003

1-1

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

+	PRAECIS	100MG/VIAL	N21320 001	NOV 25, 2003	NOV	NEWA
---	---------	------------	------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL

ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE

+	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	N40387 001	JAN 31, 2003	JAN	NEWA
---	--------	--------------------------------	------------	--------------	-----	------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	+	MIKART	750MG;50MG;40MG	N40496 001	DEC 23, 2003	DEC	NEWA
-----	---	--------	-----------------	------------	--------------	-----	------

AB		VINTAGE PHARMS	325MG;50MG;40MG	N40511 001	AUG 27, 2003	AUG	NEWA
----	--	----------------	-----------------	------------	--------------	-----	------

AB			500MG;50MG;40MG	N40513 001	AUG 25, 2003	AUG	NEWA
----	--	--	-----------------	------------	--------------	-----	------

BUTALBITAL, APAP, AND CAFFEINE

AB		AXIOM PHARM	325MG;50MG;40MG	N89536 001	FEB 16, 1988	MAY	CAHN
----	--	-------------	-----------------	------------	--------------	-----	------

ESGIC-PLUS

AB	+	MIKART	500MG;50MG;40MG	N89451 001	MAY 23, 1988	AUG	CTNA
----	---	--------	-----------------	------------	--------------	-----	------

FIORICET

AB	+	WATSON PHARMS	325MG;50MG;40MG	N88616 001	NOV 09, 1984	APR	CAHN
----	---	---------------	-----------------	------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE

AB		ABLE	325MG;50MG;40MG;30MG	N76528 001	AUG 21, 2003	AUG	NEWA
----	--	------	----------------------	------------	--------------	-----	------

FIORICET W/ CODEINE

AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CAHN
----	---	---------------	----------------------	------------	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PHENAPHEN W/ CODEINE NO. 3

@	ROBINS AH	325MG;30MG	N84445 001		JUN	DISC
---	-----------	------------	------------	--	-----	------

PHENAPHEN W/ CODEINE NO. 4

@	ROBINS AH	325MG;60MG	N84446 001		JUN	DISC
---	-----------	------------	------------	--	-----	------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		ANDRX PHARMS	300MG;15MG	N40443 001	JAN 22, 2003	JAN	NEWA
----	--	--------------	------------	------------	--------------	-----	------

AA			300MG;30MG	N40443 002	JAN 22, 2003	JAN	NEWA
----	--	--	------------	------------	--------------	-----	------

AA			300MG;60MG	N40443 003	JAN 22, 2003	JAN	NEWA
----	--	--	------------	------------	--------------	-----	------

AA	+	DURAMED PHARMS BARR	300MG;15MG	N40223 001	NOV 18, 1997	AUG	CRLD
----	---	---------------------	------------	------------	--------------	-----	------

AA		RANBAXY	300MG;60MG	N87083 001		JAN	CAHN
----	--	---------	------------	------------	--	-----	------

ACETAMINOPHEN W/ CODEINE PHOSPHATE #3

AA		RANBAXY	300MG;30MG	N85868 001		JAN	CAHN
----	--	---------	------------	------------	--	-----	------

CODRIX

+	ANDRX PHARMS	500MG;30MG	N40441 001	MAR 27, 2003	MAR	NEWA
---	--------------	------------	------------	--------------	-----	------

+		500MG;15MG	N40447 001	FEB 26, 2003	FEB	NEWA
---	--	------------	------------	--------------	-----	------

+		500MG;60MG	N40488 001	MAR 28, 2003	MAR	NEWA
---	--	------------	------------	--------------	-----	------

TYLENOL W/ CODEINE NO. 1

@	ORTHO MCNEIL PHARM	300MG;7.5MG	N85055 001		AUG	DISC
---	--------------------	-------------	------------	--	-----	------

TYLENOL W/ CODEINE NO. 2

@	ORTHO MCNEIL PHARM	300MG;15MG	N85055 002		AUG	DISC
---	--------------------	------------	------------	--	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

TYLENOL W/ CODEINE NO. 4

@ ORTHO MCNEIL PHARM 300MG;60MG

N85055 004

AUG DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MALLINCKRODT 500MG/15ML;10MG/15ML
 + MIKART 325MG/15ML;7.5MG/15ML
 AA 500MG/15ML;5MG/15ML
 AA + 500MG/15ML;5MG/15ML
 AA VINTAGE PHARMS 500MG/15ML;7.5MG/15ML

N40508 001 AUG 29, 2003 AUG NEWA
 N40482 001 SEP 25, 2003 SEP NEWA
 N81226 001 OCT 27, 1992 AUG CTEC
 N89557 001 APR 29, 1992 AUG CTEC
 N40520 001 OCT 30, 2003 OCT NEWA

TABLET; ORAL

ANEXSIA

AA MALLINCKRODT 750MG;10MG
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 AA ABLE 500MG;7.5MG
 AA 650MG;7.5MG
 AA ANDRX PHARMS 500MG;5MG
 AA 660MG;10MG
 AA 750MG;7.5MG
 AA AXIOM PHARM 500MG;5MG
 AA 650MG;10MG
 AA 650MG;7.5MG
 AA 750MG;7.5MG
 AA MIKART 325MG;7.5MG

N40468 001 OCT 31, 2002 OCT CTNA
 N40490 001 MAY 21, 2003 MAY NEWA
 N40474 001 JAN 02, 2003 JAN NEWA
 N40493 001 MAY 28, 2003 MAY NEWA
 N40495 001 MAY 28, 2003 MAY NEWA
 N40494 001 MAY 28, 2003 MAY NEWA
 N40236 001 SEP 25, 1997 MAY CAHN
 N40240 001 NOV 26, 1997 MAY CAHN
 N40240 002 NOV 26, 1997 MAY CAHN
 N40236 002 SEP 25, 1997 MAY CAHN
 N40432 001 JAN 22, 2003 JAN NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA AXIOM PHARM 500MG;5MG

N40219 001 JAN 22, 1998 MAY CAHN

TABLET; ORAL

AA WATSON LABS 325MG;7.5MG
 AA 325MG;10MG

N40535 001 SEP 05, 2003 SEP NEWA
 N40535 002 SEP 05, 2003 SEP NEWA

PERCOCET

AA + ENDO PHARMS 325MG;7.5MG
 AA + 325MG;10MG

N40434 001 NOV 23, 2001 SEP CFTG
 N40434 002 NOV 23, 2001 SEP CFTG

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA VINTAGE PHARMS 650MG;65MG

N40507 001 JUL 30, 2003 JUL NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

>A> DARVOCET A500
 >A> + AAIPHARMA 500MG;100MG
 PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN
 >D> + AAIPHARMA 500MG;100MG
 + 500MG;100MG

N76429 001 SEP 10, 2003 DEC CTNA
 N76429 001 SEP 10, 2003 DEC CTNA
 N76429 001 SEP 10, 2003 SEP NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

@ DURAMED PHARMS BARR 500MG

N12945 001

JUN CAHN

+ 500MG

N12945 003 APR 25, 1995 JUN CAHN

TABLET; ORAL

AB DURAMED PHARMS BARR 125MG

N08943 001

JUN CAHN

AB + 250MG

N08943 002 JUN CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

AP + DURAMED PHARMS BARR EQ 500MG BASE/VIAL

N09388 001 DEC 05, 1990 JUN CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

@ BAYER PHARMS 2%;1%;EQ 0.35% BASE

N50238 001

JUN DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB AAIPHARMA 200MG

N74833 001 APR 22, 1997 APR CAHN

TABLET; ORAL

@ CLONMEL HLTHCARE 400MG

N74834 001 APR 24, 1997 JUL DISC

@ 800MG

N74834 002 APR 24, 1997 JUL DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+ BAXTER HLTHCARE EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL

N74885 001 DEC 19, 1997 AUG CAHN

N74885 002 DEC 19, 1997 AUG CAHN

ACYCLOVIR SODIUM

AP BAXTER HLTHCARE EQ 500MG BASE/VIAL

N74913 001 OCT 15, 1997 AUG CAHN

AP EQ 1GM BASE/VIAL

N74913 002 OCT 15, 1997 AUG CAHN

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+ AMERSHAM HLTH 10MG/ML

N20899 001 DEC 31, 1997 JUN CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN BREATH LTD EQ 0.083% BASE

N76370 001 NOV 24, 2003 NOV NEWA

AN NOVEX EQ 0.5% BASE

N76391 001 APR 01, 2003 APR NEWA

SYRUP; ORAL

PROVENTIL

@ SCHERING EQ 2MG BASE/5ML

N18062 001 JAN 19, 1983 AUG DISC

TABLET; ORAL

ALBUTEROL SULFATE

@ CLONMEL HLTHCARE EQ 2MG BASE

N72859 001 DEC 20, 1989 JUN DISC

@ EQ 4MG BASE

N72860 001 DEC 20, 1989 JUN DISC

AB + MYLAN	EQ 2MG BASE	N72893 001	JAN 17, 1991	AUG	CRLD
AB +	EQ 4MG BASE	N72894 001	JAN 17, 1991	AUG	CRLD
PROVENTIL					
@ SCHERING	EQ 2MG BASE	N17853 001	MAY 07, 1982	AUG	DISC
@	EQ 4MG BASE	N17853 002	MAY 07, 1982	AUG	DISC
TABLET, EXTENDED RELEASE; ORAL					
@ SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987	OCT	DISC

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+ MERCK	EQ 70MG ACID/75ML	N21575 001	SEP 17, 2003	SEP	NEWA
---------	-------------------	------------	--------------	-----	------

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	MAR	CAHN
------------	------------------	------------	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+ SANOFI SYN RES	10MG	N21287 001	JUN 12, 2003	JUN	NEWA
------------------	------	------------	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB VINTAGE PHARMS	100MG	N75798 001	JUN 27, 2003	JUN	NEWA
AB	300MG	N75798 002	JUN 27, 2003	JUN	NEWA

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN ORTHO	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	APR	CAHN
+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001	APR	CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

>A> GLAXOSMITHKLINE	EQ 0.5MG BASE	N21107 002	DEC 23, 2003	DEC	NEWA
---------------------	---------------	------------	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE
SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N21163 001	MAY 18, 2000	JUN	CPOT
--------------	---	------------	--------------	-----	------

INJECTABLE; IV (INFUSION)

+ SABEX 2002	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
--------------	--

IU/ML;30UGM/ML

N21559 001 JUN 16, 2003 JUN NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID;
NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE

11.2

IU/VIAL;125MG/VIAL;60UGM/VIAL;200

IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG

/VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14

MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL

N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ CLONMEL HLTHCARE

0.25MG

N74174 001 OCT 19, 1993 JUN DISC

@

0.5MG

N74174 002 OCT 19, 1993 JUN DISC

@

1MG

N74174 003 OCT 19, 1993 JUN DISC

@

2MG

N74174 004 OCT 19, 1993 JUN DISC

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

PHARMACIA AND UPJOHN

0.5MG

N21434 001 JAN 17, 2003 JAN NEWA

1MG

N21434 002 JAN 17, 2003 JAN NEWA

2MG

N21434 003 JAN 17, 2003 JAN NEWA

+

3MG

N21434 004 JAN 17, 2003 JAN NEWA

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

@ PHARMACIA AND UPJOHN

0.01MG/ML

N20755 002 OCT 01, 1997 OCT DISC

AP +

0.02MG/VIAL

N20379 002 JUL 06, 1995 OCT CRLD

@

0.02MG/ML

N20755 003 OCT 01, 1997 OCT DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB

GENEVA PHARMS

100MG

N71293 001 FEB 18, 1987 APR CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB

ALTANA

0.1%

N76065 001 MAY 15, 2003 MAY NEWA

AB

TARO PHARM INDS

0.1%

N76229 001 MAY 31, 2002 MAY CTEC

AT

0.1%

N76229 001 MAY 31, 2002 APR NEWA

CYCLOCORT

AT

+ FUJISAWA HLTHCARE

0.1%

N18116 002

APR CFTG

AB

+

0.1%

N18116 002

MAY CTEC

OINTMENT; TOPICAL

AMCINONIDE

AB

TARO PHARM INDS

0.1%

N76367 001 MAR 19, 2003 MAR NEWA

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10% (10GM/100ML)

N75880 002 JUN 19, 2003 JUN NEWA

PREMASOL 6% IN PLASTIC CONTAINER

BAXTER HLTHCARE 6% (6GM/100ML)

N75880 001 JUN 19, 2003 JUN NEWA

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

@ BAXTER HLTHCARE 250MG/ML

N18590 001 OCT 29, 1982 AUG CAHN

@ ELKINS SINN 250MG/ML

N18590 001 OCT 29, 1982 JUN DISC

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP + ABBOTT 25MG/ML

N87601 001 JUL 23, 1982 JUN CRLD

@ ELKINS SINN 25MG/ML

N87239 001 JUN DISC

TABLET; ORAL

>D> @ GENEVA PHARMS 100MG

N85261 003 DEC DISC

>D> AB 100MG

N85262 002 DEC DISC

>D> AB 200MG

N85261 002 DEC DISC

>A> @ SANDOZ 100MG

N85261 003 DEC DISC

>A> @ 100MG

N85262 002 DEC DISC

>A> @ 200MG

N85261 002 DEC DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP APOTEX 50MG/ML

N76394 001 APR 25, 2003 APR NEWA

AP SICOR PHARMS 50MG/ML

N76163 001 SEP 05, 2003 SEP NEWA

CORDARONE

AP + WYETH PHARMS INC 50MG/ML

N20377 001 AUG 03, 1995 MAR CAHN

TABLET; ORAL

AMIODARONE HCL

AB EON 400MG

N75315 002 JUN 30, 2000 SEP CRLD

TARO 100MG

N75424 002 DEC 18, 2002 SEP CRLD

>A> 300MG

N76362 002 DEC 02, 2003 DEC NEWA

AB + 400MG

N76362 001 NOV 29, 2002 SEP CRLD

CORDARONE

AB WYETH PHARMS INC 200MG

N18972 001 DEC 24, 1985 MAR CAHN

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

@ ROCHE 40MG/ML

N85749 001 JUN DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

@ SCHERING 10MG; 2MG

N14713 007 MAR DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-25

@ SCHERING 25MG;2MG

N14713 004

MAR DISC

ETRAFON-FORTE

@ SCHERING 25MG;4MG

N14713 006

MAR DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+ ACCESS PHARMS 5%

N20511 001 DEC 17, 1996 JUL CAHN

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC 2.5MG

N21435 001 OCT 31, 2003 OCT NEWA

5MG

N21435 002 OCT 31, 2003 OCT NEWA

+

10MG

N21435 003 OCT 31, 2003 OCT NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB TARO EQ 12% BASE

N75883 001 APR 10, 2003 APR NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

AB GLAXOSMITHKLINE 50MG/ML

N62226 005

JUL CRLD

WYMOX

@ WYETH AYERST 125MG/5ML

N62131 001

JUN DISC

@ 250MG/5ML

N62131 002

JUN DISC

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

RANBAXY 200MG

N65080 002 AUG 11, 2003 AUG NEWA

+

400MG

N65080 001 AUG 11, 2003 AUG NEWA

>A>

+

600MG

N65159 001 DEC 04, 2003 DEC NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

+ TAP PHARM 500MG;500MG;30MG

N50757 001 DEC 02, 1997 MAY CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB RANBAXY 200MG/5ML;EQ 28.5MG BASE/5ML

N65132 001 MAR 19, 2003 MAR NEWA

AB 400MG/5ML;EQ 57MG BASE/5ML

N65132 002 MAR 19, 2003 MAR NEWA

TABLET, CHEWABLE; ORAL

>A> AB RANBAXY 200MG;EQ 28.5MG BASE

N65161 001 DEC 03, 2003 DEC NEWA

>A> AB 400MG;EQ 57MG BASE

N65161 002 DEC 03, 2003 DEC NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	JAN	CAHN
------------	-------------------------	------------	--------------	-----	------

ADDERALL XR 15

SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JAN	CAHN
------------	-----------------------------	------------	--------------	-----	------

ADDERALL XR 20

SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	JAN	CAHN
------------	-----------------	------------	--------------	-----	------

ADDERALL XR 25

SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JAN	CAHN
------------	-----------------------------	------------	--------------	-----	------

ADDERALL XR 30

+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	JAN	CAHN
--------------	-------------------------	------------	--------------	-----	------

ADDERALL XR 5

SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JAN	CAHN
------------	-----------------------------	------------	--------------	-----	------

TABLET; ORAL

ADDERALL 12.5

AB SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR	CFTG
---------------	---------------------------------	------------	--------------	-----	------

ADDERALL 15

AB SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR	CFTG
---------------	-----------------------------	------------	--------------	-----	------

ADDERALL 7.5

AB SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR	CFTG
---------------	---------------------------------	------------	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ABRIKA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472 001	SEP 30, 2003	SEP	NEWA
------------------	-----------------------------	------------	--------------	-----	------

AB	2.5MG;2.5MG;2.5MG;2.5MG	N40472 002	SEP 30, 2003	SEP	NEWA
----	-------------------------	------------	--------------	-----	------

AB	5MG;5MG;5MG;5MG	N40472 003	SEP 30, 2003	SEP	NEWA
----	-----------------	------------	--------------	-----	------

AB	7.5MG;7.5MG;7.5MG;7.5MG	N40472 004	SEP 30, 2003	SEP	NEWA
----	-------------------------	------------	--------------	-----	------

AB BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA
---------	---------------------------------	------------	--------------	-----	------

AB	3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA
----	---------------------------------	------------	--------------	-----	------

AB	3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA
----	-----------------------------	------------	--------------	-----	------

AB MALLINCKRODT	1.25MG;1.25MG;1.25MG;1.25MG	N40440 001	OCT 07, 2003	OCT	NEWA
-----------------	-----------------------------	------------	--------------	-----	------

AB	1.875MG;1.875MG;1.875MG;1.875MG	N40440 002	OCT 07, 2003	OCT	NEWA
----	---------------------------------	------------	--------------	-----	------

AB	2.5MG;2.5MG;2.5MG;2.5MG	N40440 003	OCT 07, 2003	OCT	NEWA
----	-------------------------	------------	--------------	-----	------

AB	3.125MG;3.125MG;3.125MG;3.125MG	N40440 004	OCT 07, 2003	OCT	NEWA
----	---------------------------------	------------	--------------	-----	------

AB	3.75MG;3.75MG;3.75MG;3.75MG	N40440 005	OCT 07, 2003	OCT	NEWA
----	-----------------------------	------------	--------------	-----	------

AB	5MG;5MG;5MG;5MG	N40440 006	OCT 07, 2003	OCT	NEWA
----	-----------------	------------	--------------	-----	------

AB	7.5MG;7.5MG;7.5MG;7.5MG	N40440 007	OCT 07, 2003	OCT	NEWA
----	-------------------------	------------	--------------	-----	------

AB MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	N40480 001	SEP 09, 2003	SEP	NEWA
-----------------	-----------------------------	------------	--------------	-----	------

AB	1.875MG;1.875MG;1.875MG;1.875MG	N40480 002	SEP 09, 2003	SEP	NEWA
----	---------------------------------	------------	--------------	-----	------

AB	2.5MG;2.5MG;2.5MG;2.5MG	N40480 003	SEP 09, 2003	SEP	NEWA
----	-------------------------	------------	--------------	-----	------

AB	3.125MG;3.125MG;3.125MG;3.125MG	N40480 004	SEP 09, 2003	SEP	NEWA
----	---------------------------------	------------	--------------	-----	------

AB	3.75MG;3.75MG;3.75MG;3.75MG	N40480 005	SEP 09, 2003	SEP	NEWA
----	-----------------------------	------------	--------------	-----	------

AB	5MG;5MG;5MG;5MG	N40480 006	SEP 09, 2003	SEP	NEWA
----	-----------------	------------	--------------	-----	------

AB	7.5MG;7.5MG;7.5MG;7.5MG	N40480 007	SEP 09, 2003	SEP	NEWA
----	-------------------------	------------	--------------	-----	------

AB WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY	NEWA
----------------	-----------------------------	------------	--------------	-----	------

AB	2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY	NEWA
----	-------------------------	------------	--------------	-----	------

AB	5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY	NEWA
----	-----------------	------------	--------------	-----	------

AB	7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY	NEWA
----	-------------------------	------------	--------------	-----	------

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001		DEC	CRLD
>A>	AP	+	EQ 125MG BASE/VIAL	N61395 001		DEC	CRLD
		@	EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 250MG BASE/VIAL	N61395 002		DEC	CRLD
>A>	AP	+	EQ 250MG BASE/VIAL	N61395 002		DEC	CRLD
		@	EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 500MG BASE/VIAL	N61395 003		DEC	CRLD
>A>	AP	+	EQ 500MG BASE/VIAL	N61395 003		DEC	CRLD
		@	EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 1GM BASE/VIAL	N61395 004		DEC	CRLD
>A>	AP	+	EQ 1GM BASE/VIAL	N61395 004		DEC	CRLD
		@	EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 2GM BASE/VIAL	N61395 005		DEC	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	N61395 005		DEC	CRLD
		@	EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 10GM BASE/VIAL	N61395 006		DEC	CRLD
>A>	AP	+	EQ 10GM BASE/VIAL	N61395 006		DEC	CRLD
		@	BAXTER HLTHCARE	N62692 001	JUN 24, 1986	AUG	CAHN
		@	EQ 125MG BASE/VIAL	N62692 002	JUN 24, 1986	AUG	CAHN
		@	EQ 250MG BASE/VIAL	N62692 003	JUN 24, 1986	AUG	CAHN
		@	EQ 500MG BASE/VIAL	N62692 004	JUN 24, 1986	AUG	CAHN
		@	EQ 1GM BASE/VIAL	N62692 005	JUN 24, 1986	AUG	CAHN
		@	EQ 2GM BASE/VIAL	N62692 006	JUN 24, 1986	AUG	CAHN
		@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	AUG	CAHN
>D>	AP	MARSAM PHARMS LLC	EQ 125MG BASE/VIAL	N62816 001	OCT 24, 1988	DEC	DISC
>A>		@	EQ 125MG BASE/VIAL	N62816 001	OCT 24, 1988	DEC	DISC
>D>	AP		EQ 250MG BASE/VIAL	N62816 002	OCT 24, 1988	DEC	DISC
>A>		@	EQ 250MG BASE/VIAL	N62816 002	OCT 24, 1988	DEC	DISC
>D>	AP		EQ 500MG BASE/VIAL	N62816 003	OCT 24, 1988	DEC	DISC
>A>		@	EQ 500MG BASE/VIAL	N62816 003	OCT 24, 1988	DEC	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62816 004	OCT 24, 1988	DEC	DISC
>A>		@	EQ 1GM BASE/VIAL	N62816 004	OCT 24, 1988	DEC	DISC
>D>	AP		EQ 2GM BASE/VIAL	N62816 005	OCT 24, 1988	DEC	DISC
>A>		@	EQ 2GM BASE/VIAL	N62816 005	OCT 24, 1988	DEC	DISC
			OMNIPEN-N				
		@	WYETH AYERST	N60626 001		JUN	DISC
		@	EQ 125MG BASE/VIAL	N60626 002		JUN	DISC
		@	EQ 250MG BASE/VIAL	N60626 003		JUN	DISC
		@	EQ 500MG BASE/VIAL	N60626 004		JUN	DISC
		@	EQ 1GM BASE/VIAL	N60626 005		JUN	DISC
		@	EQ 2GM BASE/VIAL	N60626 005		JUN	DISC
>D>		TOTACILLIN-N					
>D>	AP	+	GLAXOSMITHKLINE	N60677 001		DEC	DISC
>A>		@	EQ 125MG BASE/VIAL	N60677 001		DEC	DISC
	AP	+	EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
>D>	AP	+	EQ 250MG BASE/VIAL	N60677 002		DEC	DISC
>A>		@	EQ 250MG BASE/VIAL	N60677 002		DEC	DISC
	AP	+	EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD
>D>	AP	+	EQ 500MG BASE/VIAL	N60677 003		DEC	DISC
>A>		@	EQ 500MG BASE/VIAL	N60677 003		DEC	DISC
	AP	+	EQ 500MG BASE/VIAL	N60677 003		JUN	CRLD

>D>	AP	+	EQ 1GM BASE/VIAL	N60677 004	DEC	DISC
>A>		@	EQ 1GM BASE/VIAL	N60677 004	DEC	DISC
	AP	+	EQ 1GM BASE/VIAL	N60677 004	JUN	CRLD
>D>	AP	+	EQ 2GM BASE/VIAL	N60677 005	DEC	DISC
>A>		@	EQ 2GM BASE/VIAL	N60677 005	DEC	DISC
	AP	+	EQ 2GM BASE/VIAL	N60677 005	JUN	CRLD
>D>			EQ 10GM BASE/VIAL	N60677 006	DEC	DISC
>A>		@	EQ 10GM BASE/VIAL	N60677 006	DEC	DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

@	WYETH AYERST	250MG	N60624 001	JUN	DISC
@		500MG	N60624 002	JUN	DISC

FOR SUSPENSION; ORAL

@	WYETH AYERST	100MG/ML	N60625 001	JUN	DISC
@		125MG/5ML	N60625 002	JUN	DISC
@		250MG/5ML	N60625 003	JUN	DISC

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	N61394 001	JUN	CTEC
-----------	------------------	------------	-----	------

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

	GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
+		150MG	N21007 002	APR 15, 1999	MAR	CMFD

SOLUTION; ORAL

+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD
---	-----------------	---------	------------	--------------	-----	------

APREPITANT

CAPSULE; ORAL

EMEND

	MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
+		125MG	N21549 002	MAR 26, 2003	MAR	NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+	ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN
---	----------	----------	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
 HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	AAIPHARMA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3 6MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	JUN	CTEC
---	-----------	--	------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986	MAR	CAHN
TABLET; ORAL						
AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986	MAR	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE NO 3

AB +	WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990	MAR	CAHN
------	---------------	----------------------	------------	--------------	-----	------

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

+	WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003	DEC 29, 1983	JUN	CTEC
---	----------------------	-------------	------------	--------------	-----	------

MICRAININ

@	MEDPOINTE PHARM HLC	325MG;200MG	N84978 001		JUN	DISC
---	---------------------	-------------	------------	--	-----	------

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

AB +	IVAX PHARMS	325MG;400MG	N87211 001	DEC 22, 1982	JUN	CRLD
------	-------------	-------------	------------	--------------	-----	------

ROBAXISAL

@	ROBINS AH	325MG;400MG	N12281 001		JUN	DISC
---	-----------	-------------	------------	--	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	AXIOM PHARM	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998	MAY	CAHN
----	-------------	--------------------	------------	--------------	-----	------

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

	BRISTOL MYERS SQUIBB	81MG;20MG	N21387 001	JUN 24, 2003	JUN	NEWA
--	----------------------	-----------	------------	--------------	-----	------

		81MG;40MG	N21387 002	JUN 24, 2003	JUN	NEWA
--	--	-----------	------------	--------------	-----	------

		81MG;80MG	N21387 003	JUN 24, 2003	JUN	NEWA
--	--	-----------	------------	--------------	-----	------

		325MG;20MG	N21387 004	JUN 24, 2003	JUN	NEWA
--	--	------------	------------	--------------	-----	------

		325MG;40MG	N21387 005	JUN 24, 2003	JUN	NEWA
--	--	------------	------------	--------------	-----	------

+		325MG;80MG	N21387 006	JUN 24, 2003	JUN	NEWA
---	--	------------	------------	--------------	-----	------

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

@	AAIPHARMA LLC	325MG;65MG	N10996 005		JUL	DISC
---	---------------	------------	------------	--	-----	------

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N21567 001	JUN 20, 2003	JUN	NEWA
--	----------------------	---------------	------------	--------------	-----	------

		EQ 150MG BASE	N21567 002	JUN 20, 2003	JUN	NEWA
--	--	---------------	------------	--------------	-----	------

+		EQ 200MG BASE	N21567 003	JUN 20, 2003	JUN	NEWA
---	--	---------------	------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

@ LILLY 5MG

N21411 001 NOV 26, 2002 MAY DISC

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+ MERIDIAN MEDCL TECHN EQ 0.5MG SULFATE/0.7ML

N17106 003 JUN 19, 2003 JUL NEWA

+ EQ 1MG SULFATE/0.7ML

N17106 002 JUN 19, 2003 JUL NEWA

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

@ ABBOTT 0.4MG/ML;75MG/ML

N87847 001 NOV 26, 1982 OCT WDAG

@ 0.4MG/ML;100MG/ML

N87848 001 NOV 26, 1982 OCT WDAG

@ 0.4MG/ML;50MG/ML

N87853 001 NOV 26, 1982 OCT WDAG

AZATHIOPRINE

TABLET; ORAL

AZASAN

AAIPHARMA LLC 25MG

N75252 002 FEB 03, 2003 FEB NEWA

AB 50MG

N75252 001 JUN 07, 1999 FEB NEWA

75MG

N75252 003 FEB 03, 2003 FEB NEWA

100MG

N75252 004 FEB 03, 2003 FEB NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+ MEDPOINTE 0.05%

N21127 001 MAY 22, 2000 APR CAHN

AZITHROMYCIN

TABLET; ORAL

ZITHROMAX

PFIZER EQ 500MG BASE

N50784 001 MAY 24, 2002 AUG CRLD

BACLOFEN

TABLET; ORAL

BACLOFEN

>D> AB IVAX PHARMS 20MG

N72235 001 JUL 21, 1988 DEC CRLD

>A> AB + 20MG

N72235 001 JUL 21, 1988 DEC CRLD

>D> AB WATSON LABS 10MG

N74698 001 AUG 20, 1996 DEC DISC

>A> @ 10MG

N74698 001 AUG 20, 1996 DEC DISC

>D> AB + 20MG

N73093 001 JAN 28, 1994 DEC DISC

>A> @ 20MG

N73093 001 JAN 28, 1994 DEC DISC

>D> AB 20MG

N74698 002 AUG 20, 1996 DEC DISC

>A> @ 20MG

N74698 002 AUG 20, 1996 DEC DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SCHWARZ PHARMA 10MG

N21589 001 OCT 30, 2003 OCT NEWA

+ 20MG

N21589 002 OCT 30, 2003 OCT NEWA

KEMSTRO

SCHWARZ PHARMA 10MG

N21589 001 OCT 30, 2003 NOV CTNA

+ 20MG N21589 002 OCT 30, 2003 NOV CTNA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

@ GLAXOSMITHKLINE 0.042MG/INH

N18153 001 MAR DISC

AEROSOL, METERED; NASAL

BECONASE

@ GLAXOSMITHKLINE 0.042MG/INH

N18584 001 MAR DISC

VANCENASE

@ SCHERING 0.042MG/INH

N18521 001 MAR DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ HOLLISTER STIER LABS 60UMOLAR

N50114 001 JUL CAHN

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

VASCOR

+ ORTHO MCNEIL PHARM 200MG

N19002 001 DEC 28, 1990 NOV CRLD

@ 300MG

N19002 002 DEC 28, 1990 NOV DISC

BETAMETHASONE

TABLET; ORAL

CELESTONE

@ SCHERING 0.6MG

N12657 003 FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

AB + SAVAGE LABS EQ 0.05% BASE

N19138 001 JUN 26, 1984 MAY CRLD

DIPROSONE

@ SCHERING EQ 0.05% BASE

N17536 001 MAY DISC

CREAM, AUGMENTED; TOPICAL

>A> BETAMETHASONE DIPROPIONATE

>A> AB ALTANA EQ 0.05% BASE

N76215 001 DEC 09, 2003 DEC NEWA

>A> AB CLAY PARK EQ 0.05% BASE

N76592 001 DEC 09, 2003 DEC NEWA

>A> AB TARO EQ 0.05% BASE

N76543 001 DEC 09, 2003 DEC NEWA

DIPROLENE AF

>D> + SCHERING EQ 0.05% BASE

N19555 001 APR 27, 1987 DEC CFTG

>A> AB + EQ 0.05% BASE

N19555 001 APR 27, 1987 DEC CFTG

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALTANA EQ 0.05% BASE

N75276 001 MAY 13, 2003 MAY NEWA

>A> AB TARO EQ 0.05% BASE

N76508 001 DEC 02, 2003 DEC NEWA

DIPROLENE

AB + SCHERING EQ 0.05% BASE

N19408 002 NOV 22, 1991 MAY CFTG

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA WOCKHARDT 5MG

N40532 001 SEP 29, 2003 SEP NEWA

AA		10MG	N40533 001	SEP 29, 2003	SEP	NEWA
AA		25MG	N40534 001	SEP 29, 2003	SEP	NEWA
AA		50MG	N40518 001	SEP 29, 2003	SEP	NEWA

URECHOLINE

AA +	ODYSSEY PHARMS	5MG	N89095 001	DEC 19, 1985	SEP	CFTG
AA +		10MG	N88440 001	MAY 29, 1984	SEP	CFTG
AA +		25MG	N88441 001	MAY 29, 1984	SEP	CFTG
AA +		50MG	N89096 001	DEC 19, 1985	SEP	CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB	DURAMED PHARMS BARR	5MG	N19982 002	JUL 31, 1992	JUN	CAHN
AB +		10MG	N19982 001	JUL 31, 1992	JUN	CAHN
AB	WYETH PHARMS INC	5MG	N19982 002	JUL 31, 1992	MAR	CAHN
AB +		10MG	N19982 001	JUL 31, 1992	MAR	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

AB	DURAMED PHARMS BARR	2.5MG;6.25MG	N20186 003	MAR 26, 1993	JUN	CAHN
AB		5MG;6.25MG	N20186 001	MAR 26, 1993	JUN	CAHN
AB +		10MG;6.25MG	N20186 002	MAR 26, 1993	JUN	CAHN
AB	WYETH PHARMS INC	2.5MG;6.25MG	N20186 003	MAR 26, 1993	MAR	CAHN
AB		5MG;6.25MG	N20186 001	MAR 26, 1993	MAR	CAHN
AB +		10MG;6.25MG	N20186 002	MAR 26, 1993	MAR	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

+	MEDICINES CO	250MG/VIAL	N20873 001	DEC 15, 2000	OCT	CAHN
---	--------------	------------	------------	--------------	-----	------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084 001	JUN 01, 1996	AUG	CAHN
AP		EQ 30 UNITS BASE/VIAL	N64084 002	JUN 01, 1996	AUG	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS

VELCADE

+	MILLENNIUM PHARMS	3.5MG/VIAL	N21602 001	MAY 13, 2003	MAY	NEWA
---	-------------------	------------	------------	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

Q	BAXTER HLTHCARE	50MG/ML	N70545 001	MAY 14, 1986	AUG	CAHN
Q		50MG/ML	N70546 001	MAY 14, 1986	AUG	CAHN
Q	ELKINS SINN	50MG/ML	N70545 001	MAY 14, 1986	JUN	DISC
Q		50MG/ML	N70546 001	MAY 14, 1986	JUN	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	ALCON	0.2%	N76254 001	SEP 16, 2003	SEP	NEWA
AT +	BAUSCH AND LOMB	0.2%	N76260 001	MAY 28, 2003	SEP	CFTG
+		0.2%	N76260 001	MAY 28, 2003	MAY	NEWA

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DC

@	ALPHARMA	2MG/5ML;10MG/5ML;12.5MG/5ML	N88723 001	FEB 25, 1985	NOV	DISC
---	----------	-----------------------------	------------	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DX

@	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N19279 001	AUG 24, 1984	MAR	DISC
---	-----------	---------------------------	------------	--------------	-----	------

MYPHETANE DX

AA +	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001	JUN 07, 1985	MAR	CTEC
------	--------------	---------------------------	------------	--------------	-----	------

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

@	ASTRAZENECA	0.032MG/INH	N20233 001	FEB 14, 1994	SEP	DISC
---	-------------	-------------	------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

+	AMPHASTAR	0.375% (37.5MG/10ML);1% (100MG/10ML)	N21496 001	MAY 23, 2003	MAY	NEWA
---	-----------	---	------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB	EON	100MG	N75932 001	NOV 25, 2003	NOV	NEWA
----	-----	-------	------------	--------------	-----	------

WELLBUTRIN SR

AB	GLAXOSMITHKLINE	100MG	N20358 002	OCT 04, 1996	NOV	CFTG
----	-----------------	-------	------------	--------------	-----	------

+		150MG	N20358 003	OCT 04, 1996	OCT	CRLD
---	--	-------	------------	--------------	-----	------

		200MG	N20358 004	JUN 14, 2002	OCT	CRLD
--	--	-------	------------	--------------	-----	------

WELLBUTRIN XL

>D>	SMITHKLINE BEECHAM	150MG	N21515 001	AUG 28, 2003	DEC	CRLD
-----	--------------------	-------	------------	--------------	-----	------

>A>	+	150MG	N21515 001	AUG 28, 2003	DEC	CRLD
-----	---	-------	------------	--------------	-----	------

		150MG	N21515 001	AUG 28, 2003	AUG	NEWA
--	--	-------	------------	--------------	-----	------

>D>	+	300MG	N21515 002	AUG 28, 2003	DEC	CRLD
-----	---	-------	------------	--------------	-----	------

>A>		300MG	N21515 002	AUG 28, 2003	DEC	CRLD
-----	--	-------	------------	--------------	-----	------

	+	300MG	N21515 002	AUG 28, 2003	AUG	NEWA
--	---	-------	------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB	EGIS	15MG	N75119 003	JAN 23, 2003	JAN	NEWA
----	------	------	------------	--------------	-----	------

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+	ESP PHARMA	6MG/ML	N20954 001	FEB 04, 1999	JUN	CAHN
---	------------	--------	------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+	MEAD JOHNSON	EQ 10MG BASE/ML	N20793 001	SEP 21, 1999	JUN	CAHN
---	--------------	-----------------	------------	--------------	-----	------

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP	AAIPHARMA	0.001MG/ML	N75766 001	FEB 20, 2003	FEB	NEWA
AP		0.002MG/ML	N75766 002	FEB 20, 2003	FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003	MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003	MAR	NEWA
AP	LUITPOLD	0.001MG/ML	N75746 001	SEP 26, 2003	SEP	NEWA
AP		0.002MG/ML	N75746 002	SEP 26, 2003	SEP	NEWA
AP	LYNE	0.001MG/ML	N76206 001	SEP 17, 2003	SEP	NEWA

SOLUTION; ORAL

AA	ROXANE	1UGM/ML	N76242 001	JUL 18, 2003	JUL	NEWA
	ROCALTROL					
AA +	ROCHE	1UGM/ML	N21068 001	NOV 20, 1998	JUL	CFTG

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

@	NABI	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	CAHN
---	------	-------------------	------------	--------------	-----	------

@		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	CAHN
---	--	------------------	------------	--------------	-----	------

PHOSLO GELCAPS

+	NABI	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	CAHN
---	------	------------------	------------	--------------	-----	------

TABLET; ORAL

PHOSLO

+	NABI	EQ 169MG CALCIUM	N19976 001	DEC 10, 1990	AUG	CAHN
---	------	------------------	------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	QOL MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML ;1.9MG/ML;7.3MG/ML;0.2MG/ML	N20577 001	SEP 27, 1996	MAY	CAHN
---	-----------	--	------------	--------------	-----	------

CARBAMAZEPINE

TABLET; ORAL

TERIL

AB	TARO	200MG	N76525 001	SEP 26, 2003	SEP	NEWA
----	------	-------	------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 100

	ORION PHARMA INC	25MG;200MG;100MG	N21485 002	JUN 11, 2003	JUN	NEWA
--	------------------	------------------	------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 150

+ ORION PHARMA INC	37.5MG;200MG;150MG	N21485 003	JUN 11, 2003	JUN	NEWA
--------------------	--------------------	------------	--------------	-----	------

STALEVO 50

ORION PHARMA INC	12.5MG;200MG;50MG	N21485 001	JUN 11, 2003	JUN	NEWA
------------------	-------------------	------------	--------------	-----	------

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

+ MIKART	4MG/5ML	N40458 001	APR 25, 2003	APR	NEWA
----------	---------	------------	--------------	-----	------

TABLET; ORAL

+ MIKART	4MG	N40442 001	MAR 19, 2003	MAR	NEWA
----------	-----	------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

+ BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452 001	JUL 14, 2003	JUL	NEWA
------------------------	-----------------------	------------	--------------	-----	------

+	EQ 150MG /15ML(10MG/ML)	N20452 002	JUL 14, 2003	JUL	NEWA
---	-------------------------	------------	--------------	-----	------

+	EQ 450MG /45ML(10MG/ML)	N20452 003	JUL 14, 2003	JUL	NEWA
---	-------------------------	------------	--------------	-----	------

CARVEDILOL

TABLET; ORAL

COREG

+ GLAXOSMITHKLINE	12.5MG	N20297 002	SEP 14, 1995	APR	CRLD
-------------------	--------	------------	--------------	-----	------

	25MG	N20297 001	SEP 14, 1995	APR	CRLD
--	------	------------	--------------	-----	------

CEFACTOR

CAPSULE; ORAL

CEFACTOR

AB	CEPH INTL	EQ 250MG BASE	N62205 001		OCT CTNA
----	-----------	---------------	------------	--	----------

AB		EQ 500MG BASE	N62205 002		OCT CTNA
----	--	---------------	------------	--	----------

>A> TABLET, CHEWABLE; ORAL

>A> RANICLOR

>A>	RANBAXY	EQ 125MG BASE	N65092 001	DEC 22, 2003	DEC NEWA
-----	---------	---------------	------------	--------------	----------

>A>		EQ 187MG BASE	N65092 002	DEC 22, 2003	DEC NEWA
-----	--	---------------	------------	--------------	----------

>A>		EQ 250MG BASE	N65092 003	DEC 22, 2003	DEC NEWA
-----	--	---------------	------------	--------------	----------

>A>	+	EQ 375MG BASE	N65092 004	DEC 22, 2003	DEC NEWA
-----	---	---------------	------------	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	RANBAXY	EQ 500MG BASE	N65015 001	JUN 22, 1999	OCT CAHN
----	---------	---------------	------------	--------------	----------

FOR SUSPENSION; ORAL

AB	RANBAXY	EQ 125MG BASE/5ML	N65115 001	MAR 26, 2003	MAR NEWA
----	---------	-------------------	------------	--------------	----------

AB		EQ 250MG BASE/5ML	N65115 002	MAR 26, 2003	MAR NEWA
----	--	-------------------	------------	--------------	----------

AB		EQ 500MG BASE/5ML	N65115 003	MAR 26, 2003	MAR NEWA
----	--	-------------------	------------	--------------	----------

DURICEF

AB	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		MAR CFTG
----	-----------------	-------------------	------------	--	----------

AB		EQ 250MG BASE/5ML	N50527 003		MAR CFTG
----	--	-------------------	------------	--	----------

AB	+	EQ 500MG BASE/5ML	N50527 001		MAR CFTG
----	---	-------------------	------------	--	----------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	N65047 001	SEP 18, 2001	OCT	CAHN
AP		EQ 1GM BASE/VIAL	N65047 002	SEP 18, 2001	OCT	CAHN

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

+	PURDUE PHARMA LP	200MG	N21222 001	AUG 29, 2001	MAY	CAHN
---	------------------	-------	------------	--------------	-----	------

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

@	LEDERLE	100MG/5ML	N50622 001	APR 28, 1989	APR	DISC
---	---------	-----------	------------	--------------	-----	------

TABLET; ORAL

@	LEDERLE	200MG	N50621 001	APR 28, 1989	APR	DISC
---	---------	-------	------------	--------------	-----	------

@		400MG	N50621 002	APR 28, 1989	APR	DISC
---	--	-------	------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	LUPIN	EQ 500MG BASE/VIAL	N65124 001	SEP 24, 2003	SEP	NEWA
----	-------	--------------------	------------	--------------	-----	------

AP		EQ 1GM BASE/VIAL	N65124 002	SEP 24, 2003	SEP	NEWA
----	--	------------------	------------	--------------	-----	------

AP		EQ 2GM BASE/VIAL	N65124 003	SEP 24, 2003	SEP	NEWA
----	--	------------------	------------	--------------	-----	------

CLAFORAN

AP	AVENTIS PHARMS	EQ 1GM BASE/VIAL	N62659 001	JAN 13, 1987	SEP	CTEC
----	----------------	------------------	------------	--------------	-----	------

AP		EQ 2GM BASE/VIAL	N62659 002	JAN 13, 1987	SEP	CTEC
----	--	------------------	------------	--------------	-----	------

>D> CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	+	AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 001	MAY 20, 1985	DEC	DISC
-----	---	----------------	-----------------	------------	--------------	-----	------

>A>	@		EQ 20MG BASE/ML	N50596 001	MAY 20, 1985	DEC	DISC
-----	---	--	-----------------	------------	--------------	-----	------

>D>	+		EQ 40MG BASE/ML	N50596 003	MAY 20, 1985	DEC	DISC
-----	---	--	-----------------	------------	--------------	-----	------

>A>	@		EQ 40MG BASE/ML	N50596 003	MAY 20, 1985	DEC	DISC
-----	---	--	-----------------	------------	--------------	-----	------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	BAXTER HLTHCARE	EQ 10GM BASE/VIAL	N65050 001	SEP 11, 2000	AUG	CAHN
----	-----------------	-------------------	------------	--------------	-----	------

MEFOXIN IN PLASTIC CONTAINER

+	MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993	MAR	CRLD
---	-------	-----------------	------------	--------------	-----	------

+		EQ 40MG BASE/ML	N63182 002	JAN 25, 1993	MAR	CRLD
---	--	-----------------	------------	--------------	-----	------

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	RANBAXY	EQ 100MG BASE	N65083 001	AUG 20, 2003	AUG	NEWA
----	---------	---------------	------------	--------------	-----	------

AB		EQ 200MG BASE	N65083 002	AUG 20, 2003	AUG	NEWA
----	--	---------------	------------	--------------	-----	------

VANTIN

AB	PHARMACIA AND UPJOHN	EQ 100MG BASE	N50674 001	AUG 07, 1992	AUG	CFTG
----	----------------------	---------------	------------	--------------	-----	------

AB	+	EQ 200MG BASE	N50674 002	AUG 07, 1992	AUG	CFTG
----	---	---------------	------------	--------------	-----	------

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

FUJISAWA HLTHCARE

EQ 1GM BASE/VIAL

N63294 002 MAR 31, 1994 AUG CAHN

EQ 2GM BASE/VIAL

N63294 003 MAR 31, 1994 AUG CAHN

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP LUPIN

EQ 250MG BASE/VIAL

N65125 001 SEP 30, 2003 SEP NEWA

AP

EQ 500MG BASE/VIAL

N65125 002 SEP 30, 2003 SEP NEWA

AP

EQ 1GM BASE/VIAL

N65125 003 SEP 30, 2003 SEP NEWA

AP

EQ 2GM BASE/VIAL

N65125 004 SEP 30, 2003 SEP NEWA

ROCEPHIN

AP + HLR

EQ 250MG BASE/VIAL

N50585 001 DEC 21, 1984 SEP CFTG

AP +

EQ 500MG BASE/VIAL

N50585 002 DEC 21, 1984 SEP CFTG

AP +

EQ 1GM BASE/VIAL

N50585 003 DEC 21, 1984 SEP CFTG

AP +

EQ 2GM BASE/VIAL

N50585 004 DEC 21, 1984 SEP CFTG

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB BIOCHEMIE US

EQ 250MG BASE

N65126 001 OCT 28, 2003 OCT NEWA

AB

EQ 500MG BASE

N65126 002 OCT 28, 2003 OCT NEWA

AB

LUPIN

EQ 250MG BASE

N65135 001 JUL 25, 2003 JUL NEWA

AB

EQ 500MG BASE

N65135 002 JUL 25, 2003 JUL NEWA

AB

RANBAXY

EQ 125MG BASE

N65118 001 APR 25, 2003 APR NEWA

AB

EQ 250MG BASE

N65118 002 APR 25, 2003 APR NEWA

AB

EQ 500MG BASE

N65118 003 APR 25, 2003 APR NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB CEPH INTL

EQ 250MG BASE

N62118 001 OCT CTNA

AB

EQ 500MG BASE

N62118 002 OCT CTNA

@ TEVA

EQ 250MG BASE

N62821 001 FEB 05, 1988 OCT WDAG

FOR SUSPENSION; ORAL

+ CEPH INTL

EQ 100MG BASE/ML

N62117 001 OCT CTNA

AB

EQ 125MG BASE/5ML

N62117 002 OCT CTNA

AB +

EQ 250MG BASE/5ML

N62117 003 OCT CTNA

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY

EQ 125MG BASE

N65100 002 SEP 11, 2003 SEP NEWA

+

EQ 250MG BASE

N65100 001 SEP 11, 2003 SEP NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

+ BRISTOL

EQ 1GM BASE/VIAL

N62464 001 MAY 07, 1984 MAR CRLD

+

EQ 2GM BASE/VIAL

N62464 002 MAY 07, 1984 MAR CRLD

+

EQ 4GM BASE/VIAL

N62464 003 MAY 07, 1984 MAR CRLD

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN

@ LILLY	EQ 1GM BASE/VIAL	N50482 001	MAR	DISC
@	EQ 2GM BASE/VIAL	N50482 002	MAR	DISC
@	EQ 4GM BASE/VIAL	N50482 003	MAR	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62720 001	JUL 02, 1987	AUG	CAHN
@	EQ 1GM BASE/VIAL	N62720 002	JUL 02, 1987	AUG	CAHN
@	EQ 2GM BASE/VIAL	N62720 003	JUL 02, 1987	AUG	CAHN
@	EQ 20GM BASE/VIAL	N62720 004	JUL 02, 1987	AUG	CAHN

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+ SMITHKLINE BEECHAM	2MG	N10669 002	OCT	CAHN
----------------------	-----	------------	-----	------

CHLORAMPHENICOL

CAPSULE; ORAL

MYCHEL

@ ARMENPHARM	250MG	N60851 001	JUL	DISC
--------------	-------	------------	-----	------

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

AT + ALTANA	1%	N60133 001	MAY	CRLD
-------------	----	------------	-----	------

CHLOROMYCETIN

@ PARKEDALE	1%	N50156 001	MAY	DISC
-------------	----	------------	-----	------

CHLOROPTIC S.O.P.

@ ALLERGAN	1%	N61187 001	JUN	DISC
------------	----	------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

CHLOROPTIC

@ ALLERGAN	0.5%	N50091 001	JUN	DISC
------------	------	------------	-----	------

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

@ PARKEDALE	0.5%	N50205 001	MAY	DISC
-------------	------	------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ GRUPPO LEPETIT	EQ 1GM BASE/VIAL	N62278 001	JUL	DISC
------------------	------------------	------------	-----	------

>D> CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

>D> OINTMENT; TOPICAL

>D> ELASE-CHLOROMYCETIN

>D> + PARKE DAVIS	10MG/GM;666 UNITS/GM;1 UNITS/GM	N50294 001	DEC	DISC
-------------------	---------------------------------	------------	-----	------

>A> @	10MG/GM;666 UNITS/GM;1 UNITS/GM	N50294 001	DEC	DISC
-------	---------------------------------	------------	-----	------

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HCL

@ SANOFI SYNTHELABO

EQ 40MG BASE/ML

N06002 002

JUN DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA IMPAX LABS

EQ 300MG BASE

N40516 001 AUG 29, 2003 AUG NEWA

@ WATSON LABS

EQ 150MG BASE

N87979 001 DEC 21, 1982 SEP DISC

@

EQ 300MG BASE

N88030 001 DEC 21, 1982 SEP DISC

AA + WEST WARD

EQ 150MG BASE

N83082 001 SEP CRLD

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

@ MERCK

150MG;250MG

N16016 001

MAY DISC

ALDOCLOR-250

@ MERCK

250MG;250MG

N16016 002

MAY DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP BAXTER HLTHCARE

25MG/ML

N83329 001

JUN CAHN

TABLET; ORAL

@ LEDERLE

10MG

N84803 001

JUN DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ CLONMEL HLTHCARE

25MG

N87451 001

JUL CAHN

@

50MG

N87450 001

JUL CAHN

>D> AB IVAX PHARMS

25MG

N88164 001 JAN 09, 1984 DEC DISC

>A> @

25MG

N88164 001 JAN 09, 1984 DEC DISC

>D> AB

50MG

N87176 001 DEC DISC

>A> @

50MG

N87176 001 DEC DISC

>D> AB MUTUAL PHARM

25MG

N89285 001 JUL 21, 1986 DEC DISC

>A> @

25MG

N89285 001 JUL 21, 1986 DEC DISC

>D> AB

50MG

N89286 001 JUL 21, 1986 DEC DISC

>A> @

50MG

N89286 001 JUL 21, 1986 DEC DISC

AB + MYLAN

50MG

N86831 001 OCT CRLD

>D> AB WATSON LABS

25MG

N87100 001 DEC DISC

>A> @

25MG

N87100 001 DEC DISC

HYGROTON

@ AVENTIS PHARMS

25MG

N12283 004 OCT DISC

@

50MG

N12283 003 OCT DISC

THALITONE

@ MONARCH PHARMS

25MG

N19574 002 FEB 12, 1992 MAY DISC

CHORIOGONADOTROPIN ALFA

>A>	INJECTABLE; SUBCUTANEOUS					
>A>	IVIDREL					
>A>	+ SERONO INC	0.25MG/0.5ML(0.5MG/ML)	N21149 002	OCT 06, 2003	DEC	NEWA

CICLOPIROX

SHAMPOO; TOPICAL

LOPROX

+ MEDICIS	1%	N21159 001	FEB 28, 2003	FEB	NEWA
-----------	----	------------	--------------	-----	------

SUSPENSION; TOPICAL

+ MEDICIS	0.77%	N19824 001	DEC 30, 1988	NOV	CDFR
-----------	-------	------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

PLETAL

+ OTSUKA	50MG	N20863 001	JAN 15, 1999	OCT	CRLD
----------	------	------------	--------------	-----	------

CIMETIDINE

SOLUTION; ORAL

CIMETIDINE HCL

AA	DURAMED PHARM BARR	300MG/5ML	N75110 001	JUN 18, 1998	AUG	CAIN
----	--------------------	-----------	------------	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

AA	+ ALPHARMA	EQ 300MG BASE/5ML	N74176 001	JUN 01, 1994	AUG	CRLD
----	------------	-------------------	------------	--------------	-----	------

AA	DURAMED PHARMS BARR	EQ 300MG BASE/5ML	N75110 001	JUN 18, 1998	AUG	CAIN
----	---------------------	-------------------	------------	--------------	-----	------

TAGAMET

@ GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N17924 001		AUG	DISC
-------------------	-------------------	------------	--	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPRO XR

+ BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473 002	AUG 28, 2003	AUG	NEWA
----------------	-------------------------	------------	--------------	-----	------

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

+ ALCON	0.3%;0.1%	N21537 001	JUL 18, 2003	JUL	NEWA
---------	-----------	------------	--------------	-----	------

CITRIC ACID; UREA, C-13

FOR SOLUTION; TABLET, FOR SOLUTION; ORAL

IDKIT:HP

@ ORIDION	4GM;75MG	N21314 001	DEC 17, 2002	JUL	DISC
-----------	----------	------------	--------------	-----	------

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

AP	+ ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	APR	CTEC
----	-----------------	--------	------------	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA +	TEVA	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994	JUN	CRLD
	TAVIST					
	@ NOVARTIS	EQ 0.5MG BASE/5ML	N18675 001	JUN 28, 1985	JUN	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB	WATSON LABS	EQ 300MG BASE	N63083 002	MAR 18, 2003	MAR	NEWA
----	-------------	---------------	------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	@ BAXTER HLTHCARE	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	AUG	CAHN
		EQ 150MG BASE/ML	N62889 001	APR 25, 1988	AUG	CAHN
	@	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	AUG	CAHN

CLOBETASOL PROPIONATE

LOTION; TOPICAL

CLOBEX

+	GALDERMA LABS LP	0.05%	N21535 001	JUL 24, 2003	JUL	NEWA
---	------------------	-------	------------	--------------	-----	------

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

@	WYETH AYERST	500MG	N16099 002		JUN	DISC
---	--------------	-------	------------	--	-----	------

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

	ROCHE	0.125MG	N20813 001	DEC 23, 1997	APR	CMFD
		0.25MG	N20813 002	DEC 23, 1997	APR	CMFD
		0.5MG	N20813 003	DEC 23, 1997	APR	CMFD
+		1MG	N20813 004	DEC 23, 1997	APR	CMFD
		2MG	N20813 005	DEC 23, 1997	APR	CMFD

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

>A>	+	AAIPHARMA	0.1MG/ML	N20615 001	OCT 02, 1996	DEC	CAHN
>D>	+	ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996	DEC	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@	CLONMEL HLTHCARE	3.75MG	N71742 001	DEC 14, 1987	JUN	DISC
@		7.5MG	N71743 001	DEC 14, 1987	JUN	DISC
@		15MG	N71744 001	DEC 14, 1987	JUN	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

	IVAX PHARMS	12.5MG	N74949 003	JUL 31, 2003	JUL	NEWA
AB +		100MG	N74949 002	NOV 26, 1997	SEP	CRLD
	CLOZARIL					
AB	NOVARTIS	100MG	N19758 002	SEP 26, 1989	SEP	CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

@ WYETH AYERST 10MG/5ML;5MG/5ML;6.25MG/5ML

N08306 005 APR 02, 1984 JUN DISC

PROMETH VC W/ CODEINE

AA +	ALPHARMA	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	OCT 31, 1984	JUN	CRLD
------	----------	-----------------------------	------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

@ WYETH AYERST 10MG/5ML;6.25MG/5ML

N08306 004 APR 02, 1984 JUN DISC

PROMETH W/ CODEINE

AA +	ALPHARMA	10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984	JUN	CRLD
------	----------	---------------------	------------	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

+ PHARMACIA AND UPJOHN 1GM

N20222 001 JUL 19, 1994 MAY CRLD

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

COPPER T MODEL TCU 380A

+ FEI 309MG/COPPER

N18680 001 NOV 15, 1984 MAR CAHN

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

@ ORGANICS LAGRANGE 40 UNITS/ML

N10831 001

NOV DISC

@ 80 UNITS/ML

N10831 002

NOV DISC

H.P. ACTHAR GEL

+ QUESTCOR PHARMS 80 UNITS/ML

N08372 008

NOV CTEC

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

BP +	PHARMACIA AND UPJOHN	25MG	N08126 001		APR	CRLD
------	----------------------	------	------------	--	-----	------

CORTONE

@ MERCK 25MG

N07750 003

APR DISC

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

+ AMPHASTAR 0.25MG/VIAL

N16750 001

JUN CAHN

<u>CROMOLYN SODIUM</u>									
SOLUTION/DROPS; OPHTHALMIC									
CROMOPTIC									
	@ KING PHARMS	4%		N75088 001	APR 27, 1999	MAY	DISC		
<u>CYANOCOBALAMIN</u>									
GEL, METERED; NASAL									
NASCOBAL									
	+ QUESTCOR PHARMS	0.5MG/INH		N19722 001	NOV 05, 1996	JUN	CAHN		
INJECTABLE; INJECTION									
CYANOCOBALAMIN									
	@ BAXTER HLTHCARE	1MG/ML		N80515 002		AUG	CAHN		
	@ ELKINS SINN	1MG/ML		N80515 002		JUN	DISC		
AP	PHARMAFORCE	1MG/ML		N40451 001	SEP 23, 2003	SEP	NEWA		
	@ WYETH AYERST	0.1MG/ML		N80554 001		JUN	DISC		
	@	1MG/ML		N80554 002		JUN	DISC		
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>									
TABLET; ORAL									
FLEXERIL									
AA	MCNEIL CONS SPECT	5MG		N17821 001		MAR	CMFD		
		5MG		N17821 001		APR	CTEC		
<u>CYCLOPHOSPHAMIDE</u>									
INJECTABLE; INJECTION									
NEOSAR									
	@ GENSLA SICOR PHARMS	100MG/VIAL		N40015 001	APR 29, 1993	AUG	DISC		
AP		100MG/VIAL		N87442 001	FEB 16, 1982	AUG	CAHN		
	@	200MG/VIAL		N40015 002	APR 29, 1993	AUG	DISC		
AP		200MG/VIAL		N87442 002	FEB 16, 1982	AUG	CAHN		
	@	500MG/VIAL		N40015 003	APR 29, 1993	AUG	DISC		
AP		500MG/VIAL		N87442 003	FEB 16, 1982	AUG	CAHN		
	@	1GM/VIAL		N40015 004	APR 29, 1993	AUG	DISC		
AP		1GM/VIAL		N87442 004	JUL 08, 1983	AUG	CAHN		
	@	2GM/VIAL		N40015 005	APR 29, 1993	AUG	DISC		
AP		2GM/VIAL		N87442 005	MAR 30, 1989	AUG	CAHN		
<u>CYCLOSPORINE</u>									
CAPSULE; ORAL									
GENGRAF									
AB1	ABBOTT	25MG		N65003 001	MAY 12, 2000	FEB	CTNA		
BX		50MG		N65003 002	MAY 12, 2000	FEB	CTNA		
AB1		100MG		N65003 003	MAY 12, 2000	FEB	CTNA		
EMULSION; OPHTHALMIC									
RESTASIS									
	+ ALLERGAN	0.05%		N50790 001	DEC 23, 2002	MAR	CMS1		
INJECTABLE; INJECTION									
CYCLOSPORINE									
AP	PHARMAFORCE	50MG/ML		N65151 001	OCT 07, 2003	OCT	NEWA		

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

AA	COREPHARMA	4MG	N40537 001	SEP 30, 2003	SEP	NEWA
----	------------	-----	------------	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

	@ SICOR PHARMS	100MG/VIAL	N16793 001		NOV	DISC
AP		100MG/VIAL	N75206 001	DEC 30, 1998	JUL	CAHN
	@	500MG/VIAL	N16793 002		NOV	DISC
AP +		500MG/VIAL	N75206 002	DEC 30, 1998	JUL	CAHN
	@	1GM/VIAL	N16793 003	DEC 21, 1987	NOV	DISC
AP		1GM/VIAL	N75206 004	DEC 30, 1998	JUL	CAHN
	@	2GM/VIAL	N16793 004	DEC 21, 1987	NOV	DISC
AP		2GM/VIAL	N75206 003	DEC 30, 1998	JUL	CAHN

CYTOSAR-U

AP +	GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN	CAHN
AP +		500MG/VIAL	N16793 002		JUN	CAHN
AP +		1GM/VIAL	N16793 003	DEC 21, 1987	JUN	CAHN
AP +		2GM/VIAL	N16793 004	DEC 21, 1987	JUN	CAHN
AP	SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	NOV	CTNA
AP +		500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CTNA
AP +		1GM/VIAL	N75206 004	DEC 30, 1998	NOV	CTNA
AP +		2GM/VIAL	N75206 003	DEC 30, 1998	NOV	CTNA

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB	CAHN
	@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB	CAHN

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

	CUBIST	250MG/VIAL	N21572 001	SEP 12, 2003	SEP	NEWA
+		500MG/VIAL	N21572 002	SEP 12, 2003	SEP	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

	@ ESP PHARMA	75MG	N50261 001		OCT	CAHN
		150MG	N50261 002		OCT	CAHN
+		300MG	N50261 003		OCT	CAHN
	@ WYETH PHARMS INC	75MG	N50261 001		MAR	CAHN
		150MG	N50261 002		MAR	CAHN
+		300MG	N50261 003		MAR	CAHN

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	AVENTIS PHARMS	15MG/VIAL	N21271 001	APR 04, 2003	APR	NEWA
---	----------------	-----------	------------	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE

AB +	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	MAY	CMS1
	MINIRIN					
AB +	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	JUN	CTNA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

ORTHO-CEPT

@ ORTHO MCNEIL PHARM 0.15MG;0.03MG

N20301 001 DEC 14, 1992 MAR DISC

TABLET; ORAL-28

AB +	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002	DEC 14, 1992	MAR	CRLD
------	--------------------	---------------	------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	CLAY PARK	0.25%	N76510 001	JUL 01, 2003	JUL	NEWA
----	-----------	-------	------------	--------------	-----	------

DEXAMETHASONE

ELIXIR; ORAL

DECADRON

@ MERCK 0.5MG/5ML

N12376 002 APR DISC

HEXADROL

AA +	ORGANON	0.5MG/5ML	N12674 001		APR	CRLD
------	---------	-----------	------------	--	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

AP	BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	N84282 001		AUG	CAHN
----	-----------------	---------------------	------------	--	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

AP	AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003	APR	NEWA
----	----------	----------------------	------------	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

@ MERCK EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML

N50322 001 MAY DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

MYLARAMINE

+ MORTON GROVE 2MG/5ML

N88251 001 MAR 23, 1984 OCT CRLD

POLARAMINE

@ SCHERING 2MG/5ML

N86837 001 JUL 19, 1982 OCT DISC

TABLET; ORAL

DEXCHLORPHENIRAMINE MALEATE

+ PLIVA 2MG

N88682 001 JAN 17, 1986 OCT CRLD

POLARAMINE

@ SCHERING 2MG

N86835 001 OCT DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	GLAXOSMITHKLINE	5MG	N17078 001		JUL	CRLD
AB		10MG	N17078 002		JUL	CRLD
<u>DEXTROAMPHETAMINE SULFATE</u>						
AB	MALLINCKRODT	5MG	N76353 001	MAY 06, 2003	MAY	NEWA
AB		10MG	N76353 002	MAY 06, 2003	MAY	NEWA
AB		15MG	N76353 003	MAY 06, 2003	MAY	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ DEXTROMETHORPHAN

@ WYETH AYERST 15MG/5ML;6.25MG/5ML

N11265 002 APR 02, 1984 JUN DISC

PROMETH W/ DEXTROMETHORPHAN

AA + ALPHARMA 15MG/5ML;6.25MG/5ML

N88762 001 OCT 31, 1984 JUN CRLD

DIAZEPAM

GEL; RECTAL

DIASTAT

XCEL PHARMS 2.5MG/0.5ML

N20648 001 JUL 29, 1997 OCT CRLD

INJECTABLE; INJECTION

DIAZEPAM

@ BAXTER HLTHCARE

5MG/ML

N71308 001 JUL 17, 1987 AUG CAHN

AP 5MG/ML

N71309 001 JUL 17, 1987 AUG CAHN

AP 5MG/ML

N71310 001 JUL 17, 1987 AUG CAHN

@ ELKINS SINN 5MG/ML

N70311 001 DEC 16, 1985 JUN DISC

@ 5MG/ML

N70312 001 DEC 16, 1985 JUN DISC

@ 5MG/ML

N70313 001 DEC 16, 1985 JUN DISC

TABLET; ORAL

@ CLONMEL HLTHCARE

5MG

N70227 001 SEP 26, 1985 AUG DISC

@ 10MG

N70228 001 SEP 26, 1985 AUG DISC

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

@ MERCK 50MG

N11366 001 MAY DISC

DICLOXACILLIN SODIUM

CAPSULE; ORAL

PATHOCIL

@ WYETH AYERST EQ 250MG BASE

N50011 002 JUN DISC

@ EQ 500MG BASE

N50011 003 MAR 28, 1983 JUN DISC

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

+ APOTHECON EQ 62.5MG BASE/5ML

N61455 001 JUN CTEC

PATHOCIL

@ WYETH AYERST EQ 62.5MG BASE/5ML

N50092 001 JUN DISC

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

>D>	AB +	AVENTIS PHARMS	10MG	N07409 003	OCT 15, 1984	DEC	CAHN
>A>	AB +	AXCAN SCANDIPHARM	10MG	N07409 003	OCT 15, 1984	DEC	CAHN
		INJECTABLE; INJECTION					
	AP +	AXCAN SCANDIPHARM	10MG/ML	N08370 001	OCT 15, 1984	NOV	CAHN
		BENTYL PRESERVATIVE FREE					
	AP +	AXCAN SCANDIPHARM	10MG/ML	N08370 002	OCT 15, 1984	NOV	CAHN
		DICYCLOMINE HCL (PRESERVATIVE-FREE)					
	AP	BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN	NEWA
		SYRUP; ORAL					
		BENTYL					
		+ AXCAN SCANDIPHARM	10MG/5ML	N07961 002	OCT 15, 1984	NOV	CAHN
		TABLET; ORAL					
>D>	AB +	AVENTIS PHARMS	20MG	N07409 001	OCT 15, 1984	DEC	CAHN
>A>	AB +	AXCAN SCANDIPHARM	20MG	N07409 001	OCT 15, 1984	DEC	CAHN

DIENESTROL

CREAM; VAGINAL

DIENESTROL

		@ ORTHO MCNEIL	0.01%	N06110 005		AUG	DISC
--	--	----------------	-------	------------	--	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

	AP	SABEX 2002	0.25MG/ML	N40481 001	AUG 21, 2003	AUG	NEWA
		@ WYETH AYERST	0.25MG/ML	N84386 001		JUN	DISC
		TABLET; ORAL					
	AB	CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
	AB		0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

	AP +	XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG
		DIHYDROERGOTAMINE MESYLATE					
	AP	BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA
	AP	PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>D>	AB3 +	AVENTIS PHARMS	120MG	N20062 001	AUG 10, 1992	DEC	CAHN
>D>	AB3 +		180MG	N20062 002	DEC 27, 1991	DEC	CAHN
>D>	AB3 +		240MG	N20062 003	DEC 27, 1991	DEC	CAHN
>D>	AB3 +		300MG	N20062 004	DEC 27, 1991	DEC	CAHN
>D>	BC +		360MG	N20062 005	AUG 24, 1999	DEC	CAHN
	BC +		360MG	N20062 005	AUG 24, 1999	OCT	NEWA
>A>	AB3 +	BIOVAIL	120MG	N20062 001	AUG 10, 1992	DEC	CAHN
>A>	AB3 +		180MG	N20062 002	DEC 27, 1991	DEC	CAHN
>A>	AB3 +		240MG	N20062 003	DEC 27, 1991	DEC	CAHN

>A>	AB3 +	300MG	N20062 004	DEC 27, 1991	DEC	CAHN
>A>	BC +	360MG	N20062 005	AUG 24, 1999	DEC	CAHN
	TAZTIA XT					
	AB4	ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR NEWA
	AB4		180MG	N75401 002	APR 10, 2003	APR NEWA
	AB4		240MG	N75401 003	APR 10, 2003	APR NEWA
	AB4		300MG	N75401 004	APR 10, 2003	APR NEWA
	AB4		360MG	N75401 005	APR 10, 2003	APR NEWA
	TIAZAC					
	AB4 +	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR CFTG
	AB4		120MG	N20401 001	SEP 11, 1995	AUG CRLD
	AB4 +		180MG	N20401 002	SEP 11, 1995	APR CFTG
	AB4		180MG	N20401 002	SEP 11, 1995	AUG CRLD
	AB4 +		240MG	N20401 003	SEP 11, 1995	APR CFTG
	AB4		240MG	N20401 003	SEP 11, 1995	AUG CRLD
	AB4 +		300MG	N20401 004	SEP 11, 1995	APR CFTG
	AB4		300MG	N20401 004	SEP 11, 1995	AUG CRLD
	AB4 +		360MG	N20401 005	SEP 11, 1995	APR CFTG
	AB4		360MG	N20401 005	SEP 11, 1995	AUG CRLD
	INJECTABLE; INJECTION					
	DILTIAZEM HCL					
AP +	BEDFORD	5MG/ML	N74617 001	FEB 28, 1996	AUG	CRLD
	TABLET, EXTENDED RELEASE; ORAL					
	CARDIZEM LA					
	+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB NEWA
	+		180MG	N21392 002	FEB 06, 2003	FEB NEWA
	+		240MG	N21392 003	FEB 06, 2003	FEB NEWA
	+		300MG	N21392 004	FEB 06, 2003	FEB NEWA
	+		360MG	N21392 005	FEB 06, 2003	FEB NEWA
	+		420MG	N21392 006	FEB 06, 2003	FEB NEWA
	<u>DILTIAZEM MALATE</u>					
	TABLET, EXTENDED RELEASE; ORAL					
	TIAMATE					
	@	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY DISC
	@		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY DISC
	@		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY DISC
	<u>DIMENHYDRINATE</u>					
	INJECTABLE; INJECTION					
	DIMENHYDRINATE					
	@	BAXTER HLTHCARE	50MG/ML	N84767 001		AUG CAHN
	+	STERIS	50MG/ML	N80615 001		JUN CTEC
	@	WYETH AYERST	50MG/ML	N84316 001		JUN DISC
	<u>DIMETHYL SULFOXIDE</u>					
	SOLUTION; INTRAVESICAL					
	RIMSO-50					
AT +	EDWARDS LIFESCIENCES	50%	N17788 001		JUL	CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ IMCOR

0.92MG/VIAL;0.092MG/VIAL

N21191 001 MAY 31, 2002 AUG CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP BAXTER HLTHCARE 50MG/ML
 @ 50MG/ML
 @ WYETH AYERST 50MG/ML

N80817 002 JUN CAHN
 N83183 001 AUG CAHN
 N80577 001 JUN DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D> AP BEDFORD 5MG/ML
 >A> AP + 5MG/ML
 >D> IV PERSANTINE
 >D> AP + BOEHRINGER INGELHEIM 5MG/ML
 >A> @ 5MG/ML

N74939 001 APR 13, 1998 DEC CRLD
 N74939 001 APR 13, 1998 DEC CRLD
 N19817 001 DEC 13, 1990 DEC DISC
 N19817 001 DEC 13, 1990 DEC DISC

TABLET; ORAL

DIPYRIDAMOLE

AB CLONMEL HLTHCARE 25MG
 @ 25MG
 AB 50MG
 AB 75MG
 @ 75MG

N88999 001 FEB 05, 1991 JUL CAHN
 N88999 001 FEB 05, 1991 AUG DISC
 N89000 001 FEB 05, 1991 JUL CAHN
 N89001 001 FEB 05, 1991 JUL CAHN
 N89001 001 FEB 05, 1991 AUG DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

@ BAXTER HLTHCARE EQ 12.5MG BASE/ML
 @ ELKINS SINN EQ 12.5MG BASE/ML

N74381 001 SEP 26, 1996 AUG CAHN
 N74381 001 SEP 26, 1996 JUN DISC

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

ANZEMET

AVENTIS PHARMS

EQ 12.5MG BASE/0.625ML
 EQ 12.5MG BASE/0.625ML
 + EQ 100MG BASE/5ML
 + EQ 500MG BASE/25ML

N20624 002 SEP 11, 1997 JUL CPOT
 N20624 002 SEP 11, 1997 SEP CPOT
 N20624 001 SEP 11, 1997 SEP CPOT
 N20624 003 DEC 11, 2001 SEP NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

@ BAXTER HLTHCARE 40MG/ML
 @ 80MG/ML

N18398 001 JUN DISC
 N18398 002 MAR 22, 1982 JUN DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP + BAXTER HLTHCARE CORP 20MG/ML

N14879 001 JAN CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HCL

AP	BEDFORD	20MG/ML	N76266 001	JAN 10, 2003	JAN	NEWA
----	---------	---------	------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

@ PHARMACIA AND UPJOHN 150MG/VIAL

N50467 004	JUL 22, 1987	JUL	DISC
------------	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	AXIOM PHARM	EQ 50MG BASE	N65041 001	APR 28, 2000	MAY	CAHN
AB		EQ 100MG BASE	N65041 002	APR 28, 2000	MAY	CAHN
	+ RANBAXY	EQ 75MG BASE	N65053 003	SEP 10, 2003	OCT	NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	EQ 50MG BASE	N61717 001		MAY	CAHN
AB		EQ 100MG BASE	N61717 002		MAY	CAHN

CAPSULE, COATED PELLETS; ORAL

DORYX

FAULDING

EQ 75MG BASE

N50582 002	AUG 13, 2001	FEB	NEWA
------------	--------------	-----	------

INJECTABLE; INJECTION

DOXY 100

+ AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983	MAR	CRLD
---------------------	--------------------	------------	--------------	-----	------

DOXY 200

+ AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983	MAR	CRLD
---------------------	--------------------	------------	--------------	-----	------

DOXYCYCLINE

@ BAXTER HLTHCARE

EQ 100MG BASE/VIAL

N62450 001	OCT 27, 1983	AUG	CAHN
------------	--------------	-----	------

@

EQ 200MG BASE/VIAL

N62450 002	OCT 27, 1983	AUG	CAHN
------------	--------------	-----	------

DOXYCYCLINE HYCLATE

@ BAXTER HLTHCARE

EQ 100MG BASE/VIAL

N62992 001	FEB 16, 1989	AUG	CAHN
------------	--------------	-----	------

@

EQ 200MG BASE/VIAL

N62992 002	FEB 16, 1989	AUG	CAHN
------------	--------------	-----	------

VIBRAMYCIN

@ PFIZER

EQ 100MG BASE/VIAL

N50442 002		MAR	DISC
------------	--	-----	------

@

EQ 200MG BASE/VIAL

N50442 001		MAR	DISC
------------	--	-----	------

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	EQ 100MG BASE	N62269 002	NOV 08, 1982	MAY	CAHN
AB	WEST WARD	EQ 100MG BASE	N65095 001	JUL 02, 2003	JUL	NEWA

DOXYCYCLINE HYLATE

@ AXIOM PHARM

EQ 50MG BASE

N62269 003		MAY	CAHN
------------	--	-----	------

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

REVERSOL

@ ORGANON

10MG/ML

N89624 001	MAY 13, 1988	MAY	DISC
------------	--------------	-----	------

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAX

PFIZER IRELAND	EQ 20MG BASE
+	EQ 40MG BASE

N21016 001	DEC 26, 2002	MAR	CAHN
N21016 002	DEC 26, 2002	MAR	CAHN

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+	GILEAD	200MG
---	--------	-------

N21500 001	JUL 02, 2003	JUL	NEWA
------------	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	IVAX PHARMS	5MG;12.5MG
AB		10MG;25MG

N75736 001	MAR 25, 2003	MAR	NEWA
N75736 002	MAR 25, 2003	MAR	NEWA

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+	ROCHE	90MG/VIAL
---	-------	-----------

N21481 001	MAR 13, 2003	MAR	NEWA
------------	--------------	-----	------

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

+	AVENTIS	300MG/3ML
---	---------	-----------

N20164 009	JAN 23, 2003	JAN	NEWA
------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

+	ALLERGAN	0.05%
---	----------	-------

N21565 001	OCT 16, 2003	OCT	NEWA
------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT

+	HOLLISTER STIER LABS	0.3MG /DELIVERY
---	----------------------	-----------------

N20800 001	MAY 30, 2003	MAY	NEWA
------------	--------------	-----	------

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@	ASTRAZENECA	0.005MG/ML;1%
@	DENTSPLY PHARM	0.005MG/ML;1.5%

N17751 006		OCT	WDAG
N21384 001		MAR	DISC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

@	ELKINS SINN	0.01MG/ML;1%
@		0.01MG/ML;2%

N80406 001		JUN	DISC
N80406 002		JUN	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENC

+ PHARMACIA AND UPJOHN 2MG/ML

N50778 001 SEP 15, 1999 NOV CTEC

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

BIOVAIL

EQ 300MG BASE

N20738 004 DEC 22, 1997 JUL CAHN

EQ 400MG BASE

N20738 005 DEC 22, 1997 JUL CAHN

+ EQ 600MG BASE

N20738 006 MAY 27, 1999 JUL CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

BIOVAIL

600MG;12.5MG

N21268 001 NOV 01, 2001 JUL CAHN

+ 600MG;25MG

N21268 002 NOV 01, 2001 JUL CAHN

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ HARVEST PHARMS 2MG

N87693 001 FEB 24, 1983 MAR CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL

STATICIN

+ WESTWOOD SQUIBB 1.5%

N50526 001 APR CTEC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN

@ ELKINS SINN

EQ 500MG BASE/VIAL

N62563 001 MAR 28, 1985 JUN DISC

@

EQ 1GM BASE/VIAL

N62563 002 MAR 28, 1985 JUN DISC

ERYTHROMYCIN LACTOBIONATE

AP BAXTER HLTHCARE EQ 500MG BASE/VIAL

N62993 001 MAY 09, 1989 AUG CAHN

AP EQ 1GM BASE/VIAL

N62993 002 MAY 09, 1989 AUG CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

@ FOREST LABS

5MG

N21323 001 AUG 14, 2002 NOV DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+ BAXTER HLTHCARE CORP 10MG/ML

N19386 006 FEB 25, 2003 JUN NEWA

+ 20MG/ML

N19386 007 MAY 28, 2003 JUN NEWA

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 2GM/100ML

N19386 005 JAN 27, 2003 MAR NEWA

BREVIBLOC IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 1GM/100ML

N19386 004 FEB 16, 2001 MAR NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

BX + BERLEX LABS 0.0375MG/24HR
 + 0.06MG/24HR

N20375 005 MAY 27, 2003 JUN NEWA
 N20375 006 MAY 27, 2003 JUN NEWA

TABLET; ORAL

ESTRADIOL

@ CLONMEL HLTHCARE 0.5MG
 @ 1MG
 @ 2MG

N40275 001 DEC 29, 1998 AUG DISC
 N40275 002 DEC 29, 1998 AUG DISC
 N40275 003 DEC 29, 1998 AUG DISC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD 0.05MG/24HR
 + 0.1MG/24HR

N21367 001 MAR 20, 2003 MAR NEWA
 N21367 002 MAR 20, 2003 MAR NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

@ PHARMACIA AND UPJOHN 5MG/0.5ML;25MG/0.5ML

N20874 001 OCT 05, 2000 AUG DISC

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

@ PHARMACIA AND UPJOHN 2MG/ML;50MG/ML

N17968 001 MAY WDAG

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ NOVAVAX 0.25%

N21371 001 OCT 09, 2003 OCT NEWA

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+ BERLEX LABS 0.045MG/24HR;0.015MG/24HR

N21258 001 NOV 21, 2003 NOV NEWA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ KING PHARMS 1MG;1MG;0.09MG

N21040 001 OCT 22, 1999 MAY CTNA

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM

N20216 001 MAR CAHN

INJECTABLE; INJECTION

+ WYETH PHARMS INC 25MG/VIAL

N10402 001 MAR CAHN

TABLET; ORAL

WYETH PHARMS INC 0.3MG
 0.45MG
 + 0.625MG

N04782 003 MAR CAHN
 N04782 006 JUL 16, 2003 JUL NEWA
 N04782 004 MAR CAHN

	0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
+	1.25MG	N04782 001		MAR	CAHN
	2.5MG	N04782 002		MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATETABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@ WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	MAR	CAHN
--------------------	---------------------	------------	--------------	-----	------

PREMPHASE 14/14

+	WYETH PHARMS INC	0.625MG;0.625MG;5MG	N20527 002	NOV 17, 1995	MAR	CAHN
---	------------------	---------------------	------------	--------------	-----	------

PREMPRO

+	WYETH PHARMS INC	0.3MG;1.5MG	N20527 005	JUN 04, 2003	JUN	NEWA
---	------------------	-------------	------------	--------------	-----	------

+		0.45MG;1.5MG	N20527 004	MAR 12, 2003	MAR	NEWA
---	--	--------------	------------	--------------	-----	------

+		0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	MAR	CAHN
---	--	-----------------------------	------------	--------------	-----	------

+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	MAR	CAHN
---	--	-------------------------	------------	--------------	-----	------

PREMPRO (PREMARIN;CYCRIN)

@ WYETH PHARMS INC	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	MAR	CAHN
--------------------	-----------------------------	------------	--------------	-----	------

ESTROGENS, ESTERIFIEDTABLET; ORAL

MENEST

MONARCH PHARMS	0.3MG	N84951 001		JAN	CRLD
----------------	-------	------------	--	-----	------

ETHACRYNIC ACIDTABLET; ORAL

EDECIN

+	MERCK	25MG	N16092 001		MAY	CRLD
---	-------	------	------------	--	-----	------

@		50MG	N16092 002		MAY	DISC
---	--	------	------------	--	-----	------

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL

ETHAMBUTOL HCL

AB +	WEST WARD	400MG	N75095 002	NOV 30, 1999	JUN	CRLD
------	-----------	-------	------------	--------------	-----	------

MYAMBUTOL

@	LEDERLE	100MG	N16320 001		JUN	DISC
---	---------	-------	------------	--	-----	------

@		400MG	N16320 003		JUN	DISC
---	--	-------	------------	--	-----	------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-28

DEMULEN 1/35-28

AB +	GD SEARLE LLC	0.035MG;1MG	N18160 001		JUL	CRLD
------	---------------	-------------	------------	--	-----	------

ETHINYL ESTRADIOL; ETONOGESTRELRING; VAGINAL

NUVARING

+	ORGANON USA INC	0.015MG;0.12MG	N21187 001	OCT 03, 2001	JUN	CAHN
---	-----------------	----------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL

SEASONALE

+	BARR	0.03MG;0.15MG	N21544 001	SEP 05, 2003	SEP	NEWA
---	------	---------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB1 +	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL					

AB1	BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003	APR	NEWA
-----	------	--------------	------------	--------------	-----	------

NORDETTE-21

>A>	AB +	MONARCH PHARMS	0.03MG;0.15MG	N18668 001	MAY 10, 1982	DEC	CAHN
-----	------	----------------	---------------	------------	--------------	-----	------

>D>	AB +	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982	DEC	CAHN
-----	------	------------------	---------------	------------	--------------	-----	------

AB +		0.03MG;0.15MG	N18668 001	MAY 10, 1982	MAR	CAHN
------	--	---------------	------------	--------------	-----	------

TRIPHASIL-21

AB +	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; 0.075MG	N19192 001	NOV 01, 1984	MAR	CAHN
------	------------------	---	------------	--------------	-----	------

TABLET; ORAL-28

ALESSE

AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN
-----	------------------	--------------	------------	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003	APR	NEWA
-----	------	--------------	------------	--------------	-----	------

NORDETTE-28

>A>	AB	MONARCH PHARMS	0.03MG;0.15MG	N18782 001	JUL 21, 1982	DEC	CAHN
-----	----	----------------	---------------	------------	--------------	-----	------

>D>	AB	WYETH PHARMS INC	0.03MG;0.15MG	N18782 001	JUL 21, 1982	DEC	CAHN
-----	----	------------------	---------------	------------	--------------	-----	------

AB		0.03MG;0.15MG	N18782 001	JUL 21, 1982	MAR	CAHN
----	--	---------------	------------	--------------	-----	------

TRIPHASIL-28

AB	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; 0.075MG	N19190 001	NOV 01, 1984	MAR	CAHN
----	------------------	---	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+	ORTHO MCNEIL PHARM	0.02MG/24HR;0.15MG/24HR	N21180 001	NOV 20, 2001	NOV	CPOT
---	--------------------	-------------------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

AB +	WATSON LABS	0.035MG;0.5MG	N17566 001		AUG	CRLD
------	-------------	---------------	------------	--	-----	------

MODICON 21

@	ORTHO MCNEIL PHARM	0.035MG;0.5MG	N17488 001		AUG	DISC
---	--------------------	---------------	------------	--	-----	------

ORTHO-NOVUM 1/35-21

@	ORTHO MCNEIL PHARM	0.035MG;1MG	N17489 002		AUG	DISC
---	--------------------	-------------	------------	--	-----	------

ORTHO-NOVUM 10/11-21

@	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 001	JAN 11, 1982	AUG	DISC
---	--------------------	---------------------------	------------	--------------	-----	------

ORTHO-NOVUM 7/7/7-21

@	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 001	APR 04, 1984	AUG	DISC
---	--------------------	--	------------	--------------	-----	------

TRI-NORINYL 21-DAY

@	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977 001	APR 13, 1984	MAR	CPOT
---	-------------	---	------------	--------------	-----	------

@		0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984	FEB	DISC
---	--	---------------------------	------------	--------------	-----	------

TABLET; ORAL-28

ORTHO-NOVUM 7/7/7-28

AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 002	APR 04, 1984	FEB	CRLD
------	--------------------	--	------------	--------------	-----	------

OVCON-35					
+ WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		JAN	CRLD
OVCON-50					
+ WARNER CHILCOTT	0.05MG;1MG	N17576 001		JAN	CRLD
TRI-NORINYL 28-DAY					
+ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977 002	APR 13, 1984	MAR	CPOT
	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984	JAN	CRLD
TABLET, CHEWABLE; ORAL-28					
OVCON-35					
+ WARNER CHILCOTT	0.035MG;0.4MG	N21490 001	NOV 14, 2003	NOV	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL					
FEMHRT					
	+ GALEN CHEM	0.005MG;1MG	N21065 002	OCT 15, 1999	MAY CAHN
TABLET; ORAL-21					
ESTROSTEP 21					
	@ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	APR CAHN
	JUNEL 1.5/30				
AB	BARR	0.03MG;1.5MG	N76381 001	MAY 30, 2003	MAY NEWA
	JUNEL 1/20				
AB	BARR	0.02MG;1MG	N76380 001	MAY 30, 2003	MAY NEWA
LOESTRIN 21 1.5/30					
	+ GALEN CHEM	0.03MG;1.5MG	N17875 001		APR CAHN
AB	+	0.03MG;1.5MG	N17875 001		MAY CFTG
LOESTRIN 21 1/20					
	+ GALEN CHEM	0.02MG;1MG	N17876 001		APR CAHN
AB	+	0.02MG;1MG	N17876 001		MAY CFTG
TABLET; ORAL-28					
ESTROSTEP FE					
	+ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 002	OCT 09, 1996	APR CAHN
	JUNEL FE 1.5/30				
AB	BARR	0.03MG;1.5MG	N76064 001	SEP 18, 2003	SEP NEWA
	JUNEL FE 1/20				
AB	BARR	0.02MG;1MG	N76081 001	SEP 18, 2003	SEP NEWA
LOESTRIN FE 1.5/30					
AB	+ GALEN CHEM	0.03MG;1.5MG	N17355 001		APR CAHN
LOESTRIN FE 1/20					
AB	+ GALEN CHEM	0.02MG;1MG	N17354 001		APR CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28					
TRI-SPRINTEC					
>A>	AB	BARR	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N75808 001	DEC 29, 2003 DEC NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21					
LO/OVRAL					
AB	+	WYETH PHARMS INC	0.03MG;0.3MG	N17612 001	MAR CAHN
OGESTREL 0.5/50-21					
AB		WATSON LABS	0.05MG;0.5MG	N75406 001	DEC 15, 1999 FEB CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21					
OVRAL					
AB +	WYETH PHARMS INC	0.05MG;0.5MG	N16672 001		MAR CAHN
TABLET; ORAL-28					
LO/OVRAL-28					
AB	WYETH PHARMS INC	0.03MG;0.3MG	N17802 001		MAR CAHN
OGESTREL 0.5/50-28					
AB	WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999	FEB CAHN
OVRAL-28					
AB	WYETH PHARMS INC	0.05MG;0.5MG	N16806 001		MAR CAHN

ETHIONAMIDE

TABLET; ORAL					
TRECATOR-SC					
+	WYETH PHARMS INC	250MG	N13026 002		MAR CAHN

ETHOSUXIMIDE

SYRUP; ORAL					
ETHOSUXIMIDE					
>A> AA	MIKART	250MG/5ML	N40506 001	DEC 22, 2003	DEC NEWA

ETHOTOIN

TABLET; ORAL					
PEGANONE					
+	OVATION PHARMS	250MG	N10841 001		MAR CAHN
a		500MG	N10841 003		MAR CAHN

ETIDRONATE DISODIUM

TABLET; ORAL					
DIDRONEL					
AB	PROCTER AND GAMBLE	200MG	N17831 001		JUL CTEC
AB +		400MG	N17831 002		JUL CTEC
ETIDRONATE DISODIUM					
AB	GENPHARM	200MG	N75800 001	JAN 24, 2003	JAN NEWA
AB		400MG	N75800 002	JAN 24, 2003	JAN NEWA

ETODOLAC

CAPSULE; ORAL					
LODINE					
AB	WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991	MAR CAHN
AB +		300MG	N18922 003	JAN 31, 1991	MAR CAHN
TABLET; ORAL					
AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993	MAR CAHN
AB +		500MG	N18922 005	JUN 28, 1996	MAR CAHN
TABLET, EXTENDED RELEASE; ORAL					
ETODOLAC					
AB	TARO	400MG	N76174 001	MAR 13, 2003	MAR NEWA
AB		500MG	N76174 002	MAR 13, 2003	MAR NEWA
AB		600MG	N76174 003	MAR 13, 2003	MAR NEWA

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB	+	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996	MAR	CAHN
AB	+		500MG	N20584 003	JAN 20, 1998	MAR	CAHN
AB	+		600MG	N20584 002	OCT 25, 1996	MAR	CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP		SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994	JUL	CAHN
AP			20MG/ML	N74529 001	JUL 24, 1996	JUL	CAHN
TOPOSAR							
AP		GENSIA SICOR PHARMS	20MG/ML	N74166 001	FEB 27, 1995	JUL	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP		BAXTER HLTHCARE	10MG/ML	N75488 001	APR 16, 2001	AUG	CAHN
FAMOTIDINE PRESERVATIVE FREE							
AP		BAXTER HLTHCARE	10MG/ML	N75486 001	APR 16, 2001	JUN	CAHN

FELBAMATE

SUSPENSION; ORAL

FELBATOL

	+	MEDPOINTE	600MG/5ML	N20189 003	JUL 29, 1993	MAR	CAHN
TABLET; ORAL							
		MEDPOINTE	400MG	N20189 001	JUL 29, 1993	MAR	CAHN
	+		600MG	N20189 002	JUL 29, 1993	MAR	CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB		IMPAX LABS	67MG	N75868 001	OCT 27, 2003	OCT	NEWA
AB			134MG	N75868 002	OCT 27, 2003	OCT	NEWA
AB			200MG	N75868 003	OCT 27, 2003	OCT	NEWA
AB		TEVA	67MG	N75753 001	SEP 03, 2002	OCT	CFTG
			67MG	N75753 001	SEP 03, 2002	MAR	CTEC
AB			134MG	N75753 002	APR 09, 2002	OCT	CFTG
			134MG	N75753 002	APR 09, 2002	MAR	CTEC
AB	+		200MG	N75753 003	APR 09, 2002	OCT	CFTG
	+		200MG	N75753 003	APR 09, 2002	MAR	CRLD
TRICOR (MICRONIZED)							
	@	ABBOTT	67MG	N19304 002	FEB 09, 1998	MAR	DISC
	@		134MG	N19304 003	JUN 30, 1999	MAR	DISC
	@		200MG	N19304 004	JUN 30, 1999	MAR	DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

>D>	+	ABBOTT	EQ 10MG BASE/ML	N19922 001	SEP 23, 1997	DEC	CFTG
-----	---	--------	-----------------	------------	--------------	-----	------

>A>	AP +	EQ 10MG BASE/ML	N19922 001	SEP 23, 1997	DEC	CFTG
>A>	FENOLDOPAM MESYLATE					
>A>	AP	EQ 10MG BASE/ML	N76656 001	DEC 01, 2003	DEC	NEWA
	PHARMAFORCE					

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC

AB +	ALZA	0.6MG/24HR	N19813 004	AUG 07, 1990	NOV	CFTG
AB		1.2MG/24HR	N19813 003	AUG 07, 1990	NOV	CFTG
AB		1.8MG/24HR	N19813 002	AUG 07, 1990	NOV	CFTG
AB		2.4MG/24HR	N19813 001	AUG 07, 1990	NOV	CFTG

FENTANYL

AB	MYLAN TECHNOLOGIES	0.6MG/24HR	N76258 001	NOV 21, 2003	NOV	NEWA
AB		1.2MG/24HR	N76258 002	NOV 21, 2003	NOV	NEWA
AB		1.8MG/24HR	N76258 003	NOV 21, 2003	NOV	NEWA
AB		2.4MG/24HR	N76258 004	NOV 21, 2003	NOV	NEWA

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP +	BAXTER HLTHCARE	EQ 0.05MG BASE/ML	N19101 001	JUL 11, 1984	AUG	CAHN
------	-----------------	-------------------	------------	--------------	-----	------

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

@	OTSUKA	600MG/PACKET	N20292 001	OCT 14, 1997	AUG	CAHN
---	--------	--------------	------------	--------------	-----	------

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYDT	500MG	N21626 001	OCT 02, 2003	OCT	NEWA
+	HEYL CHEMISCH	500MG	N21626 001	OCT 02, 2003	NOV	CAHN

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HCL

AB	IMPAX PHARMS	100MG	N76234 001	AUG 28, 2003	AUG	NEWA
	URISPAS					
+	ORTHO MCNEIL PHARM	100MG	N16769 001		MAR	CAHN
AB +		100MG	N16769 001		AUG	CFTG

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	GENEVA PHARMS	50MG	N76030 001	OCT 28, 2002	JUN	CAHN
AB		100MG	N76030 002	OCT 28, 2002	JUN	CAHN
AB		150MG	N76030 003	OCT 28, 2002	JUN	CAHN
AB	RANBAXY	50MG	N76421 001	MAR 28, 2003	MAR	NEWA
AB		100MG	N76421 002	MAR 28, 2003	MAR	NEWA
AB		150MG	N76421 003	MAR 28, 2003	MAR	NEWA
AB	ROXANE	50MG	N76278 001	JAN 14, 2003	JAN	NEWA
AB		100MG	N76278 002	JAN 14, 2003	JAN	NEWA
AB		150MG	N76278 003	JAN 14, 2003	JAN	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

AP	+	BERLEX	50MG/VIAL	N20038 001	APR 18, 1991	AUG	CFTG
----	---	--------	-----------	------------	--------------	-----	------

FLUDARABINE PHOSPHATE

AP		GENSIA SICOR PHARMS	50MG/VIAL	N76349 001	AUG 28, 2003	AUG	NEWA
----	--	---------------------	-----------	------------	--------------	-----	------

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB		BARR	0.1MG	N40425 001	JAN 21, 2003	JAN	NEWA
----	--	------	-------	------------	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED; NASAL

NASAREL

+		IVAX RES	0.029MG/SPRAY	N20409 001	MAR 08, 1995	JUL	CPOT
---	--	----------	---------------	------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1		ALPHARMA US PHARM	0.05%	N73085 001	FEB 14, 1992	MAY	CTEC
-----	--	-------------------	-------	------------	--------------	-----	------

AB1		FOUGERA	0.05%	N73030 001	OCT 17, 1994	MAY	CTEC
-----	--	---------	-------	------------	--------------	-----	------

AB1		TARO	0.05%	N19117 001	JUN 26, 1984	MAY	CTEC
-----	--	------	-------	------------	--------------	-----	------

AB1			0.05%	N71500 001	JUN 10, 1987	MAY	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1		TEVA	0.05%	N72488 001	FEB 06, 1989	MAY	CTEC
-----	--	------	-------	------------	--------------	-----	------

FLUOCINONIDE EMULSIFIED BASE

AB2		ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
-----	--	-------------------	-------	------------	--------------	-----	------

AB2		DRAXIS HLTH	0.05%	N72494 001	JAN 19, 1989	MAY	CTEC
-----	--	-------------	-------	------------	--------------	-----	------

AB2		TARO	0.05%	N72494 001	JAN 19, 1989	JUN	CAHN
-----	--	------	-------	------------	--------------	-----	------

AB2		TEVA	0.05%	N72490 001	FEB 07, 1989	MAY	CTEC
-----	--	------	-------	------------	--------------	-----	------

LIDEX

AB1	+	MEDICIS	0.05%	N16908 002		MAY	CTEC
-----	---	---------	-------	------------	--	-----	------

LIDEX-E

AB2	+	MEDICIS	0.05%	N16908 003		MAY	CRLD
-----	---	---------	-------	------------	--	-----	------

FLUORESCCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

@		NOVARTIS	25%	N17869 001		JAN	DISC
---	--	----------	-----	------------	--	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP		GENSIA SICOR PHARMS	50MG/ML	N40023 001	OCT 18, 1991	JUL	CAHN
----	--	---------------------	---------	------------	--------------	-----	------

AP	+		50MG/ML	N81225 001	AUG 28, 1991	JUL	CAHN
----	---	--	---------	------------	--------------	-----	------

FLUOROURACIL

AP		SICOR PHARMS	50MG/ML	N40333 001	JAN 27, 2000	JUL	CAHN
----	--	--------------	---------	------------	--------------	-----	------

AP			50MG/ML	N40334 001	FEB 25, 2000	JUL	CAHN
----	--	--	---------	------------	--------------	-----	------

SOLUTION; TOPICAL

EFUDEX

AT	+	ICN	2%	N16831 001		NOV	CFTG
----	---	-----	----	------------	--	-----	------

AT	+		5%	N16831 002		NOV	CFTG
----	---	--	----	------------	--	-----	------

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX

@ ALLERGAN HERBERT 1%

N16765 001 JUN DISC

FLUOROURACIL

AT TARO 2%

N76526 001 NOV 05, 2003 NOV NEWA

AT 5%

N76526 002 NOV 05, 2003 NOV NEWA

>A> FLUOXETINE HYDROCHLORIDE; OLANZAPINE

>A> CAPSULE; ORAL

>A> SYMBYAX

>A> LILLY EQ 25MG BASE;EQ 6MG BASE

N21520 002 DEC 24, 2003 DEC NEWA

>A> EQ 25MG BASE;EQ 12MG BASE

N21520 004 DEC 24, 2003 DEC NEWA

>A> + EQ 50MG BASE;EQ 6MG BASE

N21520 003 DEC 24, 2003 DEC NEWA

>A> EQ 50MG BASE;EQ 12MG BASE

N21520 005 DEC 24, 2003 DEC NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ KING PHARMS 25MG/ML

N74966 001 APR 16, 1998 MAY DISC

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRAN

+ OCLASSEN 0.05%

N13790 001 MAY CTEC

+ WATSON LABS 0.05%

N13790 001 OCT CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB GENPHARM 125MG

N76224 001 MAY 09, 2003 MAY NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB GENEVA PHARMS 25MG

N75887 001 JAN 05, 2001 APR CAHN

AB 50MG

N75887 002 JAN 05, 2001 APR CAHN

AB 100MG

N75887 003 JAN 05, 2001 APR CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP + AM PHARM PARTNERS 5MG/ML

N89202 001 FEB 18, 1986 JUN CRLD

FOLVITE

AP + WYETH PHARMS INC 5MG/ML

N05897 008 MAR CAHN

@ 5MG/ML

N05897 008 JUN DISC

TABLET; ORAL

@ WYETH PHARMS INC 1MG

N05897 004 MAR CAHN

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

LEXIVA

+ GLAXOSMITHKLINE

EQ 700MG BASE

N21548 001 OCT 20, 2003 OCT NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB TEVA 10MG

N76139 001 NOV 25, 2003 NOV NEWA

AB 20MG

N76139 002 NOV 25, 2003 NOV NEWA

AB 40MG

N76139 003 NOV 25, 2003 NOV NEWA

MONOPRIL

AB BRISTOL MYERS SQUIBB 10MG

N19915 002 MAY 16, 1991 NOV CFTG

AB 20MG

N19915 003 MAY 16, 1991 NOV CFTG

AB + 40MG

N19915 004 MAR 28, 1995 NOV CFTG

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

a BAXTER HLTHCARE 10MG/ML

N18267 001 JUN DISC

AP 10MG/ML

N71439 001 SEP 14, 1990 AUG CAHN

TABLET; ORAL

AB CLONMEL HLTHCARE 20MG

N18415 001 JUL 27, 1982 JUL CAHN

a 20MG

N18415 001 JUL 27, 1982 AUG DISC

AB 40MG

N18415 002 JUL 27, 1982 JUL CAHN

a 40MG

N18415 002 JUL 27, 1982 AUG DISC

AB 80MG

N18415 003 NOV 26, 1984 JUL CAHN

a 80MG

N18415 003 NOV 26, 1984 AUG DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB PUREPAC PHARM 100MG

N75350 001 SEP 12, 2003 SEP NEWA

AB 300MG

N75350 002 SEP 12, 2003 SEP NEWA

AB 400MG

N75350 003 SEP 12, 2003 SEP NEWA

NEURONTIN

AB PFIZER PHARMS 100MG

N20235 001 DEC 30, 1993 SEP CFTG

AB 300MG

N20235 002 DEC 30, 1993 SEP CFTG

AB + 400MG

N20235 003 DEC 30, 1993 SEP CFTG

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE MULTIPACK

+ BRACCO

279.3MG/ML

N21489 001 OCT 09, 2003 OCT NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

REMINYL

+ JANSSEN PHARMA

EQ 4MG BASE

N21169 001 FEB 28, 2001 APR CRLD

EQ 12MG BASE

N21169 003 FEB 28, 2001 APR CRLD

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

AB	ROCHE PALO	250MG	N20460 001	DEC 22, 1994	JUN	CFTG
AB +		500MG	N20460 002	DEC 12, 1997	JUN	CFTG
<u>GANCICLOVIR</u>						
AB	RANBAXY	250MG	N76457 001	JUN 27, 2003	JUN	NEWA
AB		500MG	N76457 002	JUN 27, 2003	JUN	NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE IV

AP +	ROCHE PALO	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989	JUL	CFTG
<u>GANCICLOVIR SODIUM</u>						
AP	BEDFORD	EQ 500MG BASE/VIAL	N76222 001	JUL 16, 2003	JUL	NEWA

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

+	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
+		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
+		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC

ZYMAR

+	ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA
---	----------	------	------------	--------------	-----	------

GEFITINIB

TABLET; ORAL

IRESSA

+	ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA
---	-------------	-------	------------	--------------	-----	------

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

@	CLONMEL HLTHCARE	600MG	N74270 001	SEP 27, 1993	AUG	DISC
---	------------------	-------	------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+	GENESOF PHARMS	EQ 320MG BASE	N21158 001	APR 04, 2003	MAY	CAHN
+	LG LIFE	EQ 320MG BASE	N21158 001	APR 04, 2003	APR	NEWA

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

+	WYETH PHARMS INC	5MG/VIAL	N21174 001	MAY 17, 2000	MAR	CAHN
---	------------------	----------	------------	--------------	-----	------

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

@ SCHERING

GENTAMICIN SULFATE

	EQ 0.1% BASE	N60462 001		FEB	DISC
--	--------------	------------	--	-----	------

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT +	FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984	FEB	CRLD
INJECTABLE; INJECTION						
AP +	AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982	JUN	CRLD
	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N62251 002		JUN	DISC
	@	EQ 40MG BASE/ML	N62251 001		JUN	DISC
OINTMENT; OPHTHALMIC						
GARAMYCIN						
	@ SCHERING	EQ 0.3% BASE	N50425 001		APR	DISC
GENTAMICIN SULFATE						
+	AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD

GLIMEPIRIDE

TABLET; ORAL

AMARYL

+	AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995	JAN	CRLD
		4MG	N20496 003	NOV 30, 1995	JAN	CRLD

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	WATSON LABS	5MG	N76467 001	SEP 08, 2003	SEP	NEWA
AB		10MG	N76467 002	NOV 07, 2003	NOV	NEWA
GLUCOTROL XL						
AB	PFIZER	5MG	N20329 001	APR 26, 1994	SEP	CFTG
>D>	+	10MG	N20329 002	APR 26, 1994	DEC	CTEC
>A>	AB +	10MG	N20329 002	APR 26, 1994	DEC	CTEC

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

	@ AVENTIS PHARMS	1.5MG	N20055 001	APR 17, 1992	OCT	DISC
	@	3MG	N20055 002	APR 17, 1992	OCT	DISC
	@	6MG	N20055 003	MAR 08, 2000	OCT	DISC
AB	HIKMA	1.5MG	N75890 001	JUL 31, 2003	JUL	NEWA
AB		3MG	N75890 002	JUL 31, 2003	JUL	NEWA
AB		6MG	N75890 003	JUL 31, 2003	JUL	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP +	BAXTER HLTHCARE CORP	0.2MG/ML	N17558 001		AUG	CAHN
------	----------------------	----------	------------	--	-----	------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

+	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN
	@	EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN
	@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

@ FERRING	5,000 UNITS/VIAL	N17055 001	JUL	CAHN
@	10,000 UNITS/VIAL	N17055 002	JUL	CAHN
@	20,000 UNITS/VIAL	N17055 003	JUL	CAHN
@ WYETH AYERST	5,000 UNITS/VIAL	N17055 001	JUN	DISC
@	10,000 UNITS/VIAL	N17055 002	JUN	DISC
CHORIONIC GONADOTROPIN				
@ STERIS	5,000 UNITS/VIAL	N17016 006	SEP	DISC

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT + BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N64047 001	JAN 31, 1996	OCT	CRLD
----------------------	--	------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUL	CMFD
---------	------------------	------------	--------------	-----	------

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

@ OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
@	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
@	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

AB + WATSON LABS	EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN	CRLD
WYTENSIN					
@ WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN	DISC
@	EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
@	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

AP + BAXTER HLTHCARE	10 UNITS/ML	N17037 007	JUN	CAHN	
AP +	100 UNITS/ML	N17037 006	JUN	CAHN	
HEP-LOCK U/P					
AP BAXTER HLTHCARE	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN	CAHN
AP	100 UNITS/ML	N17037 011	JUN 10, 1983	JUN	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

@ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN
@	100 UNITS/ML	N17007 009		MAY	CAHN

HEPARIN SODIUM

AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001		JUN	CAHN
AP		5,000 UNITS/ML	N17037 002		JUN	CAHN
AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN	CAHN
AP		10,000 UNITS/ML	N17037 003		JUN	CAHN
	@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN
	@	2,500 UNITS/ML	N17007 007		MAY	CAHN
	@	5,000 UNITS/ML	N17007 002		MAY	CAHN
	@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
	@	7,500 UNITS/ML	N17007 003		MAY	CAHN
	@	10,000 UNITS/ML	N17007 004		MAY	CAHN
	@	15,000 UNITS/ML	N17007 005		MAY	CAHN
	@	20,000 UNITS/ML	N17007 006		MAY	CAHN
	SODIUM HEPARIN					
	@ BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	MAR 04, 1988	OCT	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN
----	-------------	-------------------	------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

WYDASE

@ BAXTER HLTHCARE	150 UNITS/ML	N06343 002		AUG	CAHN
@	150 UNITS/VIAL	N06343 006		AUG	CAHN
@	1,500 UNITS/VIAL	N06343 005		AUG	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

@ CLONMEL HLTHCARE	25MG	N86243 001		AUG	DISC
@	50MG	N86242 002		AUG	DISC
@ IMPAX LABS	50MG	N84923 001		NOV	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	CLONMEL HLTHCARE	25MG	N87059 001		JUL	CAHN
AB		50MG	N87068 001		JUL	CAHN
	@	100MG	N87060 001		JUL	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@ CLONMEL HLTHCARE	15MG;250MG	N72507 001	JUN 02, 1989	JUL	DISC
--------------------	------------	------------	--------------	-----	------

@	25MG;250MG	N72508 001	JUN 02, 1989	JUL	DISC
@	30MG;500MG	N72509 001	JUN 02, 1989	JUL	DISC
@	50MG;500MG	N72510 001	JUN 02, 1989	JUL	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

SANKYO

12.5MG;20MG

N21532 002 JUN 05, 2003 JUN NEWA

12.5MG;40MG

N21532 003 JUN 05, 2003 JUN NEWA

+

25MG;40MG

N21532 005 JUN 05, 2003 JUN NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB WYETH PHARMS INC

25MG;40MG

N18031 001

MAR CAHN

INDERIDE-80/25

AB + WYETH PHARMS INC

25MG;80MG

N18031 002

MAR CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS

25MG;160MG

N20818 003 JAN 17, 2002 JUL NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

>A> AB ANDRX PHARMS

7.5MG;200MG

N76604 001 DEC 31, 2003 DEC NEWA

AB TEVA

7.5MG;200MG

N76023 001 APR 11, 2003 APR NEWA

VICOPROFEN

AB + ABBOTT

7.5MG;200MG

N20716 001 SEP 23, 1997 APR CFTG

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT VINTAGE PHARMS

2.5%

N40417 001 JUL 30, 2003 JUL NEWA

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

@ PHARMACIA AND UPJOHN

EQ 10MG BASE/5ML

N09900 001

AUG DISC

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

@ MERCK

EQ 50MG BASE/ML

N12052 001

APR DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

@ BAXTER HLTHCARE

EQ 100MG BASE/VIAL

N86619 001

AUG CAHN

@

EQ 250MG BASE/VIAL

N87567 001

AUG CAHN

@

EQ 500MG BASE/VIAL

N87568 001

AUG CAHN

@

EQ 1GM BASE/VIAL

N87569 001

AUG CAHN

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

@ BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM

N50237 006 JUN 05, 1984 JUN DISC

@

1%;EQ 3.5MG BASE/GM

N50237 005 JUN 05, 1984 JUN DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT ALCON 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62423 001 AUG 25, 1983 FEB CMFD

SUSPENSION/DROPS; OPHTHALMIC

AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62874 001 MAY 11, 1988 FEB CMFD

SUSPENSION/DROPS; OTIC

AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62488 001 NOV 06, 1985 FEB CMFD

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBIOTIC

@ SCHERING

5MG/ML;EQ 10,000 UNITS BASE/ML

N62302 001

OCT WDAG

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

@ WYETH AYERST

50MG

N83383 001

JUN DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

@ SHIRE LABS

50MG;0.125MG

N12359 003

JUL DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP FAULDING 10MG/ML

N76444 001 APR 25, 2003 APR NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

@ ELKINS SINN

50MG/ML

N85551 002

JUN DISC

HYDROXYZINE HCL

@ ELKINS SINN

25MG/ML

N85551 001

JUN DISC

TABLET; ORAL

ATARAX

@ PFIZER

10MG

N10392 001

FEB DISC

@

25MG

N10392 004

FEB DISC

@

50MG

N10392 006

FEB DISC

@

100MG

N10392 005

FEB DISC

HYDROXYZINE HCL

AB + SIDMAK LABS NJ 10MG

N88617 001 JAN 10, 1986 FEB CRLD

AB + 25MG

N88618 001 JAN 10, 1986 FEB CRLD

AB + 50MG

N88619 001 JAN 10, 1986 FEB CRLD

@

100MG

N81054 001 SEP 25, 1995 FEB DISC

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

+ PFIZER

EQ 25MG HCL/5ML

N11795 001

OCT CRLD

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

@ ROCHE

EQ 2.5MG BASE

N21455 001 MAY 16, 2003 JUL DISC

+

EQ 2.5MG BASE

N21455 001 MAY 16, 2003 MAY NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

+ AM PHARM PARTNERS

1GM/VIAL

N76078 001 MAY 28, 2002 SEP CTNA

+

3GM/VIAL

N76078 002 MAY 28, 2002 SEP CTNA

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

@ NOVARTIS

50MG

N21335 001 MAY 10, 2001 JUN DISC

TABLET; ORAL

NOVARTIS

100MG

N21588 001 APR 18, 2003 APR NEWA

+

400MG

N21588 002 APR 18, 2003 APR NEWA

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

>A> AB

ABLE

25MG

N76666 001 DEC 17, 2003 DEC NEWA

>A> AB

50MG

N76666 002 DEC 17, 2003 DEC NEWA

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

>A>

@ ISO TEX

100MG/ML

N02282 001

DEC CAHN

>D>

@ QUESTCOR PHARMS

100MG/ML

N02282 001

DEC CAHN

@

100MG/ML

N02282 001

SEP DISC

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

@ BAXTER HLTHCARE

41%

N74629 001 NOV 06, 1996 AUG CAHN

@

51%

N74629 004 MAR 31, 1998 AUG CAHN

@

61%

N74629 002 NOV 06, 1996 AUG CAHN

@

76%

N74629 003 NOV 06, 1996 AUG CAHN

@ ELKINS SINN PHARM

41%

N74629 001 NOV 06, 1996 JUN DISC

@

51%

N74629 004 MAR 31, 1998 JUN DISC

@

61%

N74629 002 NOV 06, 1996 JUN DISC

@

76%

N74629 003 NOV 06, 1996 JUN DISC

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

@ MALLINCKRODT	51%	N20923 001	MAY 28, 1998	JUN	DISC
----------------	-----	------------	--------------	-----	------

OPTIRAY 300

+ MALLINCKRODT	64%	N20923 004	MAY 13, 1999	JUN	NEWA
----------------	-----	------------	--------------	-----	------

OPTIRAY 320

@ MALLINCKRODT	68%	N20923 002	MAY 29, 1998	JUN	DISC
----------------	-----	------------	--------------	-----	------

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

ATROVENT

AB + BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
---------------------------	---------------	------------	--------------	-----	------

AB +	0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG
------	---------------	------------	--------------	-----	------

IPRATROPIUM BROMIDE

AB BAUSCH AND LOMB	0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA
--------------------	---------------	------------	--------------	-----	------

AB	0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA
----	---------------	------------	--------------	-----	------

AB DEY	0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
--------	---------------	------------	--------------	-----	------

AB	0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
----	---------------	------------	--------------	-----	------

AB NOVEX	0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
----------	---------------	------------	--------------	-----	------

AB	0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA
----	---------------	------------	--------------	-----	------

AB ROXANE	0.021MG/SPRAY	N76664 001	NOV 05, 2003	NOV	NEWA
-----------	---------------	------------	--------------	-----	------

AB	0.042MG/SPRAY	N76598 001	NOV 05, 2003	NOV	NEWA
----	---------------	------------	--------------	-----	------

ISONIAZID

TABLET; ORAL

ISONIAZID

@ AXIOM PHARM	100MG	N80136 001		MAY	CAHN
---------------	-------	------------	--	-----	------

AA	300MG	N83633 001		MAY	CAHN
----	-------	------------	--	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

@ BAXTER HLTHCARE	0.2MG/ML	N83486 001		JUN	DISC
-------------------	----------	------------	--	-----	------

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

BC + SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988	JUN	CRLD
---------------------	------	------------	--------------	-----	------

+	40MG	N19790 001	SEP 02, 1988	JUL	CTEC
---	------	------------	--------------	-----	------

ISORDIL

@ WYETH AYERST	40MG	N12882 002	JUL 29, 1988	JUN	DISC
----------------	------	------------	--------------	-----	------

TABLET; ORAL

AB BIOVAIL	5MG	N12093 007	JUL 29, 1988	JUN	CAHN
------------	-----	------------	--------------	-----	------

AB	10MG	N12093 002	JUL 29, 1988	JUN	CAHN
----	------	------------	--------------	-----	------

AB	20MG	N12093 006	JUL 29, 1988	JUN	CAHN
----	------	------------	--------------	-----	------

AB +	30MG	N12093 005	JUL 29, 1988	JUN	CAHN
------	------	------------	--------------	-----	------

AB	40MG	N12093 001	JUL 29, 1988	JUN	CAHN
----	------	------------	--------------	-----	------

+	40MG	N12093 001	JUL 29, 1988	OCT	CRLD
---	------	------------	--------------	-----	------

AB WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
---------------------	-----	------------	--------------	-----	------

AB	10MG	N12093 002	JUL 29, 1988	MAR	CAHN
----	------	------------	--------------	-----	------

AB	20MG	N12093 006	JUL 29, 1988	MAR	CAHN
----	------	------------	--------------	-----	------

AB +	30MG	N12093 005	JUL 29, 1988	MAR	CAHN
AB	40MG	N12093 001	JUL 29, 1988	MAR	CAHN
SORBITRATE					
@ ASTRAZENECA	20MG	N86405 002	AUG 21, 1990	OCT	WDAG
@	40MG	N88125 001	AUG 21, 1990	OCT	WDAG
TABLET; SUBLINGUAL					
ISORDIL					
AB BIOVAIL	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
AB	5MG	N12940 003	JUL 29, 1988	JUN	CAHN
+	10MG	N12940 005	JUL 29, 1988	JUN	CAHN
AB WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
AB	5MG	N12940 003	JUL 29, 1988	MAR	CAHN
+	10MG	N12940 005	JUL 29, 1988	MAR	CAHN
TABLET, CHEWABLE; ORAL					
SORBITRATE					
@ ASTRAZENECA	10MG	N16776 003	APR 01, 1996	OCT	WDAG
ISOSORBIDE MONONITRATE					
TABLET, EXTENDED RELEASE; ORAL					
IMDUR					
AB + SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993	OCT	CAHN
AB +	60MG	N20225 002	AUG 12, 1993	OCT	CAHN
AB +	120MG	N20225 003	MAR 30, 1995	OCT	CAHN
ISOTRETINOIN					
CAPSULE; ORAL					
CLARAVIS					
AB BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB	20MG	N76135 002	APR 11, 2003	APR	NEWA
AB	40MG	N76135 001	APR 11, 2003	APR	NEWA
SOTRET					
RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA
ISRADIPINE					
CAPSULE; ORAL					
DYNACIRC					
RELIANT PHARMS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
+	5MG	N19546 002	DEC 20, 1990	MAY	CAHN
TABLET, EXTENDED RELEASE; ORAL					
DYNACIRC CR					
+	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
+	10MG	N20336 002	JUN 01, 1994	MAY	CAHN
KANAMYCIN SULFATE					
INJECTABLE; INJECTION					
KANAMYCIN					
@ BAXTER HLTHCARE	EQ 75MG BASE/2ML	N62324 001		AUG	CAHN
@	EQ 500MG BASE/2ML	N62324 002		AUG	CAHN
@	EQ 1GM BASE/3ML	N62324 003		AUG	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB	CLONMEL HLTHCARE	75MG	N74014 003	JAN 29, 1993	JUN	CAHN
AB +	TEVA	75MG	N73517 001	DEC 22, 1992	JUN	CRLD
	ORUDIS					
	@ WYETH AYERST	25MG	N18754 001	JUL 31, 1987	JUN	DISC
	@	50MG	N18754 002	JAN 09, 1986	JUN	DISC
	@	75MG	N18754 003	JAN 09, 1986	JUN	DISC

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN
AB		150MG	N19816 002	FEB 08, 1995	MAR	CAHN
AB +		200MG	N19816 001	SEP 24, 1993	MAR	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@ ABBOTT	15MG/ML	N74801 001	JUN 05, 1997	OCT	DISC
	@	30MG/ML	N74801 002	JUN 05, 1997	OCT	DISC
AP +	BEDFORD	30MG/ML	N75228 001	APR 26, 1999	OCT	CRLD

SOLUTION/DROPS; OPHTHALMIC

ACULAR LS

+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003	MAY	NEWA
---	----------	------	------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HCL

	@ APOTHECON	100MG	N75223 001	NOV 20, 1998	OCT	WDAG
	@	200MG	N75223 002	NOV 20, 1998	OCT	WDAG
	@	300MG	N75223 003	NOV 20, 1998	OCT	WDAG

LACTULOSE

SOLUTION; ORAL

CHRONULAC

	@ AVENTIS PHARMS	10GM/15ML	N17884 001		AUG	DISC
--	------------------	-----------	------------	--	-----	------

CONSTULOSE

AA +	ALPHARMA	10GM/15ML	N70288 001	AUG 15, 1988	AUG	CRLD
------	----------	-----------	------------	--------------	-----	------

LACTULOSE

AA	VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992	MAR	CAHN
----	------------	-----------	------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

AA	NOVEX	10GM/15ML	N76645 001	JUL 28, 2003	JUL	NEWA
----	-------	-----------	------------	--------------	-----	------

LAMIVUDINE

TABLET; ORAL

EPIVIR

	GLAXOSMITHKLINE	300MG	N20564 003	JUN 24, 2002	SEP	NEWA
--	-----------------	-------	------------	--------------	-----	------

LANSOPRAZOLE; NAPROXEN

>A> CAPSULE, DELAYED REL PELLETS; TABLET; ORAL

>A> NAPRAPAC 250 (COPACKAGED)

>A>	TAP PHARM	15MG;250MG	N21507 002	NOV 14, 2003	DEC	NEWA
-----	-----------	------------	------------	--------------	-----	------

LANSOPRAZOLE; NAPROXEN

>A>	CAPSULE, DELAYED REL PELLETS; TABLET; ORAL				
>A>	NAPRAPAC 375 (COPACKAGED)				
>A>	TAP PHARM	15MG;375MG	N21507 003	NOV 14, 2003	DEC NEWA
>A>	NAPRAPAC 500 (COPACKAGED)				
>A>	+ TAP PHARM	15MG;500MG	N21507 004	NOV 14, 2003	DEC NEWA

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+ AVENTIS PHARMS	20MG	N20905 002	SEP 10, 1998	MAR	CRLD
@	100MG	N20905 003	SEP 10, 1998	MAR	DISC

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

@ FAULDING	EQ 60MG BASE/VIAL	N08107 003	JAN 30, 1987	OCT	CAHN
------------	-------------------	------------	--------------	-----	------

INJECTABLE; INJECTION

@ ELKINS SINN	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
---------------	-------------------	------------	--------------	-----	------

@	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC
---	--------------------	------------	--------------	-----	------

@ FAULDING	EQ 3MG BASE/ML	N08107 001		OCT	CAHN
------------	----------------	------------	--	-----	------

AP +	EQ 50MG BASE/VIAL	N08107 002		OCT	CAHN
------	-------------------	------------	--	-----	------

AP +	EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988	OCT	CAHN
------	--------------------	------------	--------------	-----	------

AP +	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989	OCT	CAHN
------	--------------------	------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+ ATRIX	30MG/VIAL	N21488 001	FEB 13, 2003	FEB	NEWA
---------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+ SEPRACOR	EQ 0.0103% BASE	N20837 003	JAN 30, 2002	JUL	CPOT
------------	-----------------	------------	--------------	-----	------

+	EQ 0.25% BASE	N20837 004	JUL 18, 2003	JUL	NEWA
---	---------------	------------	--------------	-----	------

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

@ JANSSEN PHARMA	EQ 50MG BASE	N20035 001	JUN 18, 1990	NOV	DISC
------------------	--------------	------------	--------------	-----	------

LEVETIRACETAM

SOLUTION; ORAL

KEPPRA

+ UCB	100MG/ML	N21505 001	JUL 15, 2003	JUL	NEWA
-------	----------	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON	EQ 0.5% BASE	N21114 001	FEB 23, 2000	JUL	CAHN
---------	--------------	------------	--------------	-----	------

+ MEDPOINTE	EQ 0.5% BASE	N21114 001	FEB 23, 2000	MAR	CAHN
-------------	--------------	------------	--------------	-----	------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

+	ORTHO MCNEIL PHARM	500MG /20ML(25MG/ML)	N20635 001	DEC 20, 1996	OCT	CPOT
+		750MG /30ML(25MG/ML)	N20635 004	DEC 20, 1996	OCT	NEWA
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
+	ORTHO MCNEIL PHARM	250MG /50ML(5MG/ML)	N20635 002	DEC 20, 1996	OCT	CPOT
+		500MG /100ML(5MG/ML)	N20635 003	DEC 20, 1996	OCT	CPOT
+		750MG /150ML(5MG/ML)	N20635 005	DEC 20, 1996	OCT	NEWA

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

BX	+	WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
		@	75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC
NORPLANT II							
BX	+	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD
NORPLANT SYSTEM IN PLASTIC CONTAINER							
	+	WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN
		@	36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ ICN

2MG

N08720 001 DEC 19, 1991 FEB DISC

LEVORPHANOL TARTRATE

+ ROXANE

2MG

N74278 001 MAR 31, 2000 FEB CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX		ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN
BX			0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
BX			0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
BX			0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
BX			0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
BX			0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
BX			0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
>A> BX			0.137MG	N21342 012	DEC 08, 2003	DEC	NEWA
BX			0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
BX			0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
BX			0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
BX	+		0.3MG	N21342 011	MAR 01, 2002	APR	CAHN
LEVOLET							
BX		VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA
BX			0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA
BX			0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA
BX			0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA
BX			0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA
BX			0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA
BX			0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA
BX			0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA

BX	0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA
BX	0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA
BX	0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA
BX	0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA

LIDOCAINE

SOLUTION; TOPICAL

XYLOCAINE

@ ASTRAZENECA	5%	N14127 001		AUG	DISC
---------------	----	------------	--	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

@ ELKINS SINN	1%	N80407 001		JUN	DISC
---------------	----	------------	--	-----	------

@	2%	N80407 002		JUN	DISC
---	----	------------	--	-----	------

@ WYETH AYERST	1%	N83083 001		JUN	DISC
----------------	----	------------	--	-----	------

@	2%	N83083 002		JUN	DISC
---	----	------------	--	-----	------

LIDOCAINE HCL PRESERVATIVE FREE

@ ELKINS SINN	1%	N84625 001		JUN	DISC
---------------	----	------------	--	-----	------

@	2%	N84625 002		JUN	DISC
---	----	------------	--	-----	------

JELLY; TOPICAL

LIDOCAINE HCL

AT AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA
----------	----	------------	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ASTRAZENECA	2.5%;2.5%	N19941 001	DEC 30, 1992	AUG	CFTG
------------------	-----------	------------	--------------	-----	------

LIDOCAINE AND PRILOCAINE

AB ALTANA	2.5%;2.5%	N76453 001	AUG 18, 2003	AUG	NEWA
-----------	-----------	------------	--------------	-----	------

AB ATRIX	2.5%;2.5%	N76320 001	AUG 27, 2003	AUG	NEWA
----------	-----------	------------	--------------	-----	------

AB HI TECH PHARMA	2.5%;2.5%	N76290 001	SEP 25, 2003	SEP	NEWA
-------------------	-----------	------------	--------------	-----	------

>A> GEL; PERIODONTAL

>A> ORAQIX

>A> + DENTSPLY PHARM	2.5%;2.5%	N21451 001	DEC 19, 2003	DEC	NEWA
----------------------	-----------	------------	--------------	-----	------

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA
------------	------	------------	--------------	-----	------

AB WEST WARD	30MG	N76063 006	JUN 27, 2003	JUN	NEWA
--------------	------	------------	--------------	-----	------

ZESTRIL

AB ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD
----------------	------	------------	--------------	-----	------

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
-----------	-------	------------	--------------	-----	------

AB WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA
--------------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

AB + GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982	JUN	CFTG
----------------------	-------	------------	--------------	-----	------

LITHIUM CARBONATE

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA
AB	BARR	450MG	N76366 001	AUG 21, 2003	AUG	NEWA
AB	WEST WARD	450MG	N76490 001	JUN 17, 2003	JUN	NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM INTENSOL

+ ROXANE 2MG/ML

N72755 001 JUN 28, 1991 MAY CRLD

INJECTABLE; INJECTION

ATIVAN

AP + BAXTER HLTHCARE CORP 2MG/ML

N18140 001 FEB CAHN

AP + 4MG/ML

N18140 002 FEB CAHN

TABLET; ORAL

AB BIOVAIL 0.5MG

N17794 001 JUN CAHN

AB 1MG

N17794 002 JUN CAHN

AB + 2MG

N17794 003 JUN CAHN

MECAMLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+ TARGACEPT 2.5MG

N10251 001 APR CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

AB + MYLAN EQ 100MG BASE

N71081 001 SEP 03, 1986 MAY CRLD

MECLOMEN

@ PARKE DAVIS EQ 50MG BASE

N18006 001 MAY DISC

@ EQ 100MG BASE

N18006 002 MAY DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE

>A> AB BARR 250MG

N76392 001 DEC 29, 2003 DEC NEWA

MEFLOQUINE HCL

AB GENEVA PHARMS 250MG

N76175 001 FEB 20, 2002 APR CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB COPLEY PHARM 40MG/ML

N75681 001 MAY 05, 2003 MAY NEWA

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

NAMENDA

FOREST LABS 5MG

N21487 001 OCT 16, 2003 OCT NEWA

+ 10MG

N21487 002 OCT 16, 2003 OCT NEWA

@ 15MG

N21487 003 OCT 16, 2003 OCT DISC

	@	20MG	N21487 004	OCT 16, 2003	OCT	DISC
<u>MENOTROPINS (FSH;LH)</u>						
INJECTABLE; INJECTION						
REPRONEX						
BX +	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	MAY	CRLD
	@	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	MAY	DISC
<u>MEPERIDINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
MEPERIDINE HCL						
	@ BAXTER HLTHCARE	25MG/ML	N88279 001	JUN 15, 1984	AUG	CAHN
	@	50MG/ML	N88280 001	JUN 15, 1984	AUG	CAHN
	@	75MG/ML	N88281 001	JUN 15, 1984	AUG	CAHN
	@	100MG/ML	N88282 001	JUN 15, 1984	AUG	CAHN
AP	BAXTER HLTHCARE CORP	25MG/ML	N80455 007		MAY	CAHN
AP		50MG/ML	N80455 008		MAY	CAHN
AP		75MG/ML	N80455 009		MAY	CAHN
AP		100MG/ML	N80455 010		MAY	CAHN
TABLET; ORAL						
AA	AXIOM PHARM	50MG	N80448 001		MAY	CAHN
AA		100MG	N80448 002		MAY	CAHN
	@ WYETH AYERST	50MG	N80454 001		JUN	DISC
<u>MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
MEPERGAN						
	@ BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N11730 001		MAY	CAHN
<u>MEPHENTERMINE SULFATE</u>						
INJECTABLE; INJECTION						
WYAMINE SULFATE						
	@ BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N08248 002		FEB	CAHN
	@	EQ 30MG BASE/ML	N08248 001		FEB	CAHN
<u>MEPROBAMATE</u>						
TABLET; ORAL						
EQUANIL						
	@ WYETH AYERST	200MG	N10028 005		JUN	DISC
	@	400MG	N10028 004		JUN	DISC
MEPROBAMATE						
	@ MYLAN	400MG	N83618 001		NOV	DISC
+	ROXANE	600MG	N84332 001		JUN	CRLD
	@ WEST WARD	200MG	N15417 003		NOV	DISC
	@	400MG	N15417 002		NOV	DISC
MILTOWN						
AA +	MEDPOINTE	600MG	N83919 001		APR	CAHN
	@ MEDPOINTE PHARM HLC	600MG	N83919 001		JUN	DISC
<u>MERCAPTOPYRINE</u>						
TABLET; ORAL						
PURINETHOL						
+	TEVA	50MG	N09053 002		AUG	CAHN

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

a NOVARTIS

EQ 10MG BASE

N16774 001

JUN DISC

a

EQ 50MG BASE

N16774 003

JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+50 21-DAY

AB + WATSON LABS (UTAH)

0.05MG;1MG

N13625 002

AUG CRLD

ORTHO-NOVUM 1/50 21

a ORTHO MCNEIL PHARM

0.05MG;1MG

N12728 004

AUG DISC

METAXALONE

TABLET; ORAL

SKELAXIN

JONES PHARMA INC

400MG

N13217 001

JUN CAHN

+

800MG

N13217 003 AUG 30, 2002 JUN CAHN

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ RANBAXY

500MG/5ML

N21591 001 SEP 11, 2003 SEP NEWA

TABLET; ORAL

METFORMIN HCL

AB PUREPAC PHARM

1GM

N76033 003 JAN 24, 2002 FEB CMS1

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

BRISTOL MYERS SQUIBB

500MG

N21202 001 OCT 13, 2000 AUG CRLD

+

750MG

N21202 004 APR 11, 2003 APR NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMC

500MG;EQ 1MG BASE

N21410 001 OCT 10, 2002 APR CAHN

500MG;EQ 2MG BASE

N21410 002 OCT 10, 2002 APR CAHN

+

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 APR CAHN

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 AUG CRLD

1GM;EQ 2MG BASE

N21410 004 AUG 25, 2003 AUG NEWA

+

1GM;EQ 4MG BASE

N21410 005 AUG 25, 2003 AUG NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ METHAPHARM

100MG/VIAL

N19193 001 OCT 31, 1986 OCT CRLD

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HCL

+ AAIPHARMA

10MG/ML

N21624 001

APR CAHN

+ ROXANE

10MG/ML

N21624 001

FEB CMS1

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB + MIKART	50MG	N40062 002	JAN 27, 1994	JUN	CRLD
NEPTAZANE					
@ LEDERLE	25MG	N11721 002	NOV 25, 1991	JUN	DISC
@	50MG	N11721 001		JUN	DISC

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB COREPHARMA	1GM	N76411 001	JUN 20, 2003	JUN	NEWA
---------------	-----	------------	--------------	-----	------

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB LILLY	10MG	N07517 004		JUN	CRLD
----------	------	------------	--	-----	------

METHOCARBAMOL

INJECTABLE; INJECTION

ROBAXIN

AP + BAXTER HLTHCARE CORP	100MG/ML	N11790 001		AUG	CAHN
---------------------------	----------	------------	--	-----	------

TABLET; ORAL

METHOCARBAMOL

AA ABLE	500MG	N40413 001	MAR 17, 2003	MAR	NEWA
AA	750MG	N40413 002	MAR 17, 2003	MAR	NEWA
@ CLONMEL HLTHCARE	500MG	N85961 001		JUN	DISC
@	750MG	N85963 001		JUN	DISC
AA LANNETT	500MG	N84756 002	MAR 31, 2003	MAR	NEWA
@ NYLOS	750MG	N85033 001		NOV	DISC
AA VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003	JAN	NEWA
AA	750MG	N40489 002	JAN 29, 2003	JAN	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

AP + FAULDING	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	OCT	CAHN
AP + WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR	CAHN

METHOTREXATE SODIUM

@ FAULDING	EQ 2.5MG BASE/ML	N11719 004		OCT	CAHN
+	EQ 20MG BASE/VIAL	N11719 001		OCT	CAHN
AP +	EQ 25MG BASE/ML	N11719 005		OCT	CAHN
@	EQ 50MG BASE/VIAL	N11719 003		OCT	CAHN
@	EQ 100MG BASE/VIAL	N11719 006		OCT	CAHN
@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR	CAHN
+	EQ 20MG BASE/VIAL	N11719 001		MAR	CAHN
AP +	EQ 25MG BASE/ML	N11719 005		MAR	CAHN
@	EQ 50MG BASE/VIAL	N11719 003		MAR	CAHN
@	EQ 100MG BASE/VIAL	N11719 006		MAR	CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

AP + FAULDING	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	OCT	CAHN
AP + WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR	CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

PAMINE FORTE

+ BRADLEY PHARMS 5MG

N08848 002 MAR 25, 2003 MAR NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

@ MEDPOINTE PHARM HLC 5MG

N17364 001 JUN DISC

METHYLDOPA

TABLET; ORAL

ALDOMET

@ MERCK 125MG

N13400 003 MAY DISC

@ 250MG

N13400 001 MAY DISC

METHYLDOPA

@ CLONMEL HLTHCARE 125MG

N70070 003 OCT 15, 1985 JUN DISC

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

@ BAXTER HLTHCARE 50MG/ML

N70291 001 JUL 01, 1986 AUG CAHN

@ ELKINS SINN 50MG/ML

N70291 001 JUL 01, 1986 JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

CELLTECH PHARMS 10MG

N21259 003 MAY 27, 2003 JUL NEWA

BX 20MG

N21259 001 APR 03, 2001 JUL CRLD

BX + 30MG

N21259 002 JUN 19, 2003 JUL CTEC

+ 30MG

N21259 002 JUN 19, 2003 JUN NEWA

RITALIN LA

BX NOVARTIS 30MG

N21284 002 JUN 05, 2002 JUL CTEC

TABLET, CHEWABLE; ORAL

METHYLIN

MALLINCKRODT 2.5MG

N21475 001 APR 15, 2003 APR NEWA

5MG

N21475 002 APR 15, 2003 APR NEWA

+ 10MG

N21475 003 APR 15, 2003 APR NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>A> ALZA 18MG

N21121 001 AUG 01, 2000 DEC CAHN

>A> 27MG

N21121 004 APR 01, 2002 DEC CAHN

>A> 36MG

N21121 002 AUG 01, 2000 DEC CAHN

>A> + 54MG

N21121 003 DEC 08, 2000 DEC CAHN

>D> MCNEIL CONS SPECT 18MG

N21121 001 AUG 01, 2000 DEC CAHN

+ 18MG

N21121 001 AUG 01, 2000 MAY CAHN

18MG

N21121 001 AUG 01, 2000 OCT CRLD

>D> 27MG

N21121 004 APR 01, 2002 DEC CAHN

+ 27MG

N21121 004 APR 01, 2002 MAY CAHN

27MG

N21121 004 APR 01, 2002 OCT CRLD

>D> 36MG

N21121 002 AUG 01, 2000 DEC CAHN

+ 36MG

N21121 002 AUG 01, 2000 MAY CAHN

>D>	+	36MG	N21121 002	AUG 01, 2000	OCT	CRLD
	+	54MG	N21121 003	DEC 08, 2000	DEC	CAHN
	+	54MG	N21121 003	DEC 08, 2000	MAY	CAHN
<u>METHYLPREDNISOLONE</u>						
TABLET; ORAL						
MEDROL						
	@ PHARMACIA AND UPJOHN	2MG	N11153 002		JUL	DISC
<u>METHYLPREDNISOLONE ACETATE</u>						
INJECTABLE; INJECTION						
DEPO-MEDROL						
+	PHARMACIA AND UPJOHN	20MG/ML	N11757 002		NOV	CRLD
+		40MG/ML	N11757 001		NOV	CRLD
OINTMENT; TOPICAL						
MEDROL ACETATE						
	@ PHARMACIA AND UPJOHN	0.25%	N12421 001		JUN	DISC
<u>METHYSERGIDE MALEATE</u>						
TABLET; ORAL						
SANSERT						
	@ NOVARTIS	2MG	N12516 001		JUN	DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
REGLAN						
AP	+	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML			
	@		EQ 10MG BASE/ML			
			N17862 001		AUG	CAHN
			N17862 004	MAY 28, 1987	AUG	CAHN
SOLUTION; ORAL						
METOCLOPRAMIDE						
AA		VISTAPHARM	EQ 5MG BASE/5ML			
			N75051 001	JAN 26, 2001	APR	CAHN
TABLET; ORAL						
METOCLOPRAMIDE HCL						
	@ CLONMEL HLTHCARE	EQ 10MG BASE	N72639 001	MAY 09, 1991	JUN	DISC
<u>METOLAZONE</u>						
TABLET; ORAL						
METOLAZONE						
>A>	AB	EON	2.5MG	N76732 001	DEC 19, 2003	DEC NEWA
>A>	AB		5MG	N76466 001	DEC 19, 2003	DEC NEWA
>A>	AB		10MG	N76466 002	DEC 19, 2003	DEC NEWA
>A>	AB	MYLAN	2.5MG	N76698 001	DEC 23, 2003	DEC NEWA
>A>	AB	TEVA	10MG	N75543 003	DEC 24, 2003	DEC NEWA
ZAROXOLYN						
>D>		CELLTECH PHARMS	2.5MG	N17386 001		DEC CFTG
>A>	AB		2.5MG	N17386 001		DEC CFTG
			2.5MG	N17386 001		JUL CRLD
>D>	+		5MG	N17386 002		DEC CFTG
>A>	AB	+	5MG	N17386 002		DEC CFTG
	+		5MG	N17386 002		JUL CRLD
>D>	+		10MG	N17386 003		DEC CFTG
>A>	AB	+	10MG	N17386 003		DEC CFTG

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	BEDFORD LABS	1MG/ML	N76495 001	JUL 07, 2003	JUL	NEWA
----	--------------	--------	------------	--------------	-----	------

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

AB	+	GD SEARLE LLC	375MG	N20334 001	MAY 03, 1995	NOV	CFTG
----	---	---------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB		ABLE	375MG	N76505 001	NOV 13, 2003	NOV	NEWA
----	--	------	-------	------------	--------------	-----	------

TABLET; ORAL

AB		ABLE	250MG	N76519 001	JUN 27, 2003	JUN	NEWA
----	--	------	-------	------------	--------------	-----	------

AB			500MG	N76519 002	JUN 27, 2003	JUN	NEWA
----	--	--	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

AB	+	GD SEARLE LLC	750MG	N20868 001	NOV 26, 1997	JUN	CFTG
----	---	---------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB		ABLE	750MG	N76462 001	JUN 25, 2003	JUN	NEWA
----	--	------	-------	------------	--------------	-----	------

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

@	BAYER PHARMS	EQ 1GM BASE/VIAL	N50549 001		JUN	DISC
---	--------------	------------------	------------	--	-----	------

@		EQ 2GM BASE/VIAL	N50549 002		JUN	DISC
---	--	------------------	------------	--	-----	------

@		EQ 3GM BASE/VIAL	N50549 003		JUN	DISC
---	--	------------------	------------	--	-----	------

@		EQ 4GM BASE/VIAL	N50549 004		JUN	DISC
---	--	------------------	------------	--	-----	------

@		EQ 20GM BASE/VIAL	N50549 005	MAR 02, 1988	JUN	DISC
---	--	-------------------	------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

AP		BAXTER HLTHCARE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000	JUN	CAHN
----	--	-----------------	----------------	------------	--------------	-----	------

AP			EQ 5MG BASE/ML	N75243 002	JUN 20, 2000	JUN	CAHN
----	--	--	----------------	------------	--------------	-----	------

SYRUP; ORAL

AA		HI TECH PHARMA	EQ 2MG BASE/ML	N75958 001	SEP 04, 2003	SEP	NEWA
----	--	----------------	----------------	------------	--------------	-----	------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

AB		EON	2.5MG	N76514 001	SEP 11, 2003	SEP	NEWA
----	--	-----	-------	------------	--------------	-----	------

AB			5MG	N76514 002	SEP 11, 2003	SEP	NEWA
----	--	--	-----	------------	--------------	-----	------

AB		MYLAN	2.5MG	N76577 001	SEP 10, 2003	SEP	NEWA
----	--	-------	-------	------------	--------------	-----	------

AB			5MG	N76577 002	SEP 10, 2003	SEP	NEWA
----	--	--	-----	------------	--------------	-----	------

AB			10MG	N76577 003	SEP 10, 2003	SEP	NEWA
----	--	--	------	------------	--------------	-----	------

PROAMATINE

AB		SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CFTG
----	--	-------------	-------	------------	--------------	-----	------

AB	+		5MG	N19815 002	SEP 06, 1996	SEP	CFTG
----	---	--	-----	------------	--------------	-----	------

AB			10MG	N19815 003	MAR 20, 2002	SEP	CFTG
----	--	--	------	------------	--------------	-----	------

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+	ACTELION PHARMS	100MG	N21348 001	JUL 31, 2003	JUL	NEWA
---	-----------------	-------	------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	JUN	CAHN
AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003	JUN	NEWA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	AUG	CAHN
MILRINONE LACTOSE IN 5% DEXTROSE						
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	CAHN
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
AB		EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN
AB	+	EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CAHN
MINOCYCLINE HCL						
AB	TEVA	EQ 75MG BASE	N63009 002	AUG 12, 2003	AUG	NEWA
VECTRIN						
AB	MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	OCT	CMFD
AB		EQ 100MG BASE	N63067 001	JUL 31, 1990	OCT	CMFD

INJECTABLE; INJECTION

MINOCIN

+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444 001		MAR	CAHN
---	------------------	--------------------	------------	--	-----	------

TABLET; ORAL

MINOCYCLINE HCL

	MEDICIS	EQ 50MG BASE	N65131 001	APR 16, 2003	AUG	CAHN
		EQ 75MG BASE	N65131 002	APR 16, 2003	AUG	CAHN
+		EQ 100MG BASE	N65131 003	APR 16, 2003	AUG	CAHN
	PAR PHARM	EQ 50MG BASE	N65131 001	APR 16, 2003	APR	NEWA
		EQ 75MG BASE	N65131 002	APR 16, 2003	APR	NEWA
+		EQ 100MG BASE	N65131 003	APR 16, 2003	APR	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76176 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76176 003	JUN 19, 2003	JUN	NEWA
AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003	JUN	NEWA
AB		30MG	N76241 002	JUN 25, 2003	JUN	NEWA
AB		45MG	N76241 003	JUN 25, 2003	JUN	NEWA
AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003	JUN	NEWA
AB		30MG	N76336 002	JUN 20, 2003	JUN	NEWA
AB		45MG	N76336 003	JUN 20, 2003	JUN	NEWA

AB	EON	15MG	N76219 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76219 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76219 003	JUN 19, 2003	JUN	NEWA
AB	GENEVA PHARMS	15MG	N76189 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76189 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76189 003	JUN 19, 2003	JUN	NEWA
>A>	AB	IVAX PHARMS	N76244 001	DEC 22, 2003	DEC	NEWA
>A>	AB		N76244 002	DEC 22, 2003	DEC	NEWA
>A>	AB		N76244 003	DEC 22, 2003	DEC	NEWA
AB	MYLAN	15MG	N76122 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76122 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76122 003	JUN 19, 2003	JUN	NEWA
AB	PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003	JUN	NEWA
AB		30MG	N76308 002	JUN 20, 2003	JUN	NEWA
AB		45MG	N76308 003	JUN 20, 2003	JUN	NEWA
AB	ROXANE	15MG	N76270 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76270 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76270 003	JUN 19, 2003	JUN	NEWA
AB	TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
AB		30MG	N76119 002	JAN 24, 2003	JAN	NEWA
AB		45MG	N76119 003	JUN 19, 2003	JUN	NEWA
AB	WATSON LABS	15MG	N76312 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76312 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76312 003	JUN 19, 2003	JUN	NEWA
	REMERON					
AB +	ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
AB		30MG	N20415 002	JUN 14, 1996	JAN	CFTG
	TABLET, ORALLY DISINTEGRATING; ORAL					
>A>	MIRTAZAPINE					
>A>	AB	BARR	N76307 001	DEC 17, 2003	DEC	NEWA
>A>	AB		N76307 002	DEC 17, 2003	DEC	NEWA
	REMERON SOLTAB					
>D>	+ ORGANON USA INC	15MG	N21208 001	JAN 12, 2001	DEC	CFTG
>A>	AB +	15MG	N21208 001	JAN 12, 2001	DEC	CFTG
>D>		30MG	N21208 002	JAN 12, 2001	DEC	CFTG
>A>	AB	30MG	N21208 002	JAN 12, 2001	DEC	CFTG
	<u>MITOMYCIN</u>					
	INJECTABLE; INJECTION					
	MITOMYCIN					
AP	BAXTER HLTHCARE	5MG/VIAL	N64180 001	DEC 23, 1999	AUG	CAHN
AP		20MG/VIAL	N64180 002	DEC 23, 1999	AUG	CAHN
	<u>MOEXIPRIL HYDROCHLORIDE</u>					
	TABLET; ORAL					
	MOEXIPRIL HCL					
AB	TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB		15MG	N76204 002	MAY 08, 2003	MAY	NEWA
	UNIVASC					
AB	SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB +		15MG	N20312 002	APR 19, 1995	MAY	CFTG

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB	ATRIX	0.1%	N76481 001	NOV 14, 2003	NOV	NEWA
----	-------	------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	+	LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
BX	+		60MG	N21260 002	MAR 20, 2002	JUN	CAHN
	+		90MG	N21260 003	MAR 20, 2002	JUN	CAHN
	+		120MG	N21260 004	MAR 20, 2002	JUN	CAHN

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	BAXTER HLTHCARE	1MG/ML	N18565 002	SEP 18, 1984	AUG	CAHN
		INFUMORPH					
	+	BAXTER HLTHCARE	10MG/ML	N18565 003	JUL 19, 1991	AUG	CAHN
	+		25MG/ML	N18565 004	JUL 19, 1991	AUG	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ CLONMEL HLTHCARE

			15MG	N75407 001	JAN 28, 2000	JUL	DISC
AB		MALLINCKRODT	15MG	N76412 001	JUL 31, 2003	JUL	NEWA
AB			30MG	N76412 002	JUL 31, 2003	JUL	NEWA
AB			60MG	N76412 003	JUL 31, 2003	JUL	NEWA
AB			100MG	N76438 001	JUL 03, 2003	JUL	NEWA
AB			200MG	N76438 002	JUL 03, 2003	JUL	NEWA

ORAMORPH SR

>A>	BC	AAIPHARMA	15MG	N19977 004	NOV 23, 1994	DEC	CAHN
>A>	BC		30MG	N19977 001	AUG 15, 1991	DEC	CAHN
>A>	BC		60MG	N19977 002	AUG 15, 1991	DEC	CAHN
>A>	BC		100MG	N19977 003	AUG 15, 1991	DEC	CAHN
>D>	BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	DEC	CAHN
>D>	BC		30MG	N19977 001	AUG 15, 1991	DEC	CAHN
>D>	BC		60MG	N19977 002	AUG 15, 1991	DEC	CAHN
>D>	BC		100MG	N19977 003	AUG 15, 1991	DEC	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VIGAMOX

+	ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA
---	-------	------	------------	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	2%	N50591 001	DEC 31, 1987	NOV	CTEC
----	---	-----------------	----	------------	--------------	-----	------

>A> CENTANY

>A>	BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	DEC	CTNA
-----	----	---------------------	----	------------	--------------	-----	------

MUPIROCIN

AB		CLAY PARK	2%	N65123 001	NOV 07, 2003	NOV	NEWA
----	--	-----------	----	------------	--------------	-----	------

BX		CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	JAN	CTEC
----	--	----------------	----	------------	--------------	-----	------

>D>	BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	DEC	CTNA
-----	----	---------------------	----	------------	--------------	-----	------

BX			2%	N50788 001	DEC 04, 2002	APR	CAHN
----	--	--	----	------------	--------------	-----	------

AB	TEVA	2%	N65085 001	NOV 07, 2003	NOV	NEWA
<u>MYCOPHENOLATE MOFETIL</u>						
	CAPSULE; ORAL					
	CELLCEPT					
	+ ROCHE PALO	250MG	N50722 001	MAY 03, 1995	FEB	CAHN
	SUSPENSION; ORAL					
	+ ROCHE PALO	200MG/ML	N50759 001	OCT 01, 1998	FEB	CAHN
	TABLET; ORAL					
	+ ROCHE PALO	500MG	N50723 001	JUN 19, 1997	FEB	CAHN
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION					
	+ ROCHE PALO	500MG/VIAL	N50758 001	AUG 12, 1998	FEB	CAHN
<u>NABUMETONE</u>						
	TABLET; ORAL					
	NABUMETONE					
AB	IVAX PHARMS	500MG	N76009 001	JAN 24, 2003	JAN	NEWA
AB		750MG	N76009 002	JAN 24, 2003	JAN	NEWA
<u>NAFTIFINE HYDROCHLORIDE</u>						
	CREAM; TOPICAL					
	NAFTIN					
	ALLERGAN HERBERT	1%	N19599 001	FEB 29, 1988	OCT	CMFD
	@	1%	N19599 001	FEB 29, 1988	JUN	DISC
	GEL; TOPICAL					
	+ ALLERGAN HERBERT	1%	N19356 001	JUN 18, 1990	OCT	CMFD
	@	1%	N19356 001	JUN 18, 1990	JUN	DISC
<u>NALBUPHINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION					
	NALBUPHINE HCL					
	@ KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998	MAY	DISC
	@	20MG/ML	N74471 002	MAR 19, 1998	MAY	DISC
<u>NALOXONE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION					
	NALOXONE					
	@ BAXTER HLTHCARE	0.4MG/ML	N70496 001	SEP 24, 1986	AUG	CAHN
	@ ELKINS SINN	0.4MG/ML	N70299 001	SEP 24, 1986	JUN	DISC
	@ ELKINS SINN PHARM	0.4MG/ML	N70298 001	SEP 24, 1986	JUN	DISC
	NALOXONE HCL					
	@ BAXTER HLTHCARE	0.02MG/ML	N71272 001	MAY 24, 1988	AUG	CAHN
	@	1MG/ML	N71273 001	MAY 24, 1988	AUG	CAHN
	@	1MG/ML	N71274 001	MAY 24, 1988	AUG	CAHN
	@	1MG/ML	N71287 001	MAY 24, 1988	AUG	CAHN
	@ ELKINS SINN	0.02MG/ML	N71272 001	MAY 24, 1988	JUN	DISC
	@	1MG/ML	N71273 001	MAY 24, 1988	JUN	DISC
	@	1MG/ML	N71274 001	MAY 24, 1988	JUN	DISC
	@	1MG/ML	N71287 001	MAY 24, 1988	JUN	DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

a ORGANON USA INC

50MG/ML

N13132 001 JUN 12, 1986 MAY DISC

a

100MG/ML

N13132 002 JUN 12, 1986 MAY DISC

a

200MG/ML

N13132 003 JUN 12, 1986 MAY DISC

NANDROLONE DECANOATE

+ STERIS

50MG/ML

N86385 001 JAN 13, 1984 MAY CRLD

+

100MG/ML

N86598 001 JAN 13, 1984 MAY CRLD

+

200MG/ML

N88128 001 DEC 05, 1983 MAY CRLD

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB ABLE

EQ 250MG BASE

N76544 001 AUG 22, 2003 AUG NEWA

AB

EQ 500MG BASE

N76544 002 AUG 22, 2003 AUG NEWA

AB HIKMA

EQ 250MG BASE

N74480 002 FEB 18, 1998 OCT CAHN

AB

EQ 500MG BASE

N74480 001 MAY 14, 1996 OCT CAHN

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB + ELAN PHARM

EQ 375MG BASE

N20353 001 JAN 05, 1996 APR CFTG

AB +

EQ 500MG BASE

N20353 002 JAN 05, 1996 MAR CFTG

AB + ELAN PHARMA

EQ 375MG BASE

N20353 001 JAN 05, 1996 JUN CAHN

AB +

EQ 500MG BASE

N20353 002 JAN 05, 1996 JUN CAHN

a

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN CAHN

NAPROXEN SODIUM

AB ANDRX PHARMS

EQ 375MG BASE

N75416 002 APR 23, 2003 APR NEWA

AB

EQ 500MG BASE

N75416 001 AUG 27, 2002 MAR NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

AB DR REDDYS LABS INC

50MG

N76309 001 SEP 16, 2003 SEP NEWA

AB

100MG

N76309 002 SEP 16, 2003 SEP NEWA

AB

150MG

N76309 003 SEP 16, 2003 SEP NEWA

AB

200MG

N76309 004 SEP 16, 2003 SEP NEWA

AB

250MG

N76309 005 SEP 16, 2003 SEP NEWA

AB EON

50MG

N76302 001 SEP 16, 2003 SEP NEWA

AB

100MG

N76302 002 SEP 16, 2003 SEP NEWA

AB

150MG

N76302 003 SEP 16, 2003 SEP NEWA

AB

200MG

N76302 004 SEP 16, 2003 SEP NEWA

AB

250MG

N76302 005 SEP 16, 2003 SEP NEWA

AB GENEVA PHARMS

50MG

N76072 001 SEP 16, 2003 SEP NEWA

AB

100MG

N76072 002 SEP 16, 2003 SEP NEWA

AB

150MG

N76072 003 SEP 16, 2003 SEP NEWA

AB

200MG

N76072 004 SEP 16, 2003 SEP NEWA

AB

250MG

N76072 005 SEP 16, 2003 SEP NEWA

AB IVAX PHARMS

50MG

N75763 001 SEP 16, 2003 SEP NEWA

AB

100MG

N75763 002 SEP 16, 2003 SEP NEWA

AB

150MG

N75763 003 SEP 16, 2003 SEP NEWA

AB

200MG

N75763 004 SEP 16, 2003 SEP NEWA

AB

250MG

N75763 005 SEP 16, 2003 SEP NEWA

AB	MYLAN	100MG	N76129 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76129 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76129 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76129 005	SEP 16, 2003	SEP	NEWA
AB	RANBAXY	50MG	N76409 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76409 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76409 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76409 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76409 005	SEP 16, 2003	SEP	NEWA
AB	ROXANE	50MG	N76196 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76196 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76196 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76196 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76196 005	SEP 16, 2003	SEP	NEWA
AB	TEVA	50MG	N76037 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76037 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76037 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76037 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76037 005	SEP 16, 2003	SEP	NEWA
AB	WATSON LABS	100MG	N76073 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76073 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76073 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76073 005	SEP 16, 2003	SEP	NEWA
SERZONE						
AB	BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	SEP	CFTG
AB		100MG	N20152 002	DEC 22, 1994	SEP	CFTG
AB		150MG	N20152 003	DEC 22, 1994	SEP	CFTG
AB		200MG	N20152 004	DEC 22, 1994	SEP	CFTG
AB +		250MG	N20152 005	DEC 22, 1994	SEP	CFTG

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 625MG BASE

N21503 001 APR 30, 2003 APR NEWA

NICOTINE

INHALANT; ORAL

NICOTROL

>D> @ PHARMACIA AND UPJOHN 4MG/CARTRIDGE

>A> + 4MG/CARTRIDGE

N20714 001 MAY 02, 1997 DEC CMFD

N20714 001 MAY 02, 1997 DEC CMFD

NIFEDIPINE

CAPSULE; ORAL

ADALAT

@ BAYER PHARMS 10MG

@ 20MG

N19478 001 NOV 27, 1985 JUN DISC

N19478 002 SEP 17, 1986 JUN DISC

TABLET, EXTENDED RELEASE; ORAL

PROCARDIA XL

AB2 PFIZER 30MG

N19684 001 SEP 06, 1989 JUL CRLD

AB2 60MG

N19684 002 SEP 06, 1989 JUL CRLD

NITROFURANTOIN

TABLET; ORAL

FURADANTIN

@ PROCTER AND GAMBLE	50MG	N08693 001	APR	DISC
@	100MG	N08693 002	APR	DISC
NITROFURANTOIN				
@ WATSON LABS	50MG	N80447 001	APR	DISC
@ WHITEWORTH TOWN PLSN	100MG	N84085 002	APR	DISC

NITROFURAZONE

OINTMENT; TOPICAL

FURACIN

@ SHIRE PHARM	0.2%	N05795 001	MAR	DISC
---------------	------	------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL*

NITROGLYCERIN

AB2 MYLAN TECHNOLOGIES	0.1MG/HR	N75033 001	FEB 06, 1998	APR	CAHN
AB2 +	0.1MG/HR	N75033 001	FEB 06, 1998	AUG	CRLD
AB2	0.2MG/HR	N74609 001	AUG 30, 1996	APR	CAHN
AB2 +	0.2MG/HR	N74609 001	AUG 30, 1996	AUG	CRLD
AB2	0.4MG/HR	N74607 001	AUG 30, 1996	APR	CAHN
AB2 +	0.4MG/HR	N74607 001	AUG 30, 1996	AUG	CRLD
AB2	0.6MG/HR	N74559 001	AUG 30, 1996	APR	CAHN
AB2 +	0.6MG/HR	N74559 001	AUG 30, 1996	AUG	CRLD

TRANSDERM-NITRO

@ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996	AUG	DISC
@	0.2MG/HR	N20144 002	FEB 27, 1996	AUG	DISC
@	0.4MG/HR	N20144 003	FEB 27, 1996	AUG	DISC
@	0.6MG/HR	N20144 004	FEB 27, 1996	AUG	DISC
@	0.8MG/HR	N20144 005	FEB 27, 1996	AUG	DISC

INJECTABLE; INJECTION

TRIDIL

@ FAULDING	0.5MG/ML	N18537 002	JUN 16, 1983	MAY	DISC
@	5MG/ML	N18537 001		MAY	DISC

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA	2%	N87355 001	JUL 08, 1988	APR	CAHN
-----------	----	------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB TORPHARM	150MG	N76383 001	JAN 23, 2003	JAN	NEWA
AB	300MG	N76383 002	JAN 23, 2003	JAN	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP + ABBOTT	EQ 1MG BASE/ML	N07513 001		MAR	CFTG
-------------	----------------	------------	--	-----	------

NOREPINEPHRINE BITARTRATE

AP BEDFORD	EQ 1MG BASE/ML	N40462 001	OCT 31, 2003	OCT	NEWA
AP GENSLA SICOR PHARMS	EQ 1MG BASE/ML	N40455 001	MAR 03, 2003	MAR	NEWA

*SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB + DURAMED PHARMS BARR 5MG

N18405 001 APR 21, 1982 JUN CAHN

AB + WYETH PHARMS INC 5MG

N18405 001 APR 21, 1982 MAR CAHN

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

@ MERCK 0.3%

N19757 001 JUN 17, 1991 MAY DISC

NORGESTREL

TABLET; ORAL

OVRETTE

+ WYETH PHARMS INC 0.075MG

N17031 001 MAR CAHN

NYSTATIN

POWDER; ORAL

NILSTAT

@ CLONMEL HLTHCARE 100%

N50576 001 DEC 22, 1983 JUL DISC

NYSTATIN

+ PADDOCK 100%

N62613 001 NOV 26, 1985 JUL CRLD

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

@ ORTHO MCNEIL PHARM 40MG/ML

N20087 003 MAR 31, 1992 NOV DISC

FLOXIN IN DEXTROSE 5%

@ ORTHO MCNEIL PHARM 400MG/100ML

N20087 001 MAR 31, 1992 NOV DISC

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ORTHO MCNEIL PHARM 400MG/100ML

N20087 005 MAR 31, 1992 NOV DISC

OFLOXACIN

+ BEDFORD 40MG/ML

N75762 001 JAN 16, 2002 NOV CRLD

TABLET; ORAL

FLOXIN

AB ORTHO MCNEIL PHARM 200MG

N19735 001 DEC 28, 1990 SEP CFTG

AB 300MG

N19735 002 DEC 28, 1990 SEP CFTG

AB + 400MG

N19735 003 DEC 28, 1990 SEP CFTG

OFLOXACIN

AB PAR PHARM 200MG

N76093 001 SEP 02, 2003 SEP NEWA

AB 300MG

N76093 002 SEP 02, 2003 SEP NEWA

AB 400MG

N76093 003 SEP 02, 2003 SEP NEWA

AB RANBAXY 200MG

N76220 001 SEP 02, 2003 SEP NEWA

AB 300MG

N76220 002 SEP 02, 2003 SEP NEWA

AB 400MG

N76220 003 SEP 02, 2003 SEP NEWA

AB TEVA 200MG

N76182 001 SEP 02, 2003 SEP NEWA

AB 300MG

N76182 002 SEP 02, 2003 SEP NEWA

AB 400MG

N76182 003 SEP 02, 2003 SEP NEWA

OLANZAPINE

TABLET; ORAL

ZYPREXA

+	LILLY	5MG
		20MG

N20592 002 SEP 30, 1996 MAY CRLD

N20592 006 SEP 09, 1997 MAY CRLD

TABLET, ORALLY DISINTEGRATING; ORAL

ZYPREXA ZYDIS

+	LILLY	5MG
		20MG

N21086 001 APR 06, 2000 AUG CRLD

N21086 004 APR 06, 2000 AUG CRLD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	LEK SVCS	10MG
AB		20MG
AB	MYLAN	10MG
AB		20MG
AB	TORPHARM	10MG
AB		20MG

N75757 001 JAN 28, 2003 JAN NEWA

N75757 002 JAN 28, 2003 JAN NEWA

N75876 001 MAY 29, 2003 MAY NEWA

N75876 002 MAY 29, 2003 MAY NEWA

N76048 001 OCT 06, 2003 OCT NEWA

N76048 002 OCT 06, 2003 OCT NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	BEDFORD LABS	30MG/ML
----	--------------	---------

N40463 001 MAR 04, 2003 MAR NEWA

OXANDROLONE

TABLET; ORAL

OXANDRIN

>D>	BIO TECH GEN	2.5MG
>D>	+	10MG
>A>	SAVIENT PHARMS	2.5MG
>A>	+	10MG

N13718 001 DEC CAHN

N13718 002 NOV 05, 2001 DEC CAHN

N13718 001 DEC CAHN

N13718 002 NOV 05, 2001 DEC CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+	WATSON LABS (UTAH)	3.9MG/24HR
---	--------------------	------------

N21351 002 FEB 26, 2003 FEB NEWA

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

ALZA	5MG
	10MG

N20897 001 DEC 16, 1998 MAY CRLD

N20897 002 DEC 16, 1998 MAY CRLD

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXICODONE

>A>	+	AAIPHARMA	15MG
>A>			30MG
>D>	+	ELAN PHARMS	15MG
	+		15MG
>D>			30MG

N21011 001 AUG 31, 2000 DEC CAHN

N21011 002 AUG 31, 2000 DEC CAHN

N21011 001 AUG 31, 2000 DEC CAHN

N21011 001 AUG 31, 2000 OCT CRLD

N21011 002 AUG 31, 2000 DEC CAHN

	30MG		N21011 002	AUG 31, 2000	OCT	CRLD
<u>OXYTOCIN</u>						
INJECTABLE; INJECTION						
OXYTOCIN						
	@ BAXTER HLTHCARE CORP	10USP UNITS/ML	N18243 001		MAY	CAHN
<u>PALONOSETRON HYDROCHLORIDE</u>						
INJECTABLE; INTRAVENOUS						
ALOXI						
+	HELSINN HLTHCARE	EQ 0.25MG BASE/5ML(EQ 0.05MG BASE/ML)	N21372 001	JUL 25, 2003	JUL	NEWA
<u>PANCURONIUM BROMIDE</u>						
INJECTABLE; INJECTION						
PANCURONIUM BROMIDE						
AP +	GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
AP +		2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
PAVULON						
	@ ORGANON	1MG/ML	N17015 002		MAY	DISC
	@	2MG/ML	N17015 001		MAY	DISC
<u>PANTOPRAZOLE SODIUM</u>						
INJECTABLE; IV (INFUSION)						
PROTONIX IV						
+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	CAHN
TABLET, DELAYED RELEASE; ORAL						
PROTONIX						
+	WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
		EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
+		EQ 40MG BASE	N20987 001	FEB 02, 2000	MAR	CAHN
<u>PAROMOMYCIN SULFATE</u>						
CAPSULE; ORAL						
HUMATIN						
AA +	KING PHARMS	EQ 250MG BASE	N62310 001		MAY	CAHN
<u>PAROXETINE HYDROCHLORIDE</u>						
TABLET; ORAL						
PAROXETINE HCL						
AB	TORPHARM	EQ 10MG BASE	N75356 001	JUL 30, 2003	JUL	NEWA
AB		EQ 20MG BASE	N75356 002	JUL 30, 2003	JUL	NEWA
AB		EQ 30MG BASE	N75356 003	JUL 30, 2003	JUL	NEWA
AB		EQ 40MG BASE	N75356 004	JUL 30, 2003	JUL	NEWA
PAXIL						
AB	GLAXOSMITHKLINE	EQ 10MG BASE	N20031 001	DEC 29, 1992	JUL	CFTG
AB		EQ 20MG BASE	N20031 002	DEC 29, 1992	JUL	CFTG
AB		EQ 30MG BASE	N20031 003	DEC 29, 1992	JUL	CFTG
AB +		EQ 40MG BASE	N20031 005	DEC 29, 1992	JUL	CFTG
<u>PAROXETINE MESYLATE</u>						
TABLET; ORAL						
PAROXETINE MESYLATE						
	SYNTHON PHARMS	EQ 10MG BASE	N21299 001	JUL 03, 2003	JUL	NEWA

	EQ 20MG BASE	N21299 002	JUL 03, 2003	JUL	NEWA
	EQ 30MG BASE	N21299 003	JUL 03, 2003	JUL	NEWA
+	EQ 40MG BASE	N21299 004	JUL 03, 2003	JUL	NEWA

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS
SOMAVERT

+	PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
+		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
+		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

@	MARSAM PHARMS LLC	1,000,000 UNITS/VIAL	N62991 001	SEP 13, 1988	JUL	DISC
@		5,000,000 UNITS/VIAL	N62991 002	SEP 13, 1988	JUL	DISC
@		10,000,000 UNITS/VIAL	N62991 003	SEP 13, 1988	JUL	DISC
@		20,000,000 UNITS/VIAL	N62991 004	SEP 13, 1988	JUL	DISC

TABLET; ORAL

@	WYETH AYERST	200,000 UNITS	N60413 001		JUN	DISC
@		250,000 UNITS	N60413 002		JUN	DISC
@		400,000 UNITS	N60413 003		JUN	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

>D>	AA	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N62270 001		DEC	DISC
>A>		@	EQ 125MG BASE/5ML	N62270 001		DEC	DISC
>D>	AA		EQ 250MG BASE/5ML	N62270 002		DEC	DISC
>A>		@	EQ 250MG BASE/5ML	N62270 002		DEC	DISC
		LEDERCILLIN VK					
		@ LEDERLE	EQ 125MG BASE/5ML	N60136 001		JUN	DISC
		@	EQ 250MG BASE/5ML	N60136 002		JUN	DISC

TABLET; ORAL

BEEPEN-VK

>D>	AB	GLAXOSMITHKLINE	EQ 250MG BASE	N62273 001		DEC	DISC
>A>		@	EQ 250MG BASE	N62273 001		DEC	DISC
>D>	AB		EQ 500MG BASE	N62273 002		DEC	DISC
>A>		@	EQ 500MG BASE	N62273 002		DEC	DISC
>D>		BETAPEN-VK					
>D>	AB	BRISTOL	EQ 250MG BASE	N61150 001		DEC	DISC
>A>		@	EQ 250MG BASE	N61150 001		DEC	DISC
>D>	AB		EQ 500MG BASE	N61150 002		DEC	DISC
>A>		@	EQ 500MG BASE	N61150 002		DEC	DISC

LEDERCILLIN VK

@	LEDERLE	EQ 250MG BASE	N60134 001		JUN	DISC
@		EQ 500MG BASE	N60134 002		JUN	DISC

PEN-VEE K

@	WYETH AYERST	EQ 250MG BASE	N60006 002		JUN	DISC
@		EQ 500MG BASE	N60006 003		JUN	DISC

PENICILLIN V POTASSIUM

>D>	AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001		DEC	DISC
>A>		@	EQ 250MG BASE	N61528 001		DEC	DISC

>D>	AB	EQ 500MG BASE	N61528 002	DEC	DISC
>A>	@	EQ 500MG BASE	N61528 002	DEC	DISC
>D>	UTICILLIN VK				
>D>	AB PHARMACIA AND UPJOHN	EQ 250MG BASE	N61651 001	DEC	DISC
>A>	@	EQ 250MG BASE	N61651 001	DEC	DISC

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

@ BAXTER HLTHCARE	300MG/VIAL	N73617 001	DEC 18, 1995	AUG	CAHN
@ ELKINS SINN	300MG/VIAL	N73617 001	DEC 18, 1995	JUN	DISC

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

>D>	@ ABBOTT	18.2MG/5ML	N83244 001	DEC	CAHN
>A>	@ OVATION PHARMS	18.2MG/5ML	N83244 001	DEC	CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

>D>	+ ABBOTT	30MG	N84095 001	DEC	CAHN
>D>	@	50MG	N84093 001	DEC	CAHN
>D>	AA +	100MG	N83245 001	DEC	CAHN
>A>	+ OVATION PHARMS	30MG	N84095 001	DEC	CAHN
>A>	@	50MG	N84093 001	DEC	CAHN
>A>	AA +	100MG	N83245 001	DEC	CAHN

INJECTABLE; INJECTION

>D>	+ ABBOTT	50MG/ML	N83246 001	DEC	CAHN
	+	50MG/ML	N83246 001	JUN	CTEC
>A>	+ OVATION PHARMS	50MG/ML	N83246 001	DEC	CAHN

SODIUM PENTOBARBITAL

@ WYETH AYERST	50MG/ML	N83261 001	JUN	DISC
----------------	---------	------------	-----	------

SUPPOSITORY; RECTAL

NEMBUTAL

>D>	@ ABBOTT	60MG	N83247 002	JAN 25, 1982	DEC	CAHN
>D>	@	120MG	N83247 003	JAN 25, 1982	DEC	CAHN
>D>	@	200MG	N83247 004	JAN 25, 1982	DEC	CAHN
>A>	@ OVATION PHARMS	60MG	N83247 002	JAN 25, 1982	DEC	CAHN
>A>	@	120MG	N83247 003	JAN 25, 1982	DEC	CAHN
>A>	@	200MG	N83247 004	JAN 25, 1982	DEC	CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

AB	IVAX PHARMS	EQ 0.05MG BASE	N76094 001	SEP 04, 2003	SEP	NEWA
AB		EQ 0.25MG BASE	N76094 002	SEP 04, 2003	SEP	NEWA
AB		EQ 1MG BASE	N76094 003	SEP 04, 2003	SEP	NEWA

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB	CLAY PARK	5%	N76369 001	APR 21, 2003	APR	NEWA
----	-----------	----	------------	--------------	-----	------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB +	IVAX PHARMS	16MG	N89457 001	SEP 10, 1987	FEB	CRLD
	TRILAFON					
	@ SCHERING	2MG	N10775 001		FEB	DISC
	@	4MG	N10775 002		FEB	DISC
	@	8MG	N10775 003		FEB	DISC
	@	16MG	N10775 004		FEB	DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA	ABLE	15MG	N40497 001	MAR 13, 2003	MAR	NEWA
AA	AMBI PHARMS	30MG	N40083 001	MAR 07, 1997	MAY	CAHN
AA	AMIDE PHARM	15MG	N40460 001	JAN 14, 2003	JAN	NEWA
AA		30MG	N40448 001	JAN 22, 2003	JAN	NEWA
AA	MUTUAL PHARM	30MG	N40525 001	OCT 23, 2003	OCT	NEWA
AA		37.5MG	N40527 001	OCT 23, 2003	OCT	NEWA

TABLET; ORAL

AA +	EON	30MG	N88605 001	SEP 28, 1987	JAN	CFTG
AA	MUTUAL PHARM	37.5MG	N40526 001	OCT 23, 2003	OCT	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

@ WYETH AYERST 5MG/5ML;6.25MG/5ML

N08604 003 APR 02, 1984 APR DISC

PROMETH VC PLAIN

AA +	ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984	APR	CRLD
------	----------	--------------------	------------	--------------	-----	------

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB	VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001	MAR	CAHN
----	------------	-----------	------------	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE; INJECTION

DILANTIN

@ PARKE DAVIS 50MG/ML

N10151 001 MAR DISC

PHENYTOIN

+ ELKINS SINN 50MG/ML

N84307 001 MAR CRLD

PHENYTOIN SODIUM

@ ABBOTT 50MG/ML

N89521 001 MAR 17, 1987 MAR DISC

@ 50MG/ML

N89744 001 DEC 18, 1987 MAR DISC

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

DILANTIN

PARKE DAVIS 30MG

N84349 001 FEB CRLD

+ 30MG

N84349 001 JUN CRLD

EXTENDED PHENYTOIN SODIUM

AB	BARR	100MG	N40435 001	JUN 20, 2003	JUN	NEWA
----	------	-------	------------	--------------	-----	------

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

SALAGEN

MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994	APR	CRLD
+	7.5MG	N20237 002	APR 18, 2003	APR	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+ AM PHARM	EQ 2GM BASE/VIAL	N65114 001	NOV 14, 2003	NOV	NEWA
+	EQ 3GM BASE/VIAL	N65114 002	NOV 14, 2003	NOV	NEWA
+	EQ 4GM BASE/VIAL	N65114 003	NOV 14, 2003	NOV	NEWA

PIPRACIL

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002		MAR	CAHN
@	EQ 2GM BASE/VIAL	N50545 002		JUN	DISC
	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	JUN	DISC
+	EQ 3GM BASE/VIAL	N50545 003		MAR	CAHN
@	EQ 3GM BASE/VIAL	N50545 003		JUN	DISC
	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	JUN	DISC
+	EQ 4GM BASE/VIAL	N50545 004		MAR	CAHN
@	EQ 4GM BASE/VIAL	N50545 004		JUN	DISC
	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	JUN	DISC
@	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
+	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
+	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
+	EQ 36GM BASE/VIAL;EQ 4.5GM				
	BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN

ZOSYN IN PLASTIC CONTAINER

+ WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
+	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
+	EQ 4GM BASE/100ML;EQ 500MG				
	BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@ 3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC
------	-------------------	------------	--------------	-----	------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ SCS	10MG	N74036 001	MAY 29, 1992	OCT	WDAG
@	20MG	N74036 002	MAY 29, 1992	OCT	WDAG

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ BAXTER HLTHCARE 2MEQ/ML

N80203 001

AUG CAHN

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M15

UPSHER SMITH 15MEQ

N74726 003 JUN 06, 2003 JUN NEWA

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

@ BAXTER HLTHCARE CORP 300MG/ML

N18799 001 DEC 13, 1982 MAR CAHN

PROTOPAM CHLORIDE

+ BAXTER HLTHCARE CORP 1GM/VIAL

N14134 001 JUL CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

>A> BOEHRINGER INGELHEIM 0.125MG

N20667 001 JUL 01, 1997 DEC CAHN

>A> + 0.25MG

N20667 002 JUL 01, 1997 DEC CAHN

>A> 0.5MG

N20667 006 FEB 12, 1998 DEC CAHN

>A> 1MG

N20667 003 JUL 01, 1997 DEC CAHN

>A> @ 1.25MG

N20667 004 JUL 01, 1997 DEC CAHN

>A> 1.5MG

N20667 005 JUL 01, 1997 DEC CAHN

>D> PHARMACIA AND UPJOHN 0.125MG

N20667 001 JUL 01, 1997 DEC CAHN

0.125MG

N20667 001 JUL 01, 1997 NOV CRLD

>D> + 0.25MG

N20667 002 JUL 01, 1997 DEC CAHN

+ 0.25MG

N20667 002 JUL 01, 1997 OCT CRLD

>D> 0.5MG

N20667 006 FEB 12, 1998 DEC CAHN

>D> 1MG

N20667 003 JUL 01, 1997 DEC CAHN

>D> @ 1.25MG

N20667 004 JUL 01, 1997 DEC CAHN

>D> 1.5MG

N20667 005 JUL 01, 1997 DEC CAHN

1.5MG

N20667 005 JUL 01, 1997 OCT CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL

@ CLONMEL HLTHCARE EQ 2MG BASE

N72706 001 MAY 16, 1989 JUL DISC

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+ DERMIK LABS 0.1%

N20279 001 OCT 29, 1993 APR CTNA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA AXIOM PHARM 15MG/5ML

N40287 001 MAY 28, 1999 MAY CAHN

AA HI TECH PHARMA 15MG/5ML

N40401 001 FEB 27, 2003 FEB NEWA

+ KV PHARM 5MG/5ML

N40423 001 OCT 22, 2001 JUL CRLD

AA + 15MG/5ML

N40364 001 APR 10, 2002 JUL CRLD

AA MORTON GROVE 15MG/5ML

N40313 001 SEP 10, 2003 SEP NEWA

AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA
	PRELONE					
	@ MURO	5MG/5ML	N89654 001	JAN 17, 1989	JUL	DISC
AA +	TEVA	15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN
AA		15MG/5ML	N89081 001	FEB 04, 1986	JUL	CRLD

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

@ ALCON 0.125%

N17468 001 JUN DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

@ ALCON 0.25%;10%

N87771 001 AUG 06, 1993 JUN DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA HI TECH PHARMA EQ 5MG BASE/5ML

N75183 001 MAR 26, 2003 MAR NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT ALCON EQ 0.23% PHOSPHATE;10%

N73630 001 MAY 27, 1993 APR CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA
>D>	AB	WEST WARD	50MG	N88465 001	JUN 01, 1984	DEC DISC
>A>	@	50MG	N88465 001	JUN 01, 1984	DEC	DISC

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB +	XCEL PHARMS	50MG	N09170 003		JUL	CRLD
AB		250MG	N09170 002		JUL	CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

@ BAXTER HLTHCARE 100MG/ML

N89029 001 APR 17, 1986 AUG CAHN

@ 500MG/ML

N89030 001 APR 17, 1986 AUG CAHN

@ ELKINS SINN 100MG/ML

N89029 001 APR 17, 1986 JUN DISC

@ 500MG/ML

N89030 001 APR 17, 1986 JUN DISC

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

@ AM PHARM PARTNERS 1%

N80421 001 OCT DISC

@ 2%

N80421 002 OCT DISC

@ ELKINS SINN 1%

N83315 001 OCT DISC

	@	2%	N83315 002		OCT	DISC
	@ STERIS	2%	N80658 002		OCT	DISC
<u>PROCHLORPERAZINE EDISYLATE</u>						
INJECTABLE; INJECTION						
PROCHLORPERAZINE						
AP	BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759 001	OCT 01, 1982	AUG	CAHN
PROCHLORPERAZINE EDISYLATE						
	@ BAXTER HLTHCARE	EQ 5MG BASE/ML	N89523 001	MAY 03, 1988	AUG	CAHN
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003	MAY	NEWA
<u>PROMAZINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
SPARINE						
	@ BAXTER HLTHCARE CORP	25MG/ML	N10349 008		AUG	CAHN
	@	50MG/ML	N10349 006		AUG	CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
PHENERGAN						
	@ WYETH AYERST	25MG/ML	N08857 002		JUN	DISC
	@	50MG/ML	N08857 003		APR	DISC
PROMETHAZINE HCL						
AP	BAXTER HLTHCARE	25MG/ML	N83312 001		JUN	CAHN
AP		50MG/ML	N83312 002		JUN	CAHN
AP +	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
AP +		50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
AP	PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003	MAR	NEWA
SUPPOSITORY; RECTAL						
PHENERGAN						
AB +	WYETH AYERST	50MG	N11689 001		FEB	CTEC
AB	WYETH PHARMS INC	12.5MG	N10926 002		MAR	CAHN
AB +		25MG	N10926 001		MAR	CAHN
AB +		50MG	N11689 001		MAR	CAHN
PROMETHAZINE HCL						
AB	ABLE	12.5MG	N40504 001	APR 11, 2003	APR	NEWA
AB		25MG	N40504 002	APR 11, 2003	APR	NEWA
AB		50MG	N40449 001	FEB 27, 2003	FEB	NEWA
AB	CLAY PARK	12.5MG	N40500 001	JUN 30, 2003	JUN	NEWA
AB		25MG	N40500 002	JUN 30, 2003	JUN	NEWA
AB	G AND W LABS	12.5MG	N40428 002	MAR 31, 2003	MAR	NEWA
AB	PADDOCK	12.5MG	N40479 001	JUN 24, 2003	JUN	NEWA
AB		25MG	N40479 002	JUN 24, 2003	JUN	NEWA
SYRUP; ORAL						
PHENERGAN PLAIN						
	@ WYETH AYERST	6.25MG/5ML	N08381 004	APR 18, 1984	JUN	DISC
PROMETH PLAIN						
AA +	ALPHARMA	6.25MG/5ML	N85953 001		JUN	CRLD
TABLET; ORAL						
PHENERGAN						
	WYETH PHARMS INC	12.5MG	N07935 002		MAR	CAHN
BP		25MG	N07935 003		MAR	CAHN
BP +		50MG	N07935 004		MAR	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RYTHMOL SR

ABBOTT 225MG

N21416 001 SEP 04, 2003 SEP NEWA

325MG

N21416 002 SEP 04, 2003 SEP NEWA

+ 425MG

N21416 003 SEP 04, 2003 SEP NEWA

RELIANT PHARMS 225MG

N21416 001 SEP 04, 2003 NOV CAHN

325MG

N21416 002 SEP 04, 2003 NOV CAHN

+ 425MG

N21416 003 SEP 04, 2003 NOV CAHN

TABLET; ORAL

RYTHMOL

AB RELIANT PHARMS 150MG

N19151 001 NOV 27, 1989 NOV CAHN

AB 225MG

N19151 003 NOV 20, 1992 NOV CAHN

AB + 300MG

N19151 002 NOV 27, 1989 NOV CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

@ BAXTER HLTHCARE CORP 20MG/ML

N12382 002 MAY CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

+ AAIPHARMA LLC 32MG

N10997 001 NOV CTEC

DOLENE

@ CLONMEL HLTHCARE 65MG

N80530 001 AUG DISC

PROPOXYPHENE HCL

@ MYLAN 32MG

N83528 001 NOV DISC

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

@ AAIPHARMA LLC 50MG/5ML

N16861 001 JUL DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH PHARMS INC 60MG

N18553 004 MAR 18, 1987 MAR CAHN

BX 80MG

N18553 002 APR 19, 1983 MAR CTEC

BX 120MG

N18553 003 APR 19, 1983 MAR CTEC

+ 160MG

N18553 001 APR 19, 1983 MAR CAHN

INNOPRAN XL

BX RELIANT PHARMS 80MG

N21438 001 MAR 12, 2003 MAR NEWA

BX 120MG

N21438 002 MAR 12, 2003 MAR NEWA

INJECTABLE; INJECTION

INDERAL

AP + BAXTER HLTHCARE CORP 1MG/ML

N16419 001 MAY CAHN

PROPRANOLOL HCL

AP + BAXTER HLTHCARE CORP 1MG/ML

N16419 001 AUG CTNA

AP SABEX 2002 1MG/ML

N76400 001 FEB 26, 2003 FEB NEWA

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERAL

AB. +	WYETH PHARMS INC	10MG	N16418 001		MAR	CAHN
AB		20MG	N16418 003		MAR	CAHN
AB		40MG	N16418 002		MAR	CAHN
AB		60MG	N16418 009	OCT 18, 1982	MAR	CAHN
AB +		80MG	N16418 004		MAR	CAHN
@		90MG	N16418 010	OCT 18, 1982	MAR	CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@	BAXTER HLTHCARE	10MG/ML	N89474 001	NOV 05, 1986	AUG	CAHN
@		10MG/ML	N89475 001	NOV 05, 1986	AUG	CAHN
@	ELKINS SINN	10MG/ML	N89474 001	NOV 05, 1986	JUN	DISC
@		10MG/ML	N89475 001	NOV 05, 1986	JUN	DISC

PROTIRELIN

INJECTABLE; INJECTION

THYREL TRH

@	FERRING	0.5MG/ML	N18087 001		JUL	DISC
---	---------	----------	------------	--	-----	------

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

@	ORGANON	5MG/ML	N17398 001		MAY	DISC
@	SABEX 2002	5MG/ML	N17398 001		JUN	CAHN
AP		5MG/ML	N17398 001		OCT	CMFD

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

AB	BARR	60MG	N40512 001	OCT 08, 2003	OCT	NEWA
AB	IMPAX LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA
@	US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

+	ASTRAZENECA	EQ 25MG BASE	N20639 001	SEP 26, 1997	MAR	CRLD
---	-------------	--------------	------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

AB	PFIZER PHARMS	EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG
AB		EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG
AB		EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG
AB +		EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG

QUINAPRIL HCL

AB	TEVA	EQ 5MG BASE	N75504 001	MAY 30, 2003	MAY	NEWA
AB		EQ 10MG BASE	N75504 002	MAY 30, 2003	MAY	NEWA
AB		EQ 20MG BASE	N75504 003	MAY 30, 2003	MAY	NEWA

AB	EQ 40MG BASE	N75504 004	NOV 20, 1998	MAY	NEWA
<u>QUINIDINE GLUCONATE</u>					
TABLET, EXTENDED RELEASE; ORAL					
QUINAGLUTE					
	@ BERLEX LABS	324MG	N16647 001	MAR	DISC
QUINIDINE GLUCONATE					
BX +	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	APR CRLD
	+	324MG	N89338 001	FEB 11, 1987	MAY CTEC
	+ WATSON LABS	324MG	N87810 001	SEP 29, 1982	MAR CRLD
BX		324MG	N87810 001	SEP 29, 1982	APR CRLD
	@	324MG	N87810 001	SEP 29, 1982	MAY DISC
<u>QUINIDINE SULFATE</u>					
TABLET; ORAL					
QUINIDINE SULFATE					
AB	CLONMEL HLTHCARE	200MG	N87011 001	JUL	CAHN
TABLET, EXTENDED RELEASE; ORAL					
QUINIDEX					
AB +	WYETH PHARMS INC	300MG	N12796 002	MAR	CAHN
	@	300MG	N12796 002	JUN	DISC
QUINIDINE SULFATE					
	+ COPLEY PHARM	300MG	N40045 001	JUN 30, 1994	JUN CTEC
<u>RANITIDINE HYDROCHLORIDE</u>					
CAPSULE; ORAL					
RANITIDINE HCL					
AB	TEVA	EQ 150MG BASE	N75557 001	OCT 31, 2003	OCT NEWA
AB		EQ 300MG BASE	N75557 002	OCT 31, 2003	OCT NEWA
<u>RESERPINE; TRICHLORMETHIAZIDE</u>					
TABLET; ORAL					
METATENSIN #2					
	@ AVENTIS PHARMS	0.1MG;2MG	N12972 001	MAY	DISC
METATENSIN #4					
	@ AVENTIS PHARMS	0.1MG;4MG	N12972 002	MAY	DISC
<u>RIBAVIRIN</u>					
SOLUTION; ORAL					
REBETOL					
	+ SCHERING	40MG/ML	N21546 001	JUL 29, 2003	JUL NEWA
<u>RILUZOLE</u>					
TABLET; ORAL					
RILUTEK					
AB +	AVENTIS	50MG	N20599 001	DEC 12, 1995	JAN CFTG
RILUZOLE					
AB	IMPAX LABS	50MG	N76173 001	JAN 29, 2003	JAN NEWA
<u>RIMANTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
RIMANTADINE HCL					
AB	AMIDE PHARM	100MG	N76375 001	JAN 14, 2003	JAN NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

JOHNSON AND JOHNSON 25MG/VIAL
 37.5MG/VIAL
 + 50MG/VIAL

N21346 001 OCT 29, 2003 OCT NEWA
 N21346 002 OCT 29, 2003 OCT NEWA
 N21346 003 OCT 29, 2003 OCT NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JOHNSON AND JOHNSON 0.5MG
 + 1MG
 2MG

N21444 001 APR 02, 2003 APR NEWA
 N21444 002 APR 02, 2003 APR NEWA
 N21444 003 APR 02, 2003 APR NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

SB PHARMCO EQ 2MG BASE
 EQ 4MG BASE
 + EQ 8MG BASE

N21071 002 MAY 25, 1999 APR CAHN
 N21071 003 MAY 25, 1999 APR CAHN
 N21071 004 MAY 25, 1999 APR CAHN

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

ASTRAZENECA 5MG
 10MG
 20MG
 + 40MG

N21366 002 AUG 12, 2003 AUG NEWA
 N21366 003 AUG 12, 2003 AUG NEWA
 N21366 004 AUG 12, 2003 AUG NEWA
 N21366 005 AUG 12, 2003 AUG NEWA

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL 8,500 IU/ML

N20772 001 APR 09, 1998 MAY CAHN

SECOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM SECOBARBITAL

>D> SODIUM SECOBARBITAL
 >D> AA WEST WARD 100MG
 >A> @ 100MG

N84926 001 DEC DISC
 N84926 001 DEC DISC

INJECTABLE; INJECTION

@ WYETH AYERST 50MG/ML

N83262 001 JUN DISC

SECRETIN

FOR SOLUTION; INTRAVENOUS

SECFLO

+ CHIRHOCLIN 16UGM/VIAL

N21136 001 APR 04, 2002 NOV NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HCL

AB AAIPHARMA LLC 5MG

N75145 001 SEP 15, 2003 SEP NEWA

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

@ SERONO

EQ 0.5MG BASE/VIAL

N20443 001 SEP 26, 1997 JUN DISC

@

EQ 1MG BASE/VIAL

N20443 002 SEP 26, 1997 JUN DISC

>A> SERTACONAZOLE NITRATE

>A> CREAM; TOPICAL

>A> ERTACZO

>A> + JOHNSON JOHNSON

2%

N21385 001 DEC 10, 2003 DEC NEWA

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

+ GENZYME

403MG

N20926 001 OCT 30, 1998 APR CAHN

TABLET; ORAL

GENZYME

400MG

N21179 001 JUL 12, 2000 APR CAHN

+

800MG

N21179 002 JUL 12, 2000 APR CAHN

SILDENAFIL CITRATE

TABLET; ORAL

VIAGRA

PFIZER IRELAND

25MG

N20895 001 MAR 27, 1998 OCT CAHN

50MG

N20895 002 MAR 27, 1998 OCT CAHN

+

100MG

N20895 003 MAR 27, 1998 OCT CAHN

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ WYETH PHARMS INC

1MG/ML

N21083 001 SEP 15, 1999 MAR CAHN

TABLET; ORAL

WYETH PHARMS INC

1MG

N21110 001 AUG 25, 2000 MAR CRLD

+

2MG

N21110 002 AUG 22, 2002 MAR NEWA

SODIUM IODIDE, I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ DRAXIMAGE

1-250mCi

N21305 002 JAN 24, 2003 JAN NEWA

+

1-500mCi

N21305 003 JAN 24, 2003 JAN NEWA

SOLUTION; ORAL

SODIUM IODIDE I 131, KIT

+ DRAXIMAGE

1-250mCi/0.25ML

N21305 002 JAN 24, 2003 FEB CDFR

+

1-500mCi/0.5ML

N21305 003 JAN 24, 2003 FEB CDFR

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

AP + ABBOTT

50MG/VIAL

N70566 001 JUN 09, 1986 JUN CRLD

+

50MG/VIAL

N70566 001 JUN 09, 1986 AUG CTEC

SODIUM NITROPRUSSIDE

@ BAXTER HLTHCARE

50MG/VIAL

N18581 001 JUL 28, 1982 AUG CAHN

@ ELKINS SINN

50MG/VIAL

N18581 001 JUL 28, 1982 JUN DISC

SOMATROPIN

INJECTABLE; INJECTION

ZORBTIVE

>A>	BX	SERONO INC	4MG/VIAL	N21597 001	DEC 01, 2003	DEC	NEWA
>A>	BX		5MG/VIAL	N21597 002	DEC 01, 2003	DEC	NEWA
>A>	BX		6MG/VIAL	N21597 003	DEC 01, 2003	DEC	NEWA
>A>	+		8.8MG/VIAL	N21597 004	DEC 01, 2003	DEC	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

BIO-TROPIN

>D>		@ BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995	DEC	CAHN
		@	4.8MG/VIAL	N19774 001	MAY 25, 1995	MAR	DISC
>A>		@ SAVIENT PHARMS	4.8MG/VIAL	N19774 001	MAY 25, 1995	DEC	CAHN

NORDITROPIN

BX		NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995	JUL	CMFD
			8MG/VIAL	N19721 002	MAY 08, 1995	JUL	CMFD

SEROSTIM

SERONO

			4MG/VIAL	N20604 003	JUL 25, 1997	NOV	CRLD
--	--	--	----------	------------	--------------	-----	------

TEV-TROPIN

>D>	BX	+	BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	DEC	CAHN
	BX	+		5MG/ML	N19774 002	JAN 04, 2002	FEB	CTNA
>A>	BX	+	SAVIENT PHARMS	5MG/ML	N19774 002	JAN 04, 2002	DEC	CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB1		BERLEX LABS	80MG	N19865 001	OCT 30, 1992	AUG	CTEC
AB1			120MG	N19865 005	APR 20, 1994	AUG	CTEC
AB1	+		160MG	N19865 002	OCT 30, 1992	AUG	CTEC
AB1			240MG	N19865 003	OCT 30, 1992	AUG	CTEC

BETAPACE AF

@ BERLEX LABS

			40MG	N21151 006	APR 02, 2003	MAY	DISC
--	--	--	------	------------	--------------	-----	------

@

			40MG	N21151 006	APR 02, 2003	APR	NEWA
--	--	--	------	------------	--------------	-----	------

@

			60MG	N21151 007	APR 02, 2003	MAY	DISC
--	--	--	------	------------	--------------	-----	------

@

			60MG	N21151 007	APR 02, 2003	APR	NEWA
--	--	--	------	------------	--------------	-----	------

AB2			80MG	N21151 001	FEB 22, 2000	AUG	CFTG
-----	--	--	------	------------	--------------	-----	------

@

			100MG	N21151 005	MAR 14, 2003	MAY	DISC
--	--	--	-------	------------	--------------	-----	------

@

			100MG	N21151 005	MAR 14, 2003	MAR	NEWA
--	--	--	-------	------------	--------------	-----	------

AB2			120MG	N21151 002	FEB 22, 2000	AUG	CFTG
-----	--	--	-------	------------	--------------	-----	------

AB2	+		160MG	N21151 003	FEB 22, 2000	AUG	CFTG
-----	---	--	-------	------------	--------------	-----	------

SORINE

AB1		UPSHER SMITH	80MG	N75500 001	APR 27, 2001	AUG	CTEC
-----	--	--------------	------	------------	--------------	-----	------

AB1			120MG	N75500 004	APR 27, 2001	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1			160MG	N75500 002	APR 27, 2001	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1			240MG	N75500 003	APR 27, 2001	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

SOTALOL HCL

AB1		APOTEX	80MG	N76140 001	SEP 26, 2002	AUG	CTEC
-----	--	--------	------	------------	--------------	-----	------

AB1			120MG	N76140 002	SEP 26, 2002	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1			160MG	N76140 003	SEP 26, 2002	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1			240MG	N76140 004	SEP 26, 2002	AUG	CTEC
-----	--	--	-------	------------	--------------	-----	------

AB1		EON	80MG	N75366 001	MAY 01, 2000	AUG	CTEC
-----	--	-----	------	------------	--------------	-----	------

AB1		120MG	N75366 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75366 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75366 004	MAY 01, 2000	AUG	CTEC
AB1	GENPHARM	80MG	N75237 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75237 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75237 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75237 004	MAY 01, 2000	AUG	CTEC
AB1	IMPAX PHARMS	80MG	N75663 001	NOV 07, 2000	AUG	CTEC
AB1		120MG	N75663 002	NOV 07, 2000	AUG	CTEC
AB1		160MG	N75663 003	NOV 07, 2000	AUG	CTEC
AB1		240MG	N75663 004	NOV 07, 2000	AUG	CTEC
AB1	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001	AUG	CTEC
AB1		120MG	N75515 004	OCT 15, 2001	AUG	CTEC
AB1		160MG	N75515 002	OCT 15, 2001	AUG	CTEC
AB1		240MG	N75515 003	OCT 15, 2001	AUG	CTEC
AB1	MYLAN	80MG	N75725 001	DEC 19, 2000	AUG	CTEC
AB1		120MG	N75725 002	DEC 19, 2000	AUG	CTEC
AB1		160MG	N75725 003	DEC 19, 2000	AUG	CTEC
AB1		240MG	N75725 004	DEC 19, 2000	AUG	CTEC
AB1	TEVA	80MG	N75429 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75429 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75429 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75429 004	MAY 01, 2000	AUG	CTEC
AB2	TORPHARM	80MG	N76214 001	AUG 27, 2003	AUG	NEWA
AB2		120MG	N76214 002	AUG 27, 2003	AUG	NEWA
AB2		160MG	N76214 003	AUG 27, 2003	AUG	NEWA
AB1	VINTAGE PHARMS	80MG	N75563 001	NOV 07, 2003	NOV	NEWA
AB1		120MG	N75563 002	NOV 07, 2003	NOV	NEWA
AB1		160MG	N75563 003	NOV 07, 2003	NOV	NEWA
AB1		240MG	N75563 004	NOV 07, 2003	NOV	NEWA
AB1	WATSON LABS	80MG	N75238 001	JUL 13, 2000	AUG	CTEC
AB1		120MG	N75238 002	JUL 13, 2000	AUG	CTEC
AB1		160MG	N75238 003	JUL 13, 2000	AUG	CTEC
AB1		240MG	N75238 004	JUL 13, 2000	AUG	CTEC

STANZOLOL

TABLET; ORAL

WINSTROL

+	OVATION PHARMS	2MG
@		2MG

N12885 001	MAY 14, 1984	JUL	CAHN
N12885 001	MAY 14, 1984	AUG	DISC

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+ GENSLA SICOR PHARMS 1GM/VIAL

N50577 001 MAY 07, 1982 JUN CAHN

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

AP + AMERSHAM HLTH 1mCi/ML

N20134 001 JUN 18, 1993 JAN CFTG

STRONTIUM CHLORIDE SR-89

AP BIO NUCLEONICS 1mCi/ML

N75941 001 JAN 06, 2003 JAN NEWA

SUCCIMER

CAPSULE; ORAL

CHEMET

+ NOVATION PHARMS

100MG

N19998 002 JAN 30, 1991 JUL CAHN

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ AXCAN SCANDIPHARM

1GM/10ML

N19183 001 DEC 16, 1993 NOV CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SEPTRA

@ MONARCH PHARMS

80MG/ML;16MG/ML

N18452 001

MAY DISC

SULFANILAMIDE

SUPPOSITORY; VAGINAL

AVC

@ NOVAVAX

1.05GM

N06530 004 JAN 27, 1987 SEP DISC

SULINDAC

TABLET; ORAL

SULINDAC

@ CLONMEL HLTHCARE

150MG

N73261 001 SEP 06, 1991 JUN DISC

@

200MG

N73262 001 SEP 06, 1991 JUN DISC

TADALAFIL

TABLET; ORAL

CIALIS

LILLY ICOS

5MG

N21368 001 NOV 21, 2003 NOV NEWA

10MG

N21368 002 NOV 21, 2003 NOV NEWA

+

20MG

N21368 003 NOV 21, 2003 NOV NEWA

TALC

>A> POWDER; INTRAPLEURAL

>A> TALC

>A> + BRYAN

5GM/BOT

N21388 001 DEC 15, 2003 DEC NEWA

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

AB ASTRAZENECA

EQ 10MG BASE

N17970 001

FEB CTEC

AB +

EQ 20MG BASE

N17970 002 MAR 21, 1994

FEB CTEC

TAMOXIFEN CITRATE

AB AEGIS PHARMS

EQ 10MG BASE

N76398 001 MAR 31, 2003 MAR NEWA

AB

EQ 20MG BASE

N76398 002 MAR 31, 2003 MAR NEWA

AB ANDRX PHARMS

EQ 10MG BASE

N76179 001 FEB 20, 2003 FEB NEWA

AB

EQ 20MG BASE

N76179 002 FEB 20, 2003 FEB NEWA

AB BARR

EQ 10MG BASE

N70929 001 FEB 20, 2003 FEB NEWA

AB

EQ 20MG BASE

N70929 002 FEB 20, 2003 FEB NEWA

AB IVAX PHARMS

EQ 10MG BASE

N75740 001 FEB 20, 2003 FEB NEWA

AB

EQ 20MG BASE

N75740 002 FEB 20, 2003 FEB NEWA

AB	MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA
AB	PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
AB		EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA
AB	ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA
AB	TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA
AB		EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
AB		EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

TECHNISCAN MDP KIT

AP +	DRAXIMAGE	N/A	N18035 001		MAR	CRLD
------	-----------	-----	------------	--	-----	------

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

a CIS N/A

N17684 001		MAY	DISC
------------	--	-----	------

TELMISARTAN

TABLET; ORAL

MICARDIS

BOEHRINGER INGELHEIM 20MG

N20850 003	APR 04, 2000	JUL	CRLD
------------	--------------	-----	------

>D> TERIPARATIDE ACETATE

>D> INJECTABLE; SUBCUTANEOUS

>D> FORTEO

>D> + LILLY EQ 0.75MG/3ML(0.25MG/ML)

N21318 001	NOV 26, 2002	DEC	CAIN
------------	--------------	-----	------

>A> TERIPARATIDE RECOMBINANT HUMAN

>A> INJECTABLE; SUBCUTANEOUS

>A> FORTEO

>A> + LILLY EQ 0.75MG/3ML(0.25MG/ML)

N21318 001	NOV 26, 2002	DEC	CAIN
------------	--------------	-----	------

TESTOSTERONE

GEL; TOPICAL

ANDROGEL

BX + UNIMED PHARMS 1%

N21015 001	FEB 28, 2000	APR	CTEC
------------	--------------	-----	------

TESTIM

BX + AUXILIUM A2 1%

N21454 001	OCT 31, 2002	APR	CTEC
------------	--------------	-----	------

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ COLUMBIA LABS 30MG

N21543 001	JUN 19, 2003	JUN	NEWA
------------	--------------	-----	------

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

a SAVIENT PHARMS 200MG/ML

N09165 001		OCT	CAHN
------------	--	-----	------

AO + 200MG/ML

N09165 003		OCT	CAHN
------------	--	-----	------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

@ CLONMEL HLTHCARE

250MG

N50278 003

JUN DISC

@

500MG

N50278 001

JUN DISC

SUMYCIN

AB + APOTHECON

500MG

N60429 003

JUN CRLD

TETRACYCLINE HCL

AB AXIOM PHARM

250MG

N60736 001

MAY CAHN

AB

500MG

N60736 002

MAY CAHN

@ ROXANE

500MG

N61214 002

OCT DISC

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

@ ALZA

12.7MG/FIBER

N50653 001 MAR 25, 1994 JUN DISC

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE

50MG

N20785 001 JUL 16, 1998 AUG CRLD

100MG

N20785 002 JAN 17, 2003 JAN NEWA

+

200MG

N20785 003 JAN 17, 2003 JAN NEWA

THALLOUS CHLORIDE, TL-201

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

+ BRISTOL MYERS SQUIBB

2mCi/ML

N17806 002 OCT 09, 1998 OCT NEWA

THEOPHYLLINE

SYRUP; ORAL

SLO-PHYLLIN

@ AVENTIS

80MG/15ML

N85187 001

AUG DISC

TABLET; ORAL

@ AVENTIS

100MG

N85202 001

AUG DISC

@

200MG

N85204 001

AUG DISC

TABLET, EXTENDED RELEASE; ORAL

THEO-DUR

@ SCHERING

100MG

N85328 001

SEP DISC

@

200MG

N86998 001

SEP DISC

@

300MG

N85328 002

SEP DISC

@

450MG

N89131 001

JUN 25, 1986

SEP DISC

THEOPHYLLINE

AB PLIVA

300MG

N89763 001

APR 30, 1990

AUG CRLD

UNI-DUR

@ SCHERING

600MG

N89823 001

JAN 04, 1995

SEP DISC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

@ WYETH AYERST

100MG/ML

N80553 001

JUN DISC

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

@ NOVARTIS

10MG

N13247 001

JUN DISC

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

@ IMMUNEX

15MG/VIAL

N20058 001 DEC 22, 1994 JUL DISC

THIOTEPA

AP + GENSLA SICOR PHARMS

15MG/VIAL

N75730 001 APR 20, 2001 JUL CRLD

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB PFIZER

1MG

N16584 001

FEB CAHN

AB

2MG

N16584 002

FEB CAHN

AB +

5MG

N16584 003

FEB CAHN

AB

10MG

N16584 004

FEB CAHN

20MG

N16584 005

FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

AA + PFIZER

EQ 5MG BASE/ML

N16758 001

FEB CAHN

INJECTABLE; INJECTION

@ PFIZER

EQ 2MG BASE/ML

N16904 001

FEB CAHN

+

EQ 10MG BASE/VIAL

N16904 002

FEB CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT FALCON PHARMS

EQ 0.25% BASE

N74261 001 APR 28, 1995 NOV CMFD

AT

EQ 0.5% BASE

N74262 001 APR 28, 1995 NOV CMFD

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

+ GUILFORD PHARMS

EQ 0.05MG BASE/ML

N20913 001 MAY 14, 1998 OCT CAHN

+

EQ 0.25MG BASE/ML

N20912 001 MAY 14, 1998 OCT CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HCL

>A> AB ALPHAPHARM

EQ 2MG BASE

N76282 001 DEC 16, 2003 DEC NEWA

>A> AB

EQ 4MG BASE

N76282 002 DEC 16, 2003 DEC NEWA

AB AMIDE PHARM

EQ 2MG BASE

N76281 001 OCT 20, 2003 OCT NEWA

AB

EQ 4MG BASE

N76281 002 OCT 20, 2003 OCT NEWA

AB BARR

EQ 2MG BASE

N76371 001 APR 09, 2003 APR NEWA

AB

EQ 4MG BASE

N76371 002 APR 09, 2003 APR NEWA

AB CARACO

EQ 2MG BASE

N76416 001 SEP 29, 2003 SEP NEWA

AB

EQ 4MG BASE

N76416 002 SEP 29, 2003 SEP NEWA

AB MYLAN

EQ 2MG BASE

N76354 001 MAR 28, 2003 MAR NEWA

AB	EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA
<u>TOBRAMYCIN SULFATE</u>					
INJECTABLE; INJECTION					
TOBRAMYCIN SULFATE					
	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	AUG CAHN
	@	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	AUG CAHN
AP		EQ 40MG BASE/ML	N63117 001	APR 26, 1991	AUG CAHN
AP		EQ 40MG BASE/ML	N63118 001	JUL 29, 1991	AUG CAHN
	@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	AUG CAHN
<u>TOLBUTAMIDE</u>					
TABLET; ORAL					
TOLBUTAMIDE					
	@ CLONMEL HLTHCARE	500MG	N86926 001		JUL DISC
<u>TOLBUTAMIDE SODIUM</u>					
INJECTABLE; INJECTION					
ORINASE DIAGNOSTIC					
	@ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001		JUN DISC
<u>TORSEMIDE</u>					
TABLET; ORAL					
TORSEMIDE					
AB	PAR PHARM	5MG	N76226 001	MAY 27, 2003	MAY NEWA
AB		10MG	N76226 002	MAY 27, 2003	MAY NEWA
AB		20MG	N76226 003	MAY 27, 2003	MAY NEWA
AB		100MG	N76226 004	MAY 27, 2003	MAY NEWA
AB	PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003	MAY NEWA
AB		10MG	N76346 002	MAY 30, 2003	MAY NEWA
AB		20MG	N76346 003	MAY 30, 2003	MAY NEWA
<u>TRAMADOL HYDROCHLORIDE</u>					
TABLET; ORAL					
TRAMADOL HCL					
AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR CAHN
<u>TRIAMCINOLONE ACETONIDE</u>					
AEROSOL, METERED; NASAL					
NASACORT					
	@ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	JUL DISC
LOTION; TOPICAL					
TRIAMCINOLONE ACETONIDE					
AT	ALTANA	0.025%	N40467 001	APR 21, 2003	APR NEWA
AT		0.1%	N40467 002	APR 21, 2003	APR NEWA
SPRAY, METERED; NASAL					
TRI-NASAL					
	@ COLLEGIUM	0.05MG/SPRAY	N20120 001	FEB 04, 2000	JUL CAHN
<u>TRIAMCINOLONE DIACETATE</u>					
INJECTABLE; INJECTION					
ARISTOCORT					
>D>	+ FUJISAWA HLTHCARE	25MG/ML	N11685 003		DEC CAHN

>D>	+	40MG/ML	N12802 001	DEC	CAHN
>A>	+	SABEX 2002 25MG/ML	N11685 003	DEC	CAHN
>A>	+	40MG/ML	N12802 001	DEC	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

>D>	+	FUJISAWA HLTHCARE 5MG/ML	N16466 001	DEC	CAHN
>D>	+	20MG/ML	N16466 002	DEC	CAHN
>A>	+	SABEX 2002 5MG/ML	N16466 001	DEC	CAHN
>A>	+	20MG/ML	N16466 002	DEC	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

@	AVENTIS PHARMS	2MG	N12594 001	JUN 16, 1988	MAY	DISC
@		4MG	N12594 002	JUN 16, 1988	MAY	DISC

TRIHXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

ARTANE

@	LEDERLE	2MG/5ML	N06773 009		JUN	DISC
---	---------	---------	------------	--	-----	------

TRIHXYPHENIDYL HCL

AA	+	PHARM VENTURES	2MG/5ML	N89514 001	APR 07, 1989	JUN	CRLD
----	---	----------------	---------	------------	--------------	-----	------

TABLET; ORAL

ARTANE

@	LEDERLE	2MG	N06773 005		JUN	DISC
---	---------	-----	------------	--	-----	------

@		5MG	N06773 003		JUN	DISC
---	--	-----	------------	--	-----	------

TRIHXYPHENIDYL HCL

@	NYLOS	5MG	N85622 001		NOV	DISC
---	-------	-----	------------	--	-----	------

AA	+	WATSON LABS	2MG	N84363 001		JUN	CRLD
----	---	-------------	-----	------------	--	-----	------

AA	+		5MG	N84364 001		JUN	CRLD
----	---	--	-----	------------	--	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB	+	KING PHARMS	300MG	N17531 006	DEC 13, 2001	AUG	CFTG
----	---	-------------	-------	------------	--------------	-----	------

TRIMETHOBENZAMIDE HCL

AB		AMIDE PHARM	300MG	N76546 001	AUG 20, 2003	AUG	NEWA
----	--	-------------	-------	------------	--------------	-----	------

AB		MUTUAL PHARMA	300MG	N76570 001	AUG 28, 2003	AUG	NEWA
----	--	---------------	-------	------------	--------------	-----	------

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

@	MONARCH PHARMS	200MG	N17943 003	JUL 14, 1982	MAY	DISC
---	----------------	-------	------------	--------------	-----	------

TRIMETHOPRIM

+	TEVA	200MG	N71259 001	JUN 18, 1987	MAY	CRLD
---	------	-------	------------	--------------	-----	------

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

@	NOVARTIS	25MG	N83149 001		NOV	DISC
---	----------	------	------------	--	-----	------

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPLENNAMINE HCL

@ LANNETT	50MG	N83557 001		NOV	DISC
@ NYLOS	50MG	N85412 001		NOV	DISC
@ WATSON LABS.	50MG	N80713 001		NOV	DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

@ G AND W LABS	3.7%;2.86%;3.42%	N88607 001	JUN 09, 1986	OCT	DISC
----------------	------------------	------------	--------------	-----	------

SULTRIN

@ ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N05794 001		AUG	DISC
----------------------	------------------	------------	--	-----	------

TRIPLE SULFA

@ ALPHARMA	3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982	OCT	WDAG
------------	------------------	------------	--------------	-----	------

@ CLAY PARK	3.7%;2.86%;3.42%	N87285 001	NOV 15, 1982	OCT	DISC
-------------	------------------	------------	--------------	-----	------

TRYSUL

@ SAVAGE LABS	3.7%;2.86%;3.42%	N87887 001	JUL 23, 1982	OCT	DISC
---------------	------------------	------------	--------------	-----	------

UREA, C-13

FOR SOLUTION; ORAL

HELICOSOL

@ METABOLIC SOLUTIONS	125MG/VIAL	N21092 001	DEC 17, 1999	MAY	DISC
-----------------------	------------	------------	--------------	-----	------

PYLORI-CHEK BREATH TEST

@ DXS DEVICES	100MG/VIAL	N20900 001	FEB 04, 1999	MAR	CAHN
---------------	------------	------------	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

>D>	@ GLAXOSMITHKLINE	EQ 500MG BASE	N20487 001	JUN 23, 1995	DEC	CMFD
>A>		EQ 500MG BASE	N20487 001	JUN 23, 1995	DEC	CMFD
>D>	@	EQ 1GM BASE	N20487 002	JUN 23, 1995	DEC	CMFD
>A>		EQ 1GM BASE	N20487 002	JUN 23, 1995	DEC	CMFD

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP	AM PHARM	EQ 100MG BASE/ML	N76539 001	JUN 26, 2003	JUN	NEWA
----	----------	------------------	------------	--------------	-----	------

VALSARTAN

TABLET; ORAL

DIOVAN

NOVARTIS

40MG	N21283 004	AUG 14, 2002	JUL	NEWA
------	------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

+ LILLY	EQ 250MG BASE/5ML	N61667 002	JUL 13, 1983	JUN	CTEC
---------	-------------------	------------	--------------	-----	------

VANCOLED

@ LEDERLE	EQ 250MG BASE/5ML	N63321 002	OCT 15, 1993	JUN	DISC
-----------	-------------------	------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOLED

AP +	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62682 001	JUL 22, 1986	AUG	CAHN
AP +		EQ 1GM BASE/VIAL	N62682 002	MAR 30, 1988	AUG	CAHN
+		EQ 2GM BASE/VIAL	N62682 003	MAY 11, 1988	AUG	CAHN
AP +		EQ 5GM BASE/VIAL	N62682 004	MAY 11, 1988	AUG	CAHN
AP +		EQ 10GM BASE/VIAL	N62682 005	MAY 11, 1988	AUG	CAHN

VANCOMYCIN HCL

@	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	AUG	CAHN
@		EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	AUG	CAHN

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

	BAYER PHARMS	2.5MG	N21400 003	AUG 19, 2003	AUG	NEWA
		5MG	N21400 001	AUG 19, 2003	AUG	NEWA
		10MG	N21400 002	AUG 19, 2003	AUG	NEWA
+		20MG	N21400 004	AUG 19, 2003	AUG	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@	ORGANON	10MG/VIAL	N18776 002	APR 30, 1984	MAY	DISC
---	---------	-----------	------------	--------------	-----	------

VECURONIUM BROMIDE

AP	BAXTER HLTHCARE	10MG/VIAL	N75218 001	AUG 23, 1999	AUG	CAHN
AP		20MG/VIAL	N75218 002	AUG 23, 1999	AUG	CAHN
AP +	BEDFORD	10MG/VIAL	N75549 001	JUN 13, 2000	MAY	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

	WYETH PHARMS INC	EQ 37.5MG BASE	N20699 001	OCT 20, 1997	MAR	CAHN
		EQ 75MG BASE	N20699 002	OCT 20, 1997	MAR	CRLD
@		EQ 100MG BASE	N20699 003	OCT 20, 1997	MAR	CAHN
+		EQ 150MG BASE	N20699 004	OCT 20, 1997	MAR	CRLD

TABLET; ORAL

EFFEXOR

	WYETH PHARMS INC	EQ 12.5MG BASE	N20151 001	DEC 28, 1993	MAR	CAHN
		EQ 25MG BASE	N20151 002	DEC 28, 1993	MAR	CRLD
		EQ 37.5MG BASE	N20151 006	DEC 28, 1993	MAR	CAHN
>D>		EQ 50MG BASE	N20151 003	DEC 28, 1993	DEC	CRLD
>A>	+	EQ 50MG BASE	N20151 003	DEC 28, 1993	DEC	CRLD
		EQ 50MG BASE	N20151 003	DEC 28, 1993	MAR	CAHN
		EQ 75MG BASE	N20151 004	DEC 28, 1993	MAR	CAHN
>D>	+	EQ 100MG BASE	N20151 005	DEC 28, 1993	DEC	CRLD
>A>		EQ 100MG BASE	N20151 005	DEC 28, 1993	DEC	CRLD
	+	EQ 100MG BASE	N20151 005	DEC 28, 1993	MAR	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

@ CLONMEL HLTHCARE	80MG
@	120MG

N71880 001	APR 05, 1988	JUL	DISC
N71881 001	APR 05, 1988	JUL	DISC

VIDARABINE

OINTMENT; OPHTHALMIC

VIRA-A

@ PARKEDALE	3%
-------------	----

N50486 001		MAY	DISC
------------	--	-----	------

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCASAR PFS

AP	GENSIA SICOR PHARMS	1MG/ML
----	---------------------	--------

N71426 001	JUL 17, 1987	JUL	CAHN
------------	--------------	-----	------

VINCRIStINE SULFATE

AP	AM PHARM	1MG/ML
----	----------	--------

N76401 001	OCT 28, 2003	OCT	NEWA
------------	--------------	-----	------

AP +	AM PHARM PARTNERS	1MG/ML
------	-------------------	--------

N76296 001	DEC 20, 2002	OCT	CTEC
------------	--------------	-----	------

VINCRIStINE SULFATE PFS

AP	SICOR PHARMS	1MG/ML
----	--------------	--------

N75493 001	SEP 01, 1999	JUL	CAHN
------------	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP +	GLAXOSMITHKLINE	EQ 10MG BASE/ML
------	-----------------	-----------------

N20388 001	DEC 23, 1994	FEB	CFTG
------------	--------------	-----	------

VINORELBINE TARTRATE

>A>	AP	BEDFORD	EQ 10MG BASE/ML
-----	----	---------	-----------------

N76461 001	DEC 11, 2003	DEC	NEWA
------------	--------------	-----	------

AP	ESI LEDERLE	EQ 10MG BASE/ML
----	-------------	-----------------

N75992 001	JUN 10, 2003	JUN	NEWA
------------	--------------	-----	------

AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML
----	---------------------	-----------------

N76028 001	FEB 03, 2003	FEB	NEWA
------------	--------------	-----	------

>D> VITAMIN A

>D> CAPSULE; ORAL

>D> VITAMIN A

>D>	+	WEST WARD	50,000USP UNITS
-----	---	-----------	-----------------

N80985 001		DEC	DISC
------------	--	-----	------

>A>	@	50,000USP UNITS
-----	---	-----------------

N80985 001		DEC	DISC
------------	--	-----	------

VORICONAZOLE

>A> FOR SUSPENSION; ORAL

>A> VFEND

>A>	+	PFIZER	200MG/5ML
-----	---	--------	-----------

N21630 001	DEC 19, 2003	DEC	NEWA
------------	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL

JANTOVEN

AB	USL PHARMA	1MG
----	------------	-----

N40416 001	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		2MG
----	--	-----

N40416 002	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		2.5MG
----	--	-------

N40416 003	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		3MG
----	--	-----

N40416 004	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		4MG
----	--	-----

N40416 005	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		5MG
----	--	-----

N40416 006	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		6MG
----	--	-----

N40416 007	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB		7.5MG
----	--	-------

N40416 008	OCT 02, 2003	OCT	NEWA
------------	--------------	-----	------

AB	10MG	N40416 009	OCT 02, 2003	OCT	NEWA
 <u>XENON, XE-133</u>					
GAS; INHALATION					
XENON XE 133					
GEN ELECTRIC	5-100 CI/CYLINDER	N17550 001		JUL	CPOT
	0.25-5 CI/AMP	N17550 003		JUL	CPOT
 <u>ZALEPLON</u>					
CAPSULE; ORAL					
SONATA					
JONES PHARMA	5MG	N20859 001	AUG 13, 1999	JUN	CAHN
+	10MG	N20859 002	AUG 13, 1999	JUN	CAHN
 <u>ZOLEDRONIC ACID</u>					
INJECTABLE; IV (INFUSION)					
ZOMETA					
+ NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR	NEWA
 <u>ZOLMITRIPTAN</u>					
SPRAY; NASAL					
ZOMIG					
+ ASTRAZENECA	5MG/SPRAY	N21450 004	SEP 30, 2003	SEP	NEWA
 <u>ZONISAMIDE</u>					
CAPSULE; ORAL					
ZONEGRAN					
DAINIPPON	25MG	N20789 003	AUG 22, 2003	AUG	NEWA
	50MG	N20789 002	AUG 22, 2003	AUG	NEWA

PRESCRIPTION DRUG PRODUCT LIST - 23RD EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - DEC 2003

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

TYLENOL (CAPLET)

+ MCNEIL CONS SPECLT 650MG

N19872 001 JUN 08, 1994 JUN CTNA

TYLENOL (GELTAB)

+ MCNEIL CONS SPECLT 650MG

N19872 002 JAN 11, 2001 JUN NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMICON

NOVARTIS 80MG;20MG

N72687 001 JUN 28, 1989 MAR CAHN

@ 80MG;20MG

N72687 001 JUN 28, 1989 OCT WDAG

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

@ CENT PHARMS. 8MG;120MG

N19428 001 AUG 02, 1988 MAR DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ LEK PHARMS 100MG

N75122 001 JUN 19, 1998 MAR CAHN

200MG

N75122 002 JUN 19, 1998 MAR CAHN

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

@ STERLING 0.25MG/INH

N16803 001 MAY DISC

FAMOTIDINE

TABLET; ORAL

PEPCID AC

MERCK 10MG

N20325 001 APR 28, 1995 SEP CRLD

+ 20MG

N20325 002 SEP 23, 2003 SEP NEWA

PEPCID AC (GELTAB)

MERCK 10MG

N20902 001 AUG 05, 1999 AUG CTNA

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG

N75715 001 AUG 22, 2003 AUG NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

ADAMS LABS 600MG

N21282 001 JUL 12, 2002 JAN CRLD

+ 1.2GM

N21282 002 DEC 18, 2002 JAN NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

NEIL 200MG

N76460 001 NOV 26, 2003 NOV NEWA

JUNIOR STRENGTH MOTRIN

MCNEIL 100MG

N20602 001 JUN 10, 1996 JUN CRLD

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HCL

PERRIGO 100MG/5ML;15MG/5ML

N76478 001 NOV 05, 2003 NOV NEWA

>D> INSULIN SUSP ISOPHANE BEEF

>D> INJECTABLE; INJECTION

>D> NPH INSULIN

>D> + NOVO NORDISK 100 UNITS/ML

N17929 003 DEC DISC

>A> @ 100 UNITS/ML

N17929 003 DEC DISC

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HCL

LNK 2MG

N76497 001 JUN 10, 2003 JUN NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

+ MCNEIL CONS SPECLT 2MG;125MG

N21140 001 NOV 30, 2000 JAN CRLD

LORATADINE

SYRUP; ORAL

CLARITIN

+ SCHERING 1MG/ML
1MG/ML

N20641 002 NOV 27, 2002 APR CRLD

N20641 002 NOV 27, 2002 MAR NEWA

CLARITIN HIVES RELIEF

+ SCHERING 1MG/ML

N20641 003 NOV 19, 2003 NOV NEWA

LORATADINE

TEVA 1MG/ML

N75505 001 NOV 07, 2003 NOV NEWA

TABLET; ORAL

CLARITIN

+ SCHERING 10MG
10MG

N19658 002 NOV 27, 2002 APR CRLD

N19658 002 NOV 27, 2002 MAR NEWA

CLARITIN HIVES RELIEF

+ SCHERING 10MG

N19658 003 NOV 19, 2003 NOV NEWA

LORATADINE

GENEVA PHARMS 10MG

N75209 001 JAN 21, 2003 JAN NEWA

GENPHARM 10MG

N76154 001 AUG 20, 2003 AUG NEWA

RANBAXY 10MG

N76134 001 AUG 18, 2003 AUG NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

WYETH CONS 10MG

N21375 001 DEC 19, 2002 APR CRLD

CLARITIN HIVES RELIEF REDITAB

+ SCHERING 10MG

N20704 003 NOV 19, 2003 NOV NEWA

CLARITIN REDITABS

+ SCHERING 10MG
10MG

N20704 002 NOV 27, 2002 APR CRLD

N20704 002 NOV 27, 2002 MAR NEWA

LORATADINE

ANDRX PHARMS 10MG

N75990 001 NOV 03, 2003 NOV NEWA

IMPAX LABS 10MG

N76011 001 SEP 29, 2003 SEP NEWA

WYETH CONS 10MG

N75822 001 FEB 10, 2003 FEB NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+	SCHERING	5MG;120MG
		5MG;120MG

N19670 002 NOV 27, 2002 APR CRLD

N19670 002 NOV 27, 2002 MAR NEWA

CLARITIN-D 24 HOUR

+	SCHERING	10MG;240MG
		10MG;240MG

N20470 002 NOV 27, 2002 APR CRLD

N20470 002 NOV 27, 2002 MAR NEWA

LORATADINE AND PSEUDOEPHEDRINE HCL

	ANDRX PHARMS	10MG;240MG
--	--------------	------------

N75706 001 FEB 21, 2003 FEB NEWA

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	ANDRX PHARMS	10MG;240MG
--	--------------	------------

N75706 001 FEB 21, 2003 OCT CTNA

	IMPAX LABS	5MG;120MG
--	------------	-----------

N76050 001 JAN 30, 2003 JAN NEWA

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+	PERSONAL PRODS	2%,4%
---	----------------	-------

N21261 003 JUN 17, 2003 JUN NEWA

MONISTAT 3 COMBINATION PACK (PREFILLED)

+	PERSONAL PRODS	2%,4%
---	----------------	-------

N21261 001 FEB 02, 2001 JUN CTNA

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT 1 COMBINATION PACK

+	PERSONAL PRODS	1.2GM,2%
---	----------------	----------

N21308 001 JUN 29, 2001 NOV NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

	MORTON GROVE	5%
--	--------------	----

N75438 001 FEB 27, 2003 FEB NEWA

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

PROSTEP

+	AVEVA	11MG/24HR
---	-------	-----------

N19983 003 DEC 23, 1998 OCT CAHN

+		22MG/24HR
---	--	-----------

N19983 004 DEC 23, 1998 OCT CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

COMMIT

	GLAXOSMITHKLINE CONS	EQ 2MG BASE
--	----------------------	-------------

N21330 001 OCT 31, 2002 SEP CPOT

+		EQ 4MG BASE
---	--	-------------

N21330 002 OCT 31, 2002 SEP CPOT

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL

PRILOSEC

+	ASTRAZENECA	EQ 20MG BASE
---	-------------	--------------

N21229 001 JUN 20, 2003 JUN NEWA

PRILOSEC OTC

+	ASTRAZENECA	EQ 20MG BASE
---	-------------	--------------

N21229 001 JUN 20, 2003 NOV CTNA

PERMETHRIN

LOTION; TOPICAL

NIX

+	INSIGHT PHARMS	1%
---	----------------	----

N19918 001 MAY 02, 1990 MAR CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '03

NO DECEMBER 2003 APPROVALS

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

**Orphan Products Designations and Approvals List
December 2003**

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3-yl)propyl]acetamide	DD: 7/3/2003 MA:	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-bis-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003 MA:	For combination use with filgrastim to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	AnorMED Inc. 200-20353 64th Avenue Langley, BC, V2Y 1N5
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate <i>Atiprimod</i>	DD: 12/2/2003 MA: MA:	Treatment of multiple myeloma and associated bone resorption	Callisto Pharmaceuticals, 2 Executive Drive Suite 450 Somerset NJ 08873
2-O-Butyryl-1-O-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	DD: 8/15/2003 MA:	Treatment of cystic fibrosis	Inologic, Inc. 101 Elliott Ave., West Seattle WA 98119
4,5-dibromorhodamine 123 <i>Theralux Irradiation Device</i>	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel Saint-Laurent, Quebec
5,5',5"-[Phosphinothiolyldiene-tris(imino-2,1-ethanedilyl)]tris[5-methylc helldoninium]trihydroide hexahydrochloride	DD: 8/20/2003 MA:	Treatment of pancreatic cancer	Now Pharm AG 241, route d'Arlon L-1150
a-(3-aminophthalimido) <i>Actimid</i>	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059

Orphan Products Designations and Approvals List

December 2003

a-Galactosidase A Corporation <i>Plant-Produced Human a-Glactosidase</i>	DD: 1/21/2003 Treatment of Fabry's disease MA:	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
ACA125 Laboratories	DD: Treatment of epithelial ovarian cancer MA:	CellControl Biomedical AG Am Klopferspitz 19 D-82152
alendronate <i>Fosamax</i>	DD: 3/31/2003 Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older MA:	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
alteplase <i>Activase</i> Jefferson 1-109	DD: 1/27/2003 Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage MA:	Daniel F. Hanley, MD Johns Hopkins University Johns Hopkins University 600 N. Wolfe St., Baltimore MD 21287
AMG 531 91320-1799	DD: 3/27/2003 Treatment of immune thrombocytopenic purpura. MA:	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA
anti-CD23 IgG1, kappa monoclonal Inc. antibody	DD: 2/12/2003 Treatment of chronic lymphocytic leukemia MA:	IDEC Pharmaceuticals, 3030 Callan Road San Diego CA 92121
Anti-CEA Sheep-human chimeric monoclonal antibody labeled Court w/Iodine-131 (KAb201)	DD: 5/21/2003 Treatment of pancreatic cancer MA:	KS Biomedix Ltd Ground Floor, 1 Occam Surrey Research Park
anti-interferon-gamma Fab from Inc. goats Blvd. 91367	DD: For the treatment of immunologic corneal allograft rejection MA:	Advanced Biotherapy, 6355 Topanga Canyon Suite 510 Woodland Hills CA
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003 Treatment for renal cell carcinoma MA: MA:	Lorus Therapeutics, Inc 2 Meridan Road Toronto, Ontario

Orphan Products Designations and Approvals List

December 2003

arsenic trioxide <i>Trisenox</i>	DD: 5/13/2003 Treatment of chronic lymphocytic leukemia MA:	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide <i>Trisenox</i>	DD: 6/13/2003 Treatment of liver cancer MA:	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
Atomoxetine hydrochloride STRATTERA	DD: 8/26/2003 Treatment of Tourette's Syndrome MA:	ELI LILLY & Company Lilly Corporate Center Indianapolis IN 46285
baclofen NE 5604	DD: 12/2/2003 Treatment of dystonia MA:	Medtronic Neurological 710 Medtronic Parkway Minneapolis MN 55432
bifidobacterium longum infantis 35624	DD: 1/16/2003 Treatment of pediatric Crohn's disease MA:	Alimentary Health Limited Guardwell, Kinsale
bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 To treat multiple myeloma MA:	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park 4117	DD: 5/2/2003 Treatment of painful HIV-associated neuropathy MA:	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carlos CA 94070
Carboxypeptidase G2 Suite 405	DD: 8/19/2003 Treatment of patients at risk of methotrexate toxicity MA:	Protherics, Inc. 5214 Maryland Way, Brentwood TN 37027
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid) <i>Falkochol</i>	DD: 7/18/2003 Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism MA: MA:	Dr. Falk Pharma GmbH Leinenweberstrasse 5 Postfach 6529
cinacalcet 91320-1799	DD: 5/12/2003 Treatment of hypercalcemia in patients with parathyroid carcinoma MA:	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA

Orphan Products Designations and Approvals List

December 2003

Combretastatin A4 Phosphate	DD: 7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV	OXIGENE, Inc 321 Arsenal Street Watertown MA 02472
	MA:		
	MA:	papillary or follicular thyroid cancer	
conjugated bile acids	DD: 7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-
<i>COBARTin</i>	MA:		
4317			
cultured, partially T-Cell depleted, Center allogenic thymic tissue for Allergy & transplantation	DD: 8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome.	Duke University Medical Division of Pediatric Immunology Erwin Road Durham NC 27710
	MA:		
cyclosporin	DD:	Prophylaxis of acute rejection in patients requiring allogenic lung transplant	Chiron Corporation 4560 Horton Street Emeryville CA 94608
	MA:		
cyclosporine	DD:	For the treatment of refractory acute rejection in patients requiring allogenic lung	Chiron Corporation 4560 Horton Street Emeryville CA 94608
	MA:		
	MA:	transplants.	
debrase	DD: 8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd. 3, Azrieli Center 3, Azrieli Center Triangular Tower 45th
<i>Debridase</i>	MA:		
Floor			
Defibrotide	DD: 5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia (CO)
	MA:		
Dehydroepiandrosterone (DHEA)	DD: 8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc. 6111 Royalmount 6111 Royalmount Montreal, Quebec
Avenue Suite			
<i>Fidelin</i>			
Avenue Suite	MA:		
dextran 1	DD: 3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600
	MA:		
DHA-paclitaxel	DD: 5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance 2200 Renaissance Suite 450 King of Prussia PA
Boulevard			
<i>Taxoprexin</i>	MA:		
Boulevard			
19406			

Orphan Products Designations and Approvals List

December 2003

diferuloylmethane LLC	DD: 6/13/2003	Treatment of cystic fibrosis	Seer Pharmaceuticals, P. O. Box 138 Southport CT 06890
	MA:		
diphenylcyclopentenone	DD: 6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis	Lloyd E. King, Jr. 1900 Patterson Street Suite 104 Nashville TN 37203
	MA:		
	MA:	[AT]/Alopecia Universalis [AU])	
eculizumab Inc.	DD: 8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, 352 Knotter Drive Cheshire CT 06410
	MA:		
Erlotinib Hydrochloride Tarceva	DD: 7/18/2003	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA
94080-4990			
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue Seattle WA 98102
	MA:		
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 11/6/2003	For the prophylaxis of bleeding associated with congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue Seattle WA 98102
	MA:		
ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt
	MA:		
HepeX-B Ltd.	DD: 7/15/2003	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	XTL Biopharmaceuticals, Kiryat Weizmann Science Park Bldg 3
	MA:		
	MA:		
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway	DD: 1/16/2003	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-1307
	MA:		
human gammaglobulin	DD:	Treatment of idiopathic inflammatory myopathies	Protein Therapeutics, Inc. 2761 N. Country Club Suite 202 Tucson AZ 85716
Road	MA:		

Orphan Products Designations and Approvals List

December 2003

hydroxocobalamin Inc. <i>Cyanokit</i> Suite 500	DD:	Treatment of acute cyanide poisoning	EMD Pharmaceuticals, P. O. Box 13319 2311 Shannon Road, Durham NC 27707
	MA:		
Icatbant	DD:	Treatment of angioedema	Jerini AG Invalidenstr. 130 10115 Berlin
	MA:		
IDN 6556 Inc.	DD: 8/19/2003	Treatment of patients undergoing solid organ transplantation.	Idun Pharmaceuticals, 9380 Judicial drive San Diego CA 92121
	MA:		
Imexon CorporationAmpliMed,	DD: 11/1/2003	Treatment of pancreatic adenocarcinoma	AmpliMed, Corporation 2321 Camino La Zorrela Tucson AZ 85718
	MA:		
Infliximab <i>Remicade</i> Parkway	DD: 5/6/2003	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley
	MA:		Malvern PA 19355-1307
Infliximab <i>Remicade</i> Parkway	DD: 5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley
	MA:		Malvern PA 19355-1307
Infliximab Parkway <i>REMICADE</i> Parkway	DD:	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc. 200 Great Valley 200 Great Valley
	MA:		Malvern PA 19355-1307
Infliximab Parkway <i>REMICADE</i> Parkway	DD:	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Centocor, Inc. 200 Great Valley 200 Great Valley
	MA:		Malvern PA 19355-1307
INGN 201 Inc. <i>ADVEXIN</i>	DD: 1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
	MA:		
	MA:		
Iron(III)-hexacyanoferrate(II) Pharmazeutische <i>Radiogardase</i> Republic of	DD: 5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch- Fabrik GMBH & Co, KG Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
	MA:		
	MA:		

Orphan Products Designations and Approvals List

December 2003

Lactoferrin alpha	DD: 8/20/2003	For the treatment of graft versus host disease	Agennix, Inc. Greenway Plaza Suite 910 Houston TX 77046
	MA:		
Lactoferrin alpha	DD: 8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc. 8 Greenway Plaza Suite 910 Houston TX 77046
	MA:		
liposomal p-ethoxy growth Pharmaceuticals, INC. receptor bound protein-2	DD: 12/5/2003	Treatment of chronic myelogenous leukemia	Interpath 20651 Prince Creek Dr. Katy TX 77450
	MA:		
Mafofamide (formerly	DD: 1/21/2003	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Oncology) Daimlerstrasse 40 60314 Frankfurt/Main
	MA:		
MaxAdFVIII Corporation	DD: 3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
	MA:		
1113			
monarsen B, 10th Floor	DD:	Treatment of Myasthenia Gravis	Medica Venture Partners Ackerstein Towers, Bldg ISRAEL
	MA:		
motexafin gadolinium <i>Xcytrin</i> 4521	DD: 1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
	MA:		
	MA:		
Mx-dnG1 or REXIN-G retroviral Corporation <i>REXIN-G</i> 1803W	DD: 8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies 345 Pioneer Drive, Glendale CA 91203
	MA:		
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I <i>APT070</i> Walden,	DD: 5/21/2003	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Little Chesterford, Saffron
	MA:		
	MA:		
N-acetyl-sarcosyl-glycyl-L-valyl-D-a lloisoleucyl-L-threonyl-L-norvalyl- Division L-Isoleucyl-L-arginyl_L-prolylethyl amlnde acetate	DD: 12/9/2003	For the treatment of soft tissue sarcoma	Abbott Laboratories Pharmaceutical Products 200 Abbott Park Road
	MA:		

Orphan Products Designations and Approvals List

December 2003

niprisan Inc. <i>Hemoxin</i> Technology Center Building B, Suite 08901	DD: 8/15/2003 Treatment of sickle cell disease MA:	Abbott Park IL 60064 Xechem International, New Brunswick 100 Jersey Avenue, 310 New Brunswick NJ
polyinosinic-polycytidilic acid NW <i>Poly-ICLC</i> NW 3450	DD: 3/3/2003 Treatment of flavivirus infections including those due to West Nile, Japanese MA: encephalitis, dengue, St. Louis encephalitis, MA: yellow fever, Murray valley, and Banzai viruses	Oncovir 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 Treatment of ovarian cancer MA:	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 Treatment of alpha1-antitrypsin deficiency MA: MA:	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615
recombinant human neutrophil inhibitor (hNE)	DD: 12/9/2003 Treatment of cystic fibrosis MA:	Dyax Corporation 300 Technology Square Cambridge MA 02139
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 Treatment of angioedema MA:	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant T-cell receptor Square Road	DD: 5/2/2003 Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive MA: residues 35-55 MA: to myelin oligodendrocyte glycoprotein	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 Prevention of delayed graft function in solid organ transplant MA:	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotrophic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 Treatment of infantile spasms MA: MA:	Questcor 3260 Whipple Road Union City CA 94587-

Orphan Products Designations and Approvals List

December 2003

resiniferatoxin	DD: 5/13/2003	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - DASS/PPCS/NIDCR/NIH 10 Convent Drive Bethesda MD 20892
	MA:		
rhIGF-I/rhIGFBP-3	DD: 12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmed Inc. 4851 Lake Brooke Drive 4851 Lake Brooke Drive Glen Allen VA 23060
<i>SomaioKine</i>	MA:		
	MA:		
rhuMAb VEGF[bevacizumab])	DD: 11/6/2003	treatment of renal cell carcinoma	Genentech, Inc. 1 DNA Way South San Francisco CA
<i>Avastin</i>	MA:		
94080-4990			
ribavirin	DD: 4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
<i>REBETOL</i>	MA:		
SC-1 monoclonal antibody	DD:	Treatment of patients with CD55 (sc-1) positive gastric tumors	H3 Pharma, Inc. 666 Sherbrooke Street 1400 Montreal, Quebec
West, Suite	MA:		
SGN-30 (anti-CD30 mAb)	DD: 7/18/2003	Treatment of Hodgkin's disease	Seattle Genetics, Inc 21823 30th Drive, Bothell WA 98021
Southeast	MA:		
siplizumab	DD: 7/15/2003	Treatment of T-cell lymphomas	MedImmune Oncology, 35 W. Watkins Mill Road Gaithersburg Md 20878
Inc.	MA:		
sodium dichloroacetate	DD: 7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group 6120 Paseo del Norte Suite J2 Carlsbad CA 92009
	MA:		
Sodium pyruvate	DD: 3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
	MA:		
suberoylanilide hydroxamic acid	DD: 6/12/2003	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River Tarrytown NY 10591-
Road	MA:		
6717			
Tezacitabine	DD: 1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-
	MA:		
2916			

Orphan Products Designations and Approvals List

December 2003

Tinidazole	DD: 8/20/2003 For the treatment of amebiasis	Presutti Laboratories, Inc.
60004	MA:	1607 N. Douglas Avenue Arlington Heights IL
Tranilast	DD: 12/2/2003 For the treatment of malignant glioma	Angiogen
Pharmaceuticals, Pty. Ltd.	MA:	Level 31, ABN AMRO
Rizaben		88 Phillip Street
Tower		2000
Sydney, N.S.W.		
Tretinoin	DD: 4/11/2003 Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
ATRA-IV	MA:	34 Commerce Way 34 Commerce Way Woburn MA 01801
vapreotide pamoate	DD: 11/4/2003 For the treatment of acromegaly	H3 Pharma, Inc.
Sanvar	MA:	666 Sherbrooke Street
West, Suite		1400 Montreal, Quebec

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2003 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE; ZIAGEN	5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
020978 001	ABACAVIR SULFATE; ZIAGEN	5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
>ADD> 021320 001	ABARELIX; PLENAXIS				NCE	NOV 25, 2008
020213 001	ACETYLCHOLINE CHLORIDE; MIOCHOL-E	6261546	APR 29, 2019	U506		
021478 001	ACYCLOVIR; ZOVIRAX	4963555	OCT 16, 2007			
020338 001	ADAPALENE; DIFFERIN	RE34440	MAY 31, 2010	U275		
020899 001	ALBUMIN HUMAN; OPTISON	5573751	APR 25, 2012			
		5529766	JUN 25, 2013	U505		
		5558094	FEB 28, 2012	U505		
020950 001	ALBUTEROL SULFATE; DUONEB	6632842	DEC 28, 2021	U532		
020560 001	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012		I-309	SEP 29, 2003
		4621077	AUG 06, 2007	U114	PED	MAR 29, 2004
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
		6194004*PED	JUN 02, 2013			
020560 002	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	JUN 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
020560 003	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM; FOSAMAX	6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		6008207	JUN 06, 2015		PED	APR 20, 2004
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 16, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
020560 005	ALENDRONATE SODIUM; FOSAMAX	6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		5994329	JUL 17, 2018		PED	APR 20, 2004
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
021575 001	ALENDRONATE SODIUM; FOSAMAX	4621077	AUG 06, 2007		I-309	SEP 29, 2003
		4621077*PED	FEB 06, 2008		PED	MAR 29, 2004
		5462932	MAY 17, 2014		D-61	OCT 20, 2003
		5994329	JUL 17, 2018		PED	APR 20, 2004
		5994329*PED	JAN 17, 2019			
		6015801	JUL 17, 2018			
		6015801*PED	JAN 17, 2019			
		6225294	JUL 17, 2018			
		6225294*PED	JAN 17, 2019			
		4661491	MAY 27, 2006		NCE	JUN 12, 2008
021287 001	ALFUZOSIN HYDROCHLORIDE; UROXATRAL	6149940	AUG 22, 2017			
021001 001	ALMOTRIPTAN MALATE; AXERT	5565447	MAY 07, 2015			
021001 002	ALMOTRIPTAN MALATE; AXERT	5565447	MAY 07, 2015			
021107 001	ALOSETRON HYDROCHLORIDE; LOTRONEX	5360800	JAN 13, 2013	DS DP U405		
>ADD>		6284770	OCT 05, 2018	U405		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD>	021107 002 ALOSETRON HYDROCHLORIDE; LOTRONEX	5360800 6284770	JAN 13, 2013 OCT 05, 2018	DS DP U405 U405	NCE	FEB 09, 2005
	021434 001 ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
	021434 002 ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
	021434 003 ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
	021434 004 ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
	020221 002 AMIFOSTINE; ETHYOL	5424471	JUL 31, 2012			
	020965 001 AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN	5954703	OCT 31, 2017	U289		
	020364 002 AMLODIPINE BESYLATE; LOTREL	4410520 4410520*PED	AUG 11, 2003 FEB 11, 2004			
	020364 003 AMLODIPINE BESYLATE; LOTREL	4410520 4410520*PED	AUG 11, 2003 FEB 11, 2004			
	020364 004 AMLODIPINE BESYLATE; LOTREL	4410520 4410520*PED	AUG 11, 2003 FEB 11, 2004			
	020364 005 AMLODIPINE BESYLATE; LOTREL	4410520 4410520*PED	AUG 11, 2003 FEB 11, 2004		NS PED NPP PED NPP PED	JUN 20, 2005 DEC 20, 2005 JAN 08, 2007 JUL 08, 2007 JAN 08, 2007 JUL 08, 2007
>ADD> >ADD> >ADD> >ADD> >ADD>	019787 001 AMLODIPINE BESYLATE; NORVASC					
	019787 002 AMLODIPINE BESYLATE; NORVASC					
	019787 003 AMLODIPINE BESYLATE; NORVASC					
	021303 001 AMPHETAMINE ASPARTATE; ADDERALL XR 10	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	021303 006 AMPHETAMINE ASPARTATE; ADDERALL XR 15	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	021303 002 AMPHETAMINE ASPARTATE; ADDERALL XR 20	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	021303 004 AMPHETAMINE ASPARTATE; ADDERALL XR 25	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	021303 003 AMPHETAMINE ASPARTATE; ADDERALL XR 30	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	021303 005 AMPHETAMINE ASPARTATE; ADDERALL XR 5	6322819 6605300	OCT 21, 2018 OCT 21, 2018			
	040422 005 AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 006 AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 007 AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	021007 001 AMPRENAVIR; AGENERASE	5723490	MAR 03, 2015	U257		
	021549 001 APREPITANT; EMEND	5719147 5538982 6048859 6096742 6235735	JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012		NCE	MAR 26, 2008
	021549 002 APREPITANT; EMEND	5719147 5538982 6048859 6096742 6235735	JUN 29, 2012 JUL 23, 2013 JUN 29, 2012 JUL 01, 2018 JUN 29, 2012		NCE	MAR 26, 2008
	021436 001 ARIPIPRAZOLE; ABILIFY	4734416 5006528	MAR 29, 2005 OCT 20, 2009		I-401	AUG 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021436 002	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		I-401	AUG 28, 2006
		5006528	OCT 20, 2009			
021436 003	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		I-401	AUG 28, 2006
		5006528	OCT 20, 2009			
021436 004	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		I-401	AUG 28, 2006
		5006528	OCT 20, 2009			
021436 005	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		I-401	AUG 28, 2006
		5006528	OCT 20, 2009			
021436 006	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		I-401	AUG 28, 2006
		5006528	OCT 20, 2009			
021387 001	ASPIRIN;PRAVIGARD PAC (COPAC	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 002	ASPIRIN;PRAVIGARD PAC (COPAC	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
021387 003	ASPIRIN;PRAVIGARD PAC (COPAC	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 004	ASPIRIN;PRAVIGARD PAC (COPAC	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 005	ASPIRIN;PRAVIGARD PAC (COPAC	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021387 006	ASPIRIN;PRAVIGARD PAC (COPAC	4346227 4346227*PED 5030447 5030447*PED 5180589 5180589*PED 5622985 5622985*PED	OCT 20, 2005 APR 20, 2006 JUL 09, 2008 JAN 09, 2009 JUL 09, 2008 JAN 09, 2009 APR 22, 2014 OCT 22, 2014	U335 U335		
021567 001	ATAZANAVIR SULFATE;REYATAZ	5849911 6087383	APR 09, 2017 DEC 21, 2018		NCE	JUN 20, 2008
021567 002	ATAZANAVIR SULFATE;REYATAZ	5849911 6087383	APR 09, 2017 DEC 21, 2018		NCE	JUN 20, 2008
021567 003	ATAZANAVIR SULFATE;REYATAZ	5849911 6087383	APR 09, 2017 DEC 21, 2018		NCE	JUN 20, 2008
021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590 5658590*PED	JAN 11, 2015 JUL 11, 2015	U494 U494	NCE PED	NOV 26, 2007 MAY 26, 2008
020702 002	ATORVASTATIN CALCIUM;LIPITOR	5969156*PED	JAN 08, 2017			
021078 001	ATOVAQUONE;MALARONE	6166046 5053432 6291488 5053432*PED 6166046*PED 6291488*PED	NOV 25, 2013 OCT 01, 2008 NOV 25, 2013 APR 01, 2009 MAY 25, 2014 MAY 25, 2014	U406	NC PED	JUL 14, 2003 JAN 14, 2004
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046 5053432 6291488 5053432*PED 6166046*PED 6291488*PED	NOV 25, 2013 OCT 01, 2008 NOV 25, 2013 APR 01, 2009 MAY 25, 2014 MAY 25, 2014	U406	NC PED NPP PED	JUL 14, 2003 JAN 14, 2004 DEC 02, 2006 JUN 02, 2007
020259 001	ATOVAQUONE;MEPRON	4981874 5053432 5053432*PED	AUG 15, 2009 OCT 01, 2008 APR 01, 2009	U69		
020500 001	ATOVAQUONE;MEPRON	4981874*PED 6649659 6649659*PED 4981874 5053432 5053432*PED	FEB 15, 2010 JUL 10, 2016 JAN 10, 2017 AUG 15, 2009 OCT 01, 2008 APR 01, 2009	U69 DS DP U69 U69	ODE PED	JAN 05, 2006 JUL 05, 2006
021470 001	AZELAIC ACID;FINACEA	4981874*PED 6534070	FEB 15, 2010 NOV 18, 2018	U69		

>ADD>
>ADD>

>ADD>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD>	020114 001 AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2011	U207		
		5164194*PED	MAY 01, 2012			
	021589 001 BACLOFEN;KEMSTRO	6024981	APR 09, 2018	DP		
		6221392	APR 09, 2018	DP		
	021589 002 BACLOFEN;KEMSTRO	6024981	APR 09, 2018	DP		
		6221392	APR 09, 2018	DP		
	019851 001 BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	019851 002 BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	019851 003 BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	019851 004 BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	020033 001 BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	020033 002 BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	020033 003 BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	020033 004 BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
	021055 001 BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U509		
	021056 001 BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U510		
	021602 001 BORTEZOMIB;VELCADE	5780454	OCT 28, 2014		NCE	MAY 13, 2008
		6083903	OCT 28, 2014	U515	ODE	MAY 13, 2010
		6297217	OCT 28, 2014	U515		
		6617317	OCT 28, 2014	DS DP		
	021290 001 BOSENTAN;TRACLEER	5292740	NOV 20, 2015			
	021290 002 BOSENTAN;TRACLEER	5292740	NOV 20, 2015			
>ADD> >ADD>	021262 001 BRIMONIDINE TARTRATE;ALPHAGAN P	6673337	JUL 26, 2021	DP		
		6673337*PED	JAN 26, 2022			
		6562873	JUL 10, 2021			
		6562873*PED	JAN 10, 2022			
		6627210	JUL 18, 2021	DP		
		6627210*PED	JAN 18, 2022			
		6641834	JUL 28, 2021	DP		
		6641834*PED	JAN 28, 2022			
	076260 001 BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE				PC	SEP 16, 2003
	020929 001 BUDESONIDE;PULMICORT RESPULES	6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
	020929 002 BUDESONIDE;PULMICORT RESPULES	6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
	020929 003 BUDESONIDE;PULMICORT RESPULES	6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
	021515 001 BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341	OCT 30, 2018		M-10	JUN 11, 2004
		6143327	OCT 30, 2018			
	021515 002 BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341	OCT 30, 2018		M-10	JUN 11, 2004
		6143327	OCT 30, 2018			
	075766 001 CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
075766 002	CALCITRIOL; CALCITRIOL				PC	SEP 17, 2003
075823 001	CALCITRIOL; CALCITRIOL				PC	SEP 17, 2003
075823 002	CALCITRIOL; CALCITRIOL				PC	SEP 17, 2003
075836 001	CALCITRIOL; CALCITRIOL				PC	SEP 17, 2003
075836 002	CALCITRIOL; CALCITRIOL				PC	SEP 17, 2003
021160 002	CALCIUM ACETATE; PHOSLO	6576665	APR 03, 2021			
021160 003	CALCIUM ACETATE; PHOSLO GELCAPS	6576665	APR 03, 2021			
021485 002	CARBIDOPA; STALEVO 100	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 003	CARBIDOPA; STALEVO 150	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 001	CARBIDOPA; STALEVO 50	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
020452 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020637 001	CARMUSTINE; GLIADEL	4789724	AUG 01, 2006		I-382	FEB 25, 2006
		4757128	AUG 01, 2006			
020297 001	CARVEDILOL; COREG				I-388	MAR 27, 2006
020297 002	CARVEDILOL; COREG				I-388	MAR 27, 2006
020297 003	CARVEDILOL; COREG				I-388	MAR 27, 2006
020297 004	CARVEDILOL; COREG				I-388	MAR 27, 2006
021227 001	CASPOFUNGIN ACETATE; CANCIDAS				I-399	JAN 07, 2006
021227 002	CASPOFUNGIN ACETATE; CANCIDAS				I-399	JAN 07, 2006
021150 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U295		
		4525358*PED	DEC 25, 2007	U295		
		6469009	JUL 13, 2019	U295		
		6489329	APR 08, 2016			
020774 001	CHLORHEXIDINE GLUCONATE; PERIOCHIP	5002769	MAR 16, 2006			
		5023082	MAR 30, 2005			
021159 001	CICLOPIROX; LOPROX				NDF	FEB 28, 2006
>ADD>	019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444*PED			
>ADD>			5286754*PED			
>ADD>			5286754			
>ADD>			4670444		U36	
>ADD>	019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444*PED			
>ADD>			5286754*PED			
>ADD>			4670444		U36	
>ADD>			5286754			
>ADD>	019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444*PED			
>ADD>			5286754*PED			
>ADD>			4670444		U36	
>ADD>			5286754			

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444*PED	JUN 09, 2004		
>ADD>			5286754*PED	AUG 15, 2011		
>ADD>			4670444	DEC 09, 2003	U36	
>ADD>			5286754	FEB 15, 2011		
>ADD>	019847 001	CIPROFLOXACIN;CIPRO	4670444*PED	JUN 09, 2004		
>ADD>			4705789*PED	MAY 10, 2005		
>ADD>			4808583*PED	AUG 28, 2006		
>ADD>			4670444	DEC 09, 2003		
>ADD>			4705789	NOV 10, 2004		
>ADD>			4808583	FEB 28, 2006		
>ADD>	020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014		
>ADD>			4670444	DEC 09, 2003	U362	
>ADD>			6136347	JAN 06, 2013		
>ADD>			4670444*PED	JUN 09, 2004		
>ADD>			5695784*PED	JUN 09, 2015		
>ADD>			6136347*PED	JUL 06, 2013		
>ADD>	020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014		
>ADD>			4670444	DEC 09, 2003	U362	
>ADD>			6136347	JAN 06, 2013		
>ADD>			4670444*PED	JUN 09, 2004		
>ADD>			5695784*PED	JUN 09, 2015		
>ADD>			6136347*PED	JUL 06, 2013		
>ADD>	019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4670444*PED	JUN 09, 2004		
>ADD>			4705789*PED	MAY 10, 2005		
>ADD>			4957922*PED	MAR 18, 2008		
>ADD>			4808583*PED	AUG 28, 2006		
>ADD>			4670444	DEC 09, 2003		
>ADD>			4705789	NOV 10, 2004		
>ADD>			4957922	SEP 18, 2007		
>ADD>			4808583	FEB 28, 2006		
>ADD>	021473 001	CIPROFLOXACIN;CIPRO XR	4670444*PED	JUN 09, 2004	NDF	DEC 13, 2005
>ADD>			4670444	DEC 09, 2003	PED	JUN 13, 2006
>ADD>	021473 002	CIPROFLOXACIN;CIPRO XR			NDF	DEC 13, 2005
>ADD>					PED	JUN 13, 2006
>ADD>					I-416	AUG 28, 2006
>ADD>					PED	FEB 28, 2007
>ADD>	021537 001	CIPROFLOXACIN;CIPRODEX	4844902	FEB 11, 2008	NC	JUL 18, 2006
			6284804	AUG 10, 2020		
			6359016	AUG 10, 2020		
	020822 004	CITALOPRAM HYDROBROMIDE;CELEXA			NCE	JUL 17, 2003
					PED	JAN 17, 2004
					NDF	JUL 24, 2006
>ADD>	021535 001	CLOBETASOL PROPIONATE;CLOBEX	6106848	SEP 22, 2017		
>ADD>	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM	6126920	OCT 03, 2017	U484	
>ADD>	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6504030	JUN 10, 2019		
>ADD>	019758 001	CLOZAPINE;CLOZARIL			I-380	DEC 18, 2005
>ADD>	019758 002	CLOZAPINE;CLOZARIL			I-380	DEC 18, 2005
>ADD>	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U323	
>ADD>	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U323	
>ADD>	017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL			D-78	FEB 03, 2006
>ADD>	020287 001	DALTEPARIN SODIUM;FRAGMIN			I-414	DEC 10, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020287 002	DALTEPARIN SODIUM;FRAGMIN				I-414	DEC 10, 2006
>ADD> 020287 003	DALTEPARIN SODIUM;FRAGMIN				I-414	DEC 10, 2006
>ADD> 020287 004	DALTEPARIN SODIUM;FRAGMIN				I-414	DEC 10, 2006
021572 001	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
021572 002	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
020705 002	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			
021271 001	DESIRUDIN;IPRIVASK	4745177	MAY 17, 2005			
		4801576	JAN 31, 2006			
		5733874	MAR 31, 2015			
021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4863931	SEP 15, 2008		PED	JUN 21, 2007
		4804666	FEB 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		6100274	JUL 07, 2019			
		4659716*PED	OCT 21, 2004	U427		
		4804666*PED	AUG 14, 2006	U428		
		4863931*PED	MAR 15, 2009			
		5595997*PED	JUN 30, 2015	U429		
		6100274*PED	JAN 07, 2020			
021312 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4659716*PED	OCT 21, 2004	U427	PED	JUN 21, 2007
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		4804666	FEB 14, 2006	U428		
		4804666*PED	AUG 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		5595997*PED	JUN 30, 2015	U429		
		6100274	JUL 07, 2019			
		6100274*PED	JAN 07, 2020			
020648 001	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013			
020648 002	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013			
020648 003	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013			
020648 004	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013			
020648 005	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013			
021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
020941 001	DOCOSANOL;ABREVA	4874794	APR 28, 2014			
020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 003	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>		4797413	APR 28, 2008	U103		
>ADD>		4619939	OCT 28, 2003	U104		
>ADD>		4619939*PED	APR 28, 2004			
>ADD>		4797413*PED	OCT 28, 2008			
>ADD>	020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U103	
>ADD>		4619939	OCT 28, 2003	U104		
>ADD>		4619939*PED	APR 28, 2004			
>ADD>		4797413*PED	OCT 28, 2008			
020972 001	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019		U248	
		6639071	FEB 14, 2018	DS		
020972 002	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019		U248	
		6639071	FEB 14, 2018	DS		
020972 003	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019		U248	
		6639071	FEB 14, 2018	DS		
021360 001	EFAVIRENZ;SUSTIVA	5663169	SEP 02, 2014			
		6639071	FEB 14, 2018	DS		
		6639071	FEB 14, 2018	DS		
021360 002	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018	DS		
>ADD>	021500 001	EMTRICITABINE;EMTRIVA	6642245	NOV 04, 2020	U541	NCE JUL 02, 2008
>ADD>		5210085	MAY 11, 2010			
		5814639	SEP 29, 2015			
		5914331	SEP 29, 2015			
021481 001	ENFUVRTIDE;FUZEON	5464933	JUN 07, 2013		NCE	MAR 13, 2008
		6133418	JUN 07, 2013			
		6475491	JUN 07, 2015	U248		
>ADD>	020164 001	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 002	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 003	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 004	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 005	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 006	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	
>ADD>	020164 007	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	I-315 NOV 17, 2003
>ADD>	020164 008	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	I-315 NOV 17, 2003
>ADD>	020164 009	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315 NOV 17, 2003
>ADD>		5389618	FEB 14, 2012	DS DP U545		
020796 001	ENTACAPONE;COMTAN	6599530	SEP 14, 2018	DP		
021565 001	EPINASTINE HYDROCHLORIDE;ELESTAT				NCE	OCT 15, 2008
021437 001	EPLERENONE;INSPIRA	4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	DP U537		
		6534093	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
021437 002	EPLERENONE;INSPIRA	4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6534093	DEC 08, 2019	U3		
		6558707	DEC 08, 2009	DP U537		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U537		
		6410054	DEC 08, 2019	U537		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021437 003	EPLERENONE; INSPRA	4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	DP U537		
		6410054	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6534093	DEC 08, 2019	U537		
>ADD> 021323 001	ESCITALOPRAM OXALATE; LEXAPRO				I-251	DEC 18, 2006
>ADD> 021323 002	ESCITALOPRAM OXALATE; LEXAPRO				I-251	DEC 18, 2006
>ADD> 021323 003	ESCITALOPRAM OXALATE; LEXAPRO				I-251	DEC 18, 2006
>ADD> 021365 001	ESCITALOPRAM OXALATE; LEXAPRO				I-251	DEC 18, 2006
019386 002	ESMOLOL HYDROCHLORIDE; BREVIBLOC	RE34712	JUN 08, 2009			
		RE34712*PED	DEC 08, 2009			
		4593119	JUN 03, 2003			
		5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 003	ESMOLOL HYDROCHLORIDE; BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 004	ESMOLOL HYDROCHLORIDE; BREVIBLOC	6528540	JAN 12, 2021			
		4593119	JUN 03, 2003			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 006	ESMOLOL HYDROCHLORIDE; BREVIBLOC	6528540	JAN 12, 2021			
		4593119	JUN 03, 2003			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 007	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003			
		6310094	JAN 12, 2021			
		6528540	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 005	ESMOLOL HYDROCHLORIDE; BREVIBLOC DOUBLE STR	4593119	JUN 03, 2003			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
021367 001	ESTRADIOL ACETATE; FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
021367 002	ESTRADIOL ACETATE; FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
020375 005	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010			
020375 006	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010			
>ADD> 021258 001	ESTRADIOL; CLIMARA PRO	5252334	OCT 12, 2010	DP	NC	NOV 21, 2006
		5770219	OCT 12, 2010	DP		
		5393529	FEB 28, 2012	DP		
		5676968	OCT 14, 2014	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
004782 003	ESTROGENS, CONJUGATED;PREMARIN				D-82	JUL 16, 2006
004782 006	ESTROGENS, CONJUGATED;PREMARIN				D-82	JUL 16, 2006
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	RE36247	MAY 02, 2006			
020527 001	ESTROGENS, CONJUGATED;PREMPRO				D-79	MAR 12, 2006
020527 003	ESTROGENS, CONJUGATED;PREMPRO				D-79	MAR 12, 2006
020527 004	ESTROGENS, CONJUGATED;PREMPRO	RE36247	MAY 02, 2006		NP	MAR 12, 2006
		5547948	JAN 17, 2015		D-79	MAR 12, 2006
		5210081	FEB 26, 2012		D-81	JUN 04, 2006
020527 005	ESTROGENS, CONJUGATED;PREMPRO	5210081	FEB 26, 2012		NS	JUN 04, 2006
		RE36247	MAY 02, 2006		D-81	JUN 04, 2006
		5547948	JAN 17, 2015			
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	5876746	JUN 07, 2015	U514		
		5972377	JUN 07, 2015	U514		
>ADD>	019697 001	4544554	SEP 26, 2003	U66		
>ADD>		4616006	SEP 26, 2003	U66		
>ADD>		4628051	SEP 26, 2003	U66		
>ADD>		4530839	SEP 26, 2003	U112		
>ADD>		4530839*PED	MAR 26, 2004			
>ADD>		4544554*PED	MAR 26, 2004			
>ADD>		4616006*PED	MAR 26, 2004			
>ADD>		4628051*PED	MAR 26, 2004			
>ADD>	021241 001	4616006	SEP 26, 2003	U112	NP	AUG 22, 2005
>ADD>		6214815	JUN 09, 2019	U112	PED	FEB 22, 2006
>ADD>		4530839	SEP 26, 2003	U112		
>ADD>		4544554	SEP 26, 2003	U112		
>ADD>		4628051	SEP 26, 2003	U112		
>ADD>		4530839*PED	MAR 26, 2004			
>ADD>		4544554*PED	MAR 26, 2004			
>ADD>		4616006*PED	MAR 26, 2004			
>ADD>		4628051*PED	MAR 26, 2004			
>ADD>		6214815*PED	DEC 09, 2019			
021490 001	ETHINYL ESTRADIOL;OVCON-35				NDF	NOV 14, 2006
021544 001	ETHINYL ESTRADIOL;SEASONALE	5898032	JUN 23, 2017	U1	NP	SEP 05, 2006
020325 002	FAMOTIDINE;PEPCID AC				NP	SEP 23, 2006
021203 001	FENOFIBRATE;TRICOR	6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
021203 003	FENOFIBRATE;TRICOR	6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
020747 001	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 002	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 003	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 004	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 005	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 006	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
021626 001	FERRIC HEXACYANOFERRATE (II);RADIOGARDASE (PRUSSI				ODE	OCT 02, 2010
					NCE	OCT 02, 2008
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U192	M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U192		
		5738872*PED	AUG 28, 2015			
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015		M-25	MAY 12, 2006
		6037353	MAR 14, 2017	U138	PED	NOV 12, 2006
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015		M-25	MAY 12, 2006
		6037353	MAR 14, 2017	U138	PED	NOV 12, 2006
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015		M-25	MAY 12, 2006
		6037353	MAR 14, 2017	U138	PED	NOV 12, 2006
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	5578610	NOV 26, 2013		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014			
		5855912*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020180 001	FINASTERIDE; PROSCAR	6046183	MAR 20, 2011			
020038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	FEB 24, 2003			
		4357324*PED	AUG 24, 2003			
020101 001	FLUOXETINE HYDROCHLORIDE; PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE; PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE; PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
>ADD>	021520 002	FLUOXETINE HYDROCHLORIDE; SYMBYAX	522982	APR 23, 2011	DS DP	NC
>ADD>			5945416	MAR 24, 2017	DS DP	
>ADD>	021520 003	FLUOXETINE HYDROCHLORIDE; SYMBYAX	5229382	APR 23, 2011	DS DP	NC
>ADD>			5945416	MAR 24, 2017	DS DP	DEC 24, 2006
>ADD>	021520 004	FLUOXETINE HYDROCHLORIDE; SYMBYAX	5229382	APR 23, 2011	DS DP	NC
>ADD>			5945416	MAR 24, 2017	DS DP	DEC 24, 2006
>ADD>	021520 005	FLUOXETINE HYDROCHLORIDE; SYMBYAX	5229382	APR 23, 2011	DS DP	NC
>ADD>			5945416	MAR 24, 2017	DS DP	DEC 24, 2006
	021077 001	FLUTICASONE PROPIONATE; ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC
			5270305	SEP 07, 2010	U387	AUG 24, 2003
			4992474	FEB 12, 2008	U211	
			5225445	FEB 12, 2008	U211	
			5126375	FEB 12, 2008		
			5290815	MAR 01, 2011	U386	
			4335121*PED	MAY 14, 2004		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121 5270305 4992474 5225445 5126375 5290815 4335121*PED	NOV 14, 2003 SEP 07, 2010 FEB 12, 2008 FEB 12, 2008 FEB 12, 2008 MAR 01, 2011 MAY 14, 2004	U387 U211 U211 U386	NC I-410	AUG 24, 2003 NOV 17, 2006
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121 5270305 4992474 5225445 5126375 5290815 4335121*PED	NOV 14, 2003 SEP 07, 2010 FEB 12, 2008 FEB 12, 2008 FEB 12, 2008 MAR 01, 2011 MAY 14, 2004	U387 U211 U211 U386	NC	AUG 24, 2003
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004		D-76 PED M-24 PED	MAY 23, 2005 NOV 23, 2005 MAY 01, 2006 NOV 01, 2006
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121 4335121*PED	NOV 14, 2003 MAY 14, 2004	U409 U409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772 5354772	OCT 11, 2011 OCT 11, 2011	U109 U413	I-394	MAY 27, 2006
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772 5354772	OCT 11, 2011 OCT 11, 2011	U109 U413	I-394	MAY 27, 2006
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772 5354772	OCT 11, 2011 OCT 11, 2011	U413 U109	I-394	MAY 27, 2006
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATI	5442049 5595978 4689320 5264423 5276019	AUG 15, 2012 AUG 15, 2012 OCT 15, 2004 NOV 23, 2010 JAN 04, 2011	U522 U522 U522 U522		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021345 001	FONDAPARINUX SODIUM;ARIXTRA				I-397	JUN 17, 2006
020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019		I-342	SEP 25, 2004
					NPP	JUN 27, 2006
021548 001	FOSAMPRENAVIR CALCIUM;LEXIVA	6436989	DEC 24, 2017	U257	NE	OCT 20, 2006
		6514953	JUL 15, 2019	U257		
>ADD> 076139 001	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
>ADD> 076139 002	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
>ADD> 076139 003	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002		NPP	MAY 27, 2006
		5006344	JUL 10, 2009		PED	NOV 27, 2006
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002		NPP	MAY 27, 2006
		5006344	JUL 10, 2009		PED	NOV 27, 2006
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002		NPP	MAY 27, 2006
		5006344	JUL 10, 2009		PED	NOV 27, 2006
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
021489 001	GADOTERIDOL;PROHANCE MULTIPACK	5474756	DEC 12, 2012	U536		
		6143274	DEC 12, 2012	U536		
		4885363	DEC 05, 2006			
		5846519	DEC 08, 2015			
076457 001	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
076457 002	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
021061 001	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021061 002	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021062 001	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021062 002	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021062 003	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021062 004	GATIFLOXACIN;TEQUIN				I-329	OCT 17, 2005
021493 001	GATIFLOXACIN;ZYMAR	5880283	DEC 05, 2015		NDF	MAR 28, 2006
		4980470	DEC 15, 2009		NCE	DEC 17, 2004
021399 001	GEFITINIB;IRESSA	5457105	JAN 19, 2013		NCE	MAY 05, 2008
		5616582	JAN 19, 2013			
		5770599	APR 26, 2016			
021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6262071	SEP 21, 2019	U513	NCE	APR 04, 2008
		6331550	SEP 21, 2019	U511		
		6340689	SEP 14, 2019	U512		
		6455540	SEP 21, 2019	U511		
		5633262	JUN 15, 2015			
		5776944	JUN 15, 2015			
		5962468	JUN 15, 2015	U282		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020622 001	GLATIRAMER ACETATE;COPAXONE	6620847	MAY 24, 2014	DS		
020622 002	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		ODE	DEC 20, 2003
		6054430	MAY 24, 2014			
		6342476	MAY 24, 2014	U441		
		6362161	MAY 24, 2014	U441		
		6620847	MAY 24, 2014	DS		
076467 001	GLIPIZIDE;GLIPIZIDE				PC	OCT 19, 2003
020329 001	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
020329 002	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
020329 003	GLIPIZIDE;GLUCOTROL XL	4612008	SEP 16, 2003			
		5024843	SEP 05, 2009			
		5082668	SEP 16, 2003			
		5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
		5591454	JAN 07, 2014	U111		
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	5952340	SEP 14, 2016	U519		
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	5952340	SEP 14, 2016	U519		
021282 002	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U489		
>ADD> 019967 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 16, 2004			
019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 16, 2004			
021532 002	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
021532 003	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
021532 005	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
020818 003	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U3		
		6294197	JUN 18, 2017	U3		
>ADD> 020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U538	I-415	SEP 30, 2006
		5153197*PED	APR 06, 2010	U538		
>ADD> 020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U538	I-415	SEP 30, 2006
		5153197*PED	APR 06, 2010	U538		
021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	6358986	JAN 10, 2020			
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	6358986	JAN 10, 2020			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6599531	JUN 10, 2017			
020453 001	HYDROCORTISONE PROBUTATE;PANDEL	4794106	AUG 28, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021455 001	IBANDRONATE SODIUM; BONIVA	4927814 6143326 6294196	JUL 09, 2007 APR 21, 2017 OCT 07, 2019	U520 U520	NCE	MAY 16, 2008
021472 001	IBUPROFEN; IBUPROFEN	6251426	JUN 25, 2018			
021321 001	ICODextrin; EXTRANEAL	6248726 4761237 4886789 6077836	JUN 19, 2018 AUG 02, 2005 DEC 12, 2006 JUN 20, 2017	U495 U495 U495 U495	ODE	DEC 20, 2009
021335 001	IMATINIB MESYLATE; GLEEVEC				I-392	MAY 20, 2006
021335 002	IMATINIB MESYLATE; GLEEVEC				I-392	MAY 20, 2006
021588 001	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
021588 002	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
020367 002	IMIGLUCERASE; CERESZYME	5549982	AUG 27, 2013	U252		
020685 001	INDINAVIR SULFATE; CRIXIVAN	6645961	MAR 04, 2018	DP		
020685 003	INDINAVIR SULFATE; CRIXIVAN	6645961	MAR 04, 2018	DP		
020685 005	INDINAVIR SULFATE; CRIXIVAN	6645961	MAR 04, 2018	DP		
020685 006	INDINAVIR SULFATE; CRIXIVAN	6645961	MAR 04, 2018	DP		
021081 001	INSULIN GLARGINE; LANTUS				D-80	MAY 01, 2006
020563 001	INSULIN LISPRO; HUMALOG	5474978 5514646	JUN 16, 2014 MAY 07, 2013	U534 U534		
020563 002	INSULIN LISPRO; HUMALOG PEN	5474978 5514646	JUN 16, 2014 MAY 07, 2013	U534 U534		
021425 001	IOPROMIDE; ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U498		
021425 002	IOPROMIDE; ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U498		
021528 001	KETOROLAC TROMETHAMINE; ACULAR LS	5110493 5110493*PED	MAY 05, 2009 NOV 05, 2009		NP	MAY 30, 2006
020857 001	LAMIVUDINE; COMBIVIR	5047407*PED 5047407	MAY 17, 2010 NOV 17, 2009			
021003 001	LAMIVUDINE; EPIVIR-HBV	5047407 5047407*PED	NOV 17, 2009 MAY 17, 2010			
021004 001	LAMIVUDINE; EPIVIR-HBV	5047407 5047407*PED	NOV 17, 2009 MAY 17, 2010			
020241 001	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 002	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 003	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 004	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 005	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
					I-404	JUN 20, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020241 006	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
020764 001	LAMOTRIGINE;LAMICTAL CD				I-404	JUN 20, 2006
020764 002	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
020764 003	LAMOTRIGINE;LAMICTAL CD				I-404	JUN 20, 2006
>ADD> >ADD> >ADD>	020764 004	LAMOTRIGINE;LAMICTAL CD	5698226 4602017	JAN 29, 2012 JUL 22, 2008	U106	I-387 I-404 JUN 17, 2006 JUN 10, 2006
021281 001	LANSOPRAZOLE;PREVACID	4628098 4689333 5013743 5026560 5045321 5093132 5433959	MAY 10, 2009 JUL 29, 2005 FEB 12, 2010 JUN 25, 2008 SEP 03, 2008 SEP 03, 2008 SEP 03, 2008		U126 U452	
021281 002	LANSOPRAZOLE;PREVACID	4628098 4689333 5013743 5026560 5045321 5093132 5433959	MAY 10, 2009 JUL 29, 2005 FEB 12, 2010 JUN 25, 2008 SEP 03, 2008 SEP 03, 2008 SEP 03, 2008		U126 U452	
020905 001	LEFLUNOMIDE;ARAVA				NCE I-395 PED	SEP 10, 2003 JUN 13, 2006 MAR 10, 2004
020905 002	LEFLUNOMIDE;ARAVA				PED NCE I-395 PED	DEC 13, 2006 SEP 10, 2003 JUN 13, 2006 MAR 10, 2004
020905 003	LEFLUNOMIDE;ARAVA				PED NCE I-395 PED PED NP	DEC 13, 2006 SEP 10, 2003 JUN 13, 2006 MAR 10, 2004 DEC 13, 2006 FEB 13, 2006
021488 001	LEUPROLIDE ACETATE;ELIGARD	4938763 5278201 5324519 5599552 5733950 5739176 5362755	OCT 03, 2008 JAN 11, 2011 OCT 20, 2011 FEB 04, 2014 OCT 03, 2008 OCT 03, 2008 NOV 08, 2011		U332	
>ADD> >ADD> >ADD> >ADD>	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	4943639	AUG 06, 2009		
	021035 001	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		
	021035 002	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		
	021035 003	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		
	021505 001	LEVETIRACETAM;KEPPRA	4943639 4837223	AUG 06, 2009 JUN 06, 2006	NCE	NOV 30, 2004
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 07, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020634 001	LEVOFLOXACIN; LEVAQUIN				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020634 002	LEVOFLOXACIN; LEVAQUIN				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020634 003	LEVOFLOXACIN; LEVAQUIN				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020635 001	LEVOFLOXACIN; LEVAQUIN				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020635 004	LEVOFLOXACIN; LEVAQUIN	5053407	DEC 20, 2010		I-393 D-83	MAY 23, 2006 OCT 23, 2006
>ADD>					I-372 D-83	OCT 30, 2005 OCT 23, 2006
020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393 D-83	MAY 23, 2006 OCT 23, 2006
020635 005	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE	5053407	DEC 20, 2010		I-393 I-372 D-83	MAY 23, 2006 OCT 30, 2005 OCT 23, 2006
>ADD>						
021199 001	LEVOFLOXACIN; QUIXIN	5053407	DEC 20, 2010			
021301 001	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 002	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 003	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 004	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 005	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 006	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 007	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 008	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 009	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 010	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 011	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
021301 012	LEVOTHYROXINE SODIUM; LEVOXYL	6555581	FEB 15, 2022			
020612 001	LIDOCAINE; LIDODERM	5589180	MAR 17, 2009		U485	
		5411738	MAY 02, 2012			
		5827529	OCT 27, 2015		U486	
		5709869	MAR 17, 2009		U485	
		5601838	MAY 02, 2012		U488	
>ADD>						
021451 001	LIDOCAINE; ORAQIX				NDF	DEC 19, 2006
021130 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021		NPP	DEC 19, 2005
		6514529	MAR 15, 2021		I-402	JUL 22, 2006
021130 002	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DP	NPP	DEC 19, 2005
		6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
021131 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
021132 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
019558 001	LISINAPRIL; PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 002	LISINAPRIL; PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 003	LISINAPRIL; PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
019558 004	LISINOPRIL; PRINIVIL				NPP	MAY 29, 2006
019558 006	LISINOPRIL; PRINIVIL				PED	NOV 29, 2006
019777 001	LISINOPRIL; ZESTRIL				NPP	MAY 29, 2006
019777 002	LISINOPRIL; ZESTRIL				PED	NOV 29, 2006
019777 003	LISINOPRIL; ZESTRIL				PED	NOV 29, 2006
019777 004	LISINOPRIL; ZESTRIL				NPP	MAY 29, 2006
019777 005	LISINOPRIL; ZESTRIL				PED	NOV 29, 2006
019777 006	LISINOPRIL; ZESTRIL				NPP	MAY 29, 2006
021226 001	LOPINAVIR; KALETRA	6521651	NOV 01, 2017			
019658 002	LORATADINE; CLARITIN	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020641 002	LORATADINE; CLARITIN	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		6132758	JUN 01, 2018			
020704 002	LORATADINE; CLARITIN REDITABS	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
019670 002	LORATADINE; CLARITIN-D	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020470 002	LORATADINE; CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		5314697	OCT 23, 2012			
		5314697*PED	APR 23, 2013			
075209 001	LORATADINE; LORATADINE				PC	JUL 21, 2003
075822 001	LORATADINE; LORATADINE				PC	AUG 09, 2003
075706 001	LORATADINE; LORATADINE AND PSEUD				PC	NOV 29, 2003
076050 001	LORATADINE; LORATADINE AND PSEUD				PC	JUL 30, 2003
020386 001	LOSARTAN POTASSIUM; COZAAR	5210079	MAY 11, 2010	U496	I-383	SEP 17, 2005
		5210079*PED	NOV 11, 2010	U496		
020386 002	LOSARTAN POTASSIUM; COZAAR	5210079	MAY 11, 2010	U496	I-383	SEP 17, 2005
		5210079*PED	NOV 11, 2010	U496		
020386 003	LOSARTAN POTASSIUM; COZAAR	5210079	MAY 11, 2010	U496	I-383	SEP 17, 2005
		5210079*PED	NOV 11, 2010	U496		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021487 001	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 002	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 003	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 004	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
021410 004	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
021410 005	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
>ADD>	021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6660300	MAR 19, 2018	U542	
>ADD>	021202 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6660300	MAR 19, 2018	U542	NDF
		6475521	MAR 19, 2018			OCT 13, 2003
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003	U372		
		5082668	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021259 002	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021259 003	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5081154	MAR 19, 2008			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5081154	MAR 19, 2008			
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	5081154	MAR 19, 2008	U107		
021348 001	MIGLUSTAT;ZAVESCA	5472969	MAY 13, 2013		NCE	JUL 31, 2008
		5525616	JUN 11, 2013		ODE	JUL 31, 2010
076119 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
076119 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
076204 001	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-385	FEB 28, 2006
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL	4990517	JUN 30, 2009	U298	I-385	FEB 28, 2006
		5607942	MAR 04, 2014	U298		
		5849752	DEC 05, 2016	U298		
021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	4990517	JUN 30, 2009		NDF	APR 15, 2006
		5607942	MAR 04, 2014		PED	OCT 15, 2006
		5849752	DEC 05, 2016		NCE	DEC 10, 2004
		4990517*PED	DEC 30, 2009		PED	JUN 10, 2004
		5607942*PED	SEP 04, 2014			
		5849752*PED	JUN 05, 2017			
>ADD>		6641841	NOV 14, 2017	DP U214	I-411	OCT 20, 2006
>ADD>	021204 001	6559188	SEP 17, 2019			
		6641841	NOV 14, 2017	DP U214	I-411	OCT 20, 2006
>ADD>	021204 002	6559188	SEP 17, 2019			
		5484926	OCT 07, 2013			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5952343*PED	APR 07, 2014	U257		
		5484926*PED	APR 07, 2014			
		6162812*PED	APR 07, 2014	U248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5484926*PED	APR 07, 2014			
		5952343*PED	APR 07, 2014	U257		
		6162812*PED	APR 07, 2014	U248		
021503 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		5952343	OCT 07, 2013	U257		
		5952343*PED	APR 07, 2014	U257		
		6162812	OCT 07, 2013	U248		
		6162812*PED	APR 07, 2014	U248		
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U167		
020933 001	NEVIRAPINE;VIRAMUNE	5366972*PED	MAY 22, 2012			
		5366972	NOV 22, 2011			
		5366972*PED	MAY 22, 2012			
021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
020076 004	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 005	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 006	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
019983 003	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
019983 004	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
021498 001	NITAZOXANIDE;ALINIA	5387598	FEB 07, 2012	U524		
		5578621	SEP 08, 2014	U525		
		5965590	JUL 03, 2017	U523		
		5968961	MAY 07, 2017			
		6020353	SEP 08, 2014			
		6117894	MAY 07, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021232 001	NITISINONE; ORFADIN	5006158	APR 09, 2008			
021232 002	NITISINONE; ORFADIN	5550165	AUG 27, 2013			
021232 003	NITISINONE; ORFADIN	5006158	APR 09, 2008			
020845 002	NITRIC OXIDE; INOMAX	5550165	AUG 27, 2013			
020845 003	NITRIC OXIDE; INOMAX	5006158	APR 09, 2008			
020799 001	OFLOXACIN; FLOXIN	5550165	AUG 27, 2013			
019921 001	OFLOXACIN; OCUPLOX	5873359	JAN 23, 2013	U297		
		5873359	JAN 23, 2013	U297		
		4382892	SEP 02, 2003		D-84	SEP 30, 2006
		4551456	NOV 14, 2003		ODE	MAY 22, 2003
		4382892*PED	MAR 02, 2004	U80	PED	NOV 22, 2003
		4551456*PED	MAY 14, 2004	U80		
020592 001	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
020592 002	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
020592 003	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
020592 004	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
020592 005	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
020592 006	OLANZAPINE; ZYPREXA				I-400	JUL 10, 2006
021286 002	OLMESARTAN MEDOXOMIL; BENEVAS	5616599	APR 01, 2014	U500		
021286 001	OLMESARTAN MEDOXOMIL; BENICAR	5616599	APR 01, 2014	U500		
021286 003	OLMESARTAN MEDOXOMIL; BENICAR	5616599	APR 01, 2014	U500		
021229 001	OMEPRazole MAGNESIUM; PRILOSEC OTC	4738974	APR 19, 2005		RTO	JUN 20, 2006
		5900424	MAY 04, 2016			
		4786505	APR 20, 2007			
		4853230	APR 20, 2007			
		5690960	NOV 25, 2014			
		5817338	OCT 06, 2015			
		5753265	JUN 07, 2015			
		6403616	NOV 15, 2019			
		6428810	NOV 03, 2019			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFran PRESERVATIVE	4695578	JAN 25, 2005			
020766 001	ORLISTAT; XENICAL	4753789	JUN 24, 2006	U44		
		4598089	JUN 18, 2009		NCE	APR 23, 2004
		6004996	JAN 06, 2018		PED	OCT 23, 2004
		4598089*PED	DEC 18, 2009		M-29	DEC 12, 2006
		6004996*PED	JUL 06, 2018		PED	JUN 12, 2007
		6030643	MAY 16, 2017	U497		
>ADD>					M-28	APR 15, 2006
>ADD>					PED	OCT 15, 2006
>ADD>					M-28	APR 15, 2006
>ADD>					PED	OCT 15, 2006
020897 001	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
020897 002	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	OCT 15, 2006
020897 003	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
					PED	OCT 15, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021351 002	OXYBUTYNIN; OXYTROL	5164190 5601839 5834010	DEC 11, 2010 APR 26, 2015 APR 26, 2015		NDF	FEB 26, 2006
021372 001	PALONOSETRON HYDROCHLORIDE; ALOXI	5202333	APR 13, 2010	U528	NCE	JUL 25, 2008
020987 001	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2010			
020987 002	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2010			
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV	4758579	JUL 19, 2010			
020819 001	PARICALCITOL; ZEMPLAR	5246925 5587497 6136799 6361758 5246925*PED 5587497*PED 6136799*PED 6361758*PED	APR 17, 2012 DEC 24, 2013 APR 08, 2018 APR 08, 2018 OCT 17, 2012 JUN 24, 2014 OCT 08, 2019 OCT 08, 2018	U314 DP		
075356 001	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 002	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 003	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 004	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR	6548084 6548084*PED	JUL 19, 2016 JAN 19, 2017		I-405	AUG 28, 2006
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR	6548084 6548084*PED	JUL 19, 2016 JAN 19, 2017		I-405	AUG 28, 2006
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR	6548084 6548084*PED	JUL 19, 2016 JAN 19, 2017		I-405	AUG 28, 2006
021299 001	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447 5874447 5874447	JUN 10, 2017 JUN 10, 2017 JUN 10, 2017	U286 U518 U46		
021299 002	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447 5874447 5874447	JUN 10, 2017 JUN 10, 2017 JUN 10, 2017	U286 U518 U46		
021299 003	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447 5874447 5874447	JUN 10, 2017 JUN 10, 2017 JUN 10, 2017	U286 U518 U46		
021299 004	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447 5874447 5874447	JUN 10, 2017 JUN 10, 2017 JUN 10, 2017	U286 U518 U46		
021106 001	PEGVISOMANT; SOMAVERT	6057292 5849535 5958879 5350836 5681809 5583115	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011	U507 U507 U507 U507 U507	NCE ODE	MAR 25, 2008 MAR 25, 2010
021106 002	PEGVISOMANT; SOMAVERT	6057292 5849535 5958879 5350836 5681809 5583115	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011	U507 U507 U507 U507 U507	NCE ODE	MAR 25, 2008 MAR 25, 2010
021106 003	PEGVISOMANT; SOMAVERT	6057292 5849535 5958879 5350836 5681809 5583115	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011	U507 U507 U507 U507 U507	NCE ODE	MAR 25, 2008 MAR 25, 2010

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020629 001	PENCICLOVIR SODIUM;DENA VIR	6469015 6573378 6579981	OCT 22, 2019 SEP 24, 2010 JUN 17, 2020	U501 U501	NPP	OCT 10, 2006
076061 001	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
076061 002	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
076061 003	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
020184 001	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	DS DP U531		
020184 002	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	DS DP U531		
020184 003	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	DS DP U531		
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2011			
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2011			
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777 6150384	JAN 17, 2011 JUN 19, 2016	U419		
020451 001	PORFIMER SODIUM;PHOTOFRIN				I-391 ODE PC	AUG 01, 2006 AUG 01, 2010 DEC 24, 2003
074726 003	POTASSIUM CHLORIDE;KLOR-CON M15				NDF	SEP 04, 2006
021416 001	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 002	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 003	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021438 001	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
021438 002	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5045552	MAY 08, 2013	U385		
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	MAY 08, 2013	U385		
019901 001	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
019901 002	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
019901 003	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
019901 004	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
020903 001	RIBAVIRIN;REBETOL	6524570 6524570*PED	NOV 01, 2016 MAY 01, 2017	U499 U499	M-26 ODE PED	MAR 06, 2005 JUL 29, 2010 JAN 29, 2011
020903 002	RIBAVIRIN;REBETOL				M-26 ODE PED	MAR 06, 2005 JUL 29, 2010 JAN 29, 2011
021546 001	RIBAVIRIN;REBETOL	6472373 6472373*PED 6461605 6461605*PED 6172046 6172046*PED 6063772 6063772*PED 5767097 5767097*PED	SEP 21, 2017 MAR 21, 2018 NOV 01, 2016 MAY 01, 2017 SEP 21, 2017 MAR 21, 2018 JAN 23, 2016 JUL 23, 2016 JAN 23, 2016 JUL 23, 2016	U521 U521 U521 U521 U521 U521 U521 U521 U521 U521	NDF PED ODE PED	JUL 29, 2006 JAN 29, 2007 JUL 29, 2010 JAN 29, 2011
020835 001	RISEDRONATE SODIUM;ACTONEL	6096342	NOV 22, 2011			
020835 002	RISEDRONATE SODIUM;ACTONEL	6096342	NOV 22, 2011			
020835 003	RISEDRONATE SODIUM;ACTONEL	5583122 6096342 6165513	DEC 10, 2013 NOV 22, 2011 JUN 10, 2018	U222		
>ADD> >ADD>	020272 001	RISPERIDONE;RISPERDAL			I-412 I-413	DEC 04, 2006 DEC 04, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020272 002	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020272 003	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020272 004	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020272 005	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020272 007	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020272 008	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	020588 001	RISPERIDONE;RISPERDAL			I-412	DEC 04, 2006
>ADD>					I-413	DEC 04, 2006
>ADD>	021444 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U516	M-15 MAR 03, 2005
>ADD>		5648093	JUL 15, 2014		I-412	DEC 04, 2006
>ADD>		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
>ADD>	021444 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U516	M-15 MAR 03, 2005
>ADD>		5648093	JUL 15, 2014		I-412	DEC 04, 2006
>ADD>		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
>ADD>	021444 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007		M-15 MAR 03, 2005
>ADD>		5648093	JUL 15, 2014		I-412	DEC 04, 2006
>ADD>		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
>ADD>				U516		
>ADD>	021346 001	RISPERIDONE;RISPERDAL CONSTA	6544559	NOV 19, 2013		NDF OCT 29, 2006
>ADD>		6368632	NOV 19, 2013	U543		
>ADD>		6403114	MAY 02, 2017			
		4804663	DEC 29, 2007			
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
>ADD>	021346 002	RISPERIDONE;RISPERDAL CONSTA	6544559	NOV 19, 2013		NDF OCT 29, 2006
>ADD>		6368632	NOV 19, 2013	U543		
>ADD>		6403114	MAY 02, 2017			
		4804663	DEC 29, 2007			
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD>	021346 003 RISPERIDONE;RISPERDAL CONSTA	6379704	MAY 19, 2020	DP	NDF	OCT 29, 2006
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
		4804663	DEC 29, 2007			
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
6379703	DEC 30, 2018	DP				
6379704	MAY 19, 2020	DP				
6534092	MAY 19, 2020	DP				
021042 001	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021042 002	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021042 003	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021052 001	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021052 002	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008			
>ADD>	020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		
>ADD>	020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		
>ADD>	020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		
>ADD>	020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		
021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021366 002	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 003	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 004	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 005	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U503		
021136 001	SECRETIN;SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
					I-408	NOV 01, 2005
>ADD>	021385 001	SERTACONAZOLE NITRATE;ERTACZO			NCE	DEC 10, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
019766 001	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 002	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 003	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 004	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
019766 005	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
021083 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
021110 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5989591	MAR 11, 2018			
>ADD> 020231 001	SODIUM FLUORIDE;COLGATE TOTAL	4894220	JAN 16, 2007	DP		
>ADD>		5037635	JAN 16, 2007	DP		
>ADD>		5156835	OCT 20, 2009	DP		
>ADD>		5538715	JAN 16, 2007	DP		
>ADD>		5776435	JAN 16, 2007	DP		
>ADD>		5344641	MAR 09, 2010	DP		
		5288480	JUL 16, 2008			
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				I-398	JUL 25, 2006
021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352 5849700 5849704	MAY 27, 2014 DEC 15, 2015 DEC 15, 2015	U340		
>ADD> 021597 001	SOMATROPIN; ZORBTIVE				NP	DEC 01, 2006
>ADD> 021597 002	SOMATROPIN; ZORBTIVE				ODE	DEC 01, 2010
>ADD> 021597 003	SOMATROPIN; ZORBTIVE				NP	DEC 01, 2006
>ADD> 021597 004	SOMATROPIN; ZORBTIVE				ODE	DEC 01, 2010
>ADD> 021151 005	SOTALOL HYDROCHLORIDE; BETAPACE AF				NP	DEC 01, 2006
>ADD> 021151 006	SOTALOL HYDROCHLORIDE; BETAPACE AF				ODE	DEC 01, 2010
>ADD> 021151 007	SOTALOL HYDROCHLORIDE; BETAPACE AF				NP	DEC 01, 2006
020413 001	STAVUDINE; ZERIT	4978655 4978655*PED	JUN 24, 2008 DEC 24, 2008		ODE	DEC 01, 2010
021453 001	STAVUDINE; ZERIT XR	4978655 4978655*PED	JUN 24, 2008 DEC 24, 2008	U248	NP	FEB 22, 2003
021453 002	STAVUDINE; ZERIT XR	4978655 4978655*PED	JUN 24, 2008 DEC 24, 2008	U248	PED	AUG 22, 2003
021453 003	STAVUDINE; ZERIT XR	4978655 4978655*PED	JUN 24, 2008 DEC 24, 2008	U248	NP	FEB 22, 2003
021453 004	STAVUDINE; ZERIT XR	4978655 4978655*PED	JUN 24, 2008 DEC 24, 2008	U248	PED	AUG 22, 2003
>ADD> 021368 001	TADALAFIL; CIALIS				NP	FEB 22, 2003
>ADD> 021368 002	TADALAFIL; CIALIS				PED	AUG 22, 2003
>ADD> 021368 003	TADALAFIL; CIALIS				NP	FEB 22, 2003
020600 001	TAZAROTENE; TAZORAC	5914334 6258830 5914334 6258830	JUN 07, 2014 JUN 07, 2014 JUN 07, 2014 JUN 07, 2014	U517 U517 U517 U517		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVUE				I-396	FEB 28, 2006
020850 001	TELMISARTAN; MICARDIS	6358986	JAN 10, 2020			
020850 002	TELMISARTAN; MICARDIS	6358986	JAN 10, 2020			
020850 003	TELMISARTAN; MICARDIS	5591762 6358986	JAN 07, 2014 JAN 10, 2020	U3	NCE	NOV 10, 2003
021356 001	TENOFOVIR DISOPROXIL FUMARATE; VIREAD				NPP	AUG 15, 2006
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	6121314	MAY 18, 2012	U502		
021124 001	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	6121314	MAY 18, 2012	U504		
020489 001	TESTOSTERONE; ANDRODERM	4863970 4983395 5152997 5164190 4849224 4855294 4849224 4855294 4863970 4983395 5152997 5164190	NOV 14, 2006 NOV 12, 2007 DEC 11, 2010 DEC 11, 2010 NOV 12, 2007 SEP 06, 2008 NOV 12, 2007 SEP 06, 2008 NOV 14, 2006 NOV 12, 2007 DEC 11, 2010 DEC 11, 2010	U490 U490		
020489 002	TESTOSTERONE; ANDRODERM					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021543 001	TESTOSTERONE; STRIANT	4615697 6248358	OCT 07, 2003 AUG 23, 2019	U527	NP	JUN 19, 2006
021454 001	TESTOSTERONE; TESTIM				NP	OCT 31, 2005
020785 001	THALIDOMIDE; THALOMID	6561977 6561976 6045501	OCT 23, 2020 AUG 28, 2018 AUG 28, 2018	U371 U371 U371	ODE NCE	JUL 16, 2005 JUL 16, 2003
020785 002	THALIDOMIDE; THALOMID	6315720 6561977 6561976 6045501	OCT 23, 2020 OCT 23, 2020 AUG 28, 2018 AUG 28, 2018	U442 U371 U371 U371		
020785 003	THALIDOMIDE; THALOMID	6315720 6561977 6561976	OCT 23, 2020 OCT 23, 2020 AUG 28, 2018	U442 U371 U371	ODE NCE	JUL 16, 2005 JUL 16, 2003
>ADD>	020771 001	TOLTERODINE TARTRATE; DETROL	5382600 5559269	MAR 25, 2012 NOV 05, 2013	U318	
>ADD>			5382600*PED	SEP 25, 2012		
>ADD>			5559269*PED	MAY 05, 2014		
>ADD>	020771 002	TOLTERODINE TARTRATE; DETROL	5382600	MAR 25, 2012	U318	
>ADD>			5559269	NOV 05, 2013		
>ADD>			5382600*PED	SEP 25, 2012		
>ADD>			5550269*PED	MAY 05, 2014		
>ADD>	021228 001	TOLTERODINE TARTRATE; DETROL LA	5382600	MAR 25, 2012	U318	NDF DEC 22, 2003
>ADD>			5559269	NOV 05, 2013	PED	JUN 22, 2004
>ADD>			5382600*PED	SEP 25, 2012		
>ADD>			5559269*PED	MAY 05, 2014		
>ADD>			6630162	NOV 11, 2019	DP U544	
>ADD>			6630162*PED	MAY 11, 2020		
>ADD>	021228 002	TOLTERODINE TARTRATE; DETROL LA	5382600	MAR 25, 2012	U318	NDF DEC 22, 2003
>ADD>			5559269	NOV 05, 2013	PED	JUN 22, 2004
>ADD>			5382600*PED	SEP 25, 2012		
>ADD>			5559269*PED	MAY 05, 2014		
>ADD>			6630162	NOV 11, 2019	DP U544	
>ADD>			6630162*PED	MAY 11, 2020		
020505 001	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020505 002	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020505 003	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020505 004	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020505 005	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020505 006	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2004			
020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
021257 001	TRAVOPROST; TRAVATAN				M-23	FEB 13, 2006
021108 001	TRETINOIN; RENOVA	6531141	MAR 07, 2020			
>ADD>	020487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	JUN 23, 2009	U530	D-67 JUN 25, 2004
>ADD>			5879706	JAN 19, 2016	U530	I-381 SEP 09, 2005
>ADD>			6107302	JAN 19, 2016	U530	I-403 AUG 29, 2006
>ADD>						I-389 APR 01, 2006
>ADD>	020487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	5879706	JAN 19, 2016	U530	D-67 JUN 25, 2004
>ADD>			6107302	JAN 19, 2016	U530	I-381 SEP 09, 2005
>ADD>			4957924	JUN 23, 2009	U530	I-403 AUG 29, 2006
>ADD>						I-389 APR 01, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021304 001	VALGANCICLOVIR HYDROCHLORIDE; VALCYTE				I-406	SEP 12, 2006
021400 001	VARDENAFIL HYDROCHLORIDE; LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 002	VARDENAFIL HYDROCHLORIDE; LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 003	VARDENAFIL HYDROCHLORIDE; LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 004	VARDENAFIL HYDROCHLORIDE; LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6444708	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6444708	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6444708	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	6444708	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4612008	SEP 16, 2003			
		6146662	AUG 14, 2007	U366		
020552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4612008	SEP 16, 2003			
		6146662	AUG 14, 2007	U366		
021266 001	VORICONAZOLE; VFEND	5116844	AUG 11, 2009	DP U540	I-409	NOV 14, 2006
		5364938	NOV 15, 2011	DS		
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021266 002	VORICONAZOLE; VFEND	5116844	AUG 11, 2009	DP U540	I-409	NOV 14, 2006
		5364938	NOV 15, 2011	DS		
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021267 001	VORICONAZOLE; VFEND	5773443	JAN 25, 2011	DS DP U540	I-409	NOV 14, 2006
		5116844	AUG 11, 2009	DP U540		
		5364938	NOV 15, 2011	DS		
		5567817	OCT 22, 2013	DS DP U540		
		6632803	JUN 02, 2018	DP		
		5376645	JAN 23, 2010	DP		
		5134127	JAN 23, 2010	DP		
020859 001	ZALEPLON; SONATA	4626538	JUN 06, 2008			
020859 002	ZALEPLON; SONATA	4626538	JUN 06, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021223 002	ZOLEDRONIC ACID; ZOMETA	4777163 4939130	JUL 24, 2007 NOV 13, 2007	U53	NCE I-361 ODE	AUG 20, 2006 FEB 22, 2005 AUG 20, 2008
>ADD>	020768 001	ZOLMITRIPTAN; ZOMIG	5466699*PED 5863935*PED	MAY 14, 2013 MAY 14, 2013		
>ADD>		5466699	NOV 14, 2012			
>ADD>		5863935	NOV 14, 2012			
>ADD>	020768 002	ZOLMITRIPTAN; ZOMIG	5466699*PED 5863935*PED	MAY 14, 2013 MAY 14, 2013		
>ADD>		5466699	NOV 14, 2012			
>ADD>		5863935	NOV 14, 2012			
>ADD>	021450 004	ZOLMITRIPTAN; ZOMIG	5466699*PED	MAY 14, 2013	NDF	SEP 26, 2006
>ADD>		5466699	NOV 14, 2012	U436	PED	MAR 26, 2007
>ADD>	021231 001	ZOLMITRIPTAN; ZOMIG-ZMT	5466699*PED	MAY 14, 2013	NDF	FEB 13, 2004
>ADD>		5466699	NOV 14, 2012		PED	AUG 13, 2004
>ADD>	021231 002	ZOLMITRIPTAN; ZOMIG-ZMT	5466699*PED	MAY 14, 2013	NDF	FEB 13, 2004
>ADD>		5466699	NOV 14, 2012		PED	AUG 13, 2004
020789 002	ZONISAMIDE; ZONEGRAN				NCE	MAR 27, 2005
020789 003	ZONISAMIDE; ZONEGRAN				NCE	MAR 27, 2005

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c)(3)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 DS = Drug Substance claim
 DP = Drug Product claim
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS

EXCLUSIVITY INDICATION

- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN $\geq$ 2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 INTENTIONALLY LEFT BLANK
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS

- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY
- I-395 REVASCULARIZATION PROCEDURES
TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING
EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL
ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC
EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF
TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A
HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD
EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD
EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING
REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS
TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
(EJECTION FRACTION $\leq 40\%$) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN
ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF
VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-
PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE
THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED
WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES
ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN
MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY
RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL
EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED
PYELONEPHRITIS

EXCLUSIVITY MISCELLANEOUS

- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN
PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY
INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED
TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE
REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION
WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR
PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL
CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS
AGED 12 TO 16 YEARS

PATENT USE

- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND

- CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE
- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT